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1 Introduction 
 The role of chemoradiotherapy in the treatment of cancer 
Cancer is the leading cause of death in Western Europe and North America (Ferlay, 
2007; Jemal, 2011). Surgery, chemotherapy and radiotherapy (RT) are the three major 
treatment options for solid cancers. Current estimates state that more than 50% of 
patients with cancer should receive radiation treatment at least once during their illness 
(Delaney, 2005) and the U. S. cancer treatment and survivorship statistics 2012 show 
that RT belongs to the most frequently employed treatments for solid cancers (Siegel, 
2012). 
Thus, finding ways to improve the efficacy of RT and advancing the understanding of its 
actions is an important task in oncology. The past 2 decades have seen impressive 
achievements in delivery and targeting of the radiation dose contributing to this aim 
(Ahmad, 2012; Thariat, 2013). Despite these advances recurrence after initial 
eradication of detectable disease remains a major problem (Catton, 2003; Siglin, 2012). 
Recurrence may be due to radiation resistant sub-populations within the tumor or occult 
metastases.  
An approach that can address both of these issues is the combination of chemotherapy 
with RT (Seiwert, 2007; Fietkau, 2012). One of the potential benefits of this combination 
is the gain of systemic action through chemotherapy that can complement the local 
action of irradiation. Importantly, for a variety of chemotherapeutics a synergistic action 
with ionizing radiation (IR) has also been observed that results from sensitization of cells 
to the killing effects of radiation. 
Nucleoside analogs (NAs) represent an important family of antimetabolite drugs, several 
members of which have been demonstrated to possess radiosensitizing potential 
(Galmarini, 2002; Jordheim, 2013; Lee, 2013). A better understanding of the basic 
principles of this radiosensitization will help to develop treatments that increase the 
efficacy of radiotherapy and improve local control. In the present thesis mechanisms of 
radiosensitization by nucleoside analogs (NAs) are studied at the example of 
9-β-D-arabinofuranosyladenosine (ara-A) and compared to the effects of other NAs. 
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In the following, the roles and effects of nucleoside chemotherapy and radiotherapy as 
single treatments will be described first to lay the basis for the understanding of their 
synergistic effects. 
 
 Nucleoside analogs and their role in chemotherapy 
 Overview and general considerations 
NAs represent a class of rationally designed anticancer drugs. They were and are 
developed based on the knowledge of the chemical structure of nucleic acids and their 
building blocks. These compounds share high structural similarity with naturally 
occurring cellular nucleosides. Due to this similarity NAs can interfere with various 
enzymatic processes and compete with endogenous nucleosides. Prominent among 
these are processes of the nucleic acid metabolism, namely the synthesis of 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and nucleoside/nucleotide 
biosynthesis, where they can be used as fraudulent substrates. Therefore, nucleoside 
analogs used in anticancer therapy are classified as anti-metabolite drugs. The 
therapeutic gain of cytotoxic NA treatment derives from the differences in division and 
replication rates of rapidly proliferating tumor vs. normal somatic cells. 
In order to unfold their therapeutic potential, NAs have to pass the cell membrane and 
become activated by mono-, di- and triphosphorylation by intracellular nucleoside and 
nucleotide kinases (Parker, 2009). Cellular uptake can occur by passive diffusion or by 
active transport via membrane proteins of the human concentrative and equilibrative 
nucleoside transporter families (hCNT and hENT respectively). Human cells possess 
four principal deoxyribonucleoside kinases that can perform the initial 
monophosphorylation of nucleosides. These are deoxycytidine kinase (dCK), thymidine 
kinases 1 & 2 and deoxyguanosine kinase (Arner and Eriksson, 1995). Adenosine 
kinase can be considered as a fifth deoxyribonucleoside kinase, as it was found to 
phosphorylate deoxyadenosine and several purine analogs (Hershfield, 1982; Cory and 
Cory, 1994). The nucleoside kinase which is critical for the initial activation of most NAs 
in cancer therapy is dCK. 
Introduction 
____________________________________________________________________________________________________________________________________________ 
3 
 
Many purine- and pyrimidine analogs have been tested for or are currently in clinical use 
in cancer therapy. Purine analogs include 6-mercaptopurine (6-MP), 6-thioguanine, 
cladribine, clofarabine, deoxycoformicin (pentostatin), nelarabine, 9-β-D-
arabinofuranosyladenine (ara-A) and 9-β-D-arabinofuranosyl-2-fluoroadenine 
(fludarabine or F-ara-A). Pyrimidine analogs include 5-fluorouracil (5-FU), capecitabine 
(a 5-FU prodrug), 5-aza-2-deoxycytidine (decitabine), 1-β-D-arabinofuranosylcytosine 
(cytarabine or ara-C), and 2´,2´-difluorodeoxycytidine (gemcitabine or dFdC) (Miser, 
1992; Galmarini, 2002; Hajdo, 2010). Several other nucleoside analogs like sapacitabine 
(CNDAC) and troxacitabine are currently in development or being evaluated in clinical 
trials (Szafraniec, 2004). In their diversity NAs comprise one of the largest classes of 
cancer therapeutics (Parker, 2009). 
NAs often differ from each other or the natural nucleosides they resemble only by small 
modifications like single substitutions (e.g. a halogenation) or sugar isomery (e.g. 
arabinoside NAs) (Figure 1). Despite the structural likeness among NAs there is a 
remarkably high variance in clinical activities between different of these molecules 
(Ewald, 2008). Ara-C and Fludarabine for example are both extensively used in the 
treatment of hematological malignancies, but display little action against solid tumors 
(ara-C against acute lymphoid leukemia [ALL] and acute myeloid leukemia [AML]; 
fludarabine against chronic lymphoid leukemia [CLL], AML or non-Hodgkin lymphoma 
[NHL]))(Chun, 1991). Gemcitabine on the other hand has been found to be effective (as 
a single treatment or together with platinum agents) in the treatment of a number of solid 
malignancies including non-small cell lung cancer, pancreatic cancer, breast and 
bladder cancer, while also displaying some activity against hematological malignancies 
(Jordheim, 2013). 5-FU and its pro-drugs (capecitabine, floxuridine) show activity 
against a number of solid tumor types, including breast, head and neck and most 
notably colorectal cancers (Longley, 2003), but find seldom use against hematological 
malignancies (Pardee, 2012). 
This surprisingly high selectivity of structurally similar drugs may on one hand be 
explained by differences in the uptake, concentration and activation of individual drugs 
in different cellular compartments, and on the other hand by mechanistic differences of 
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their actions. The former conditions can arise from differences in the expression of 
transporters and activating or inactivating enzymes between tissues and lineages. 
Regarding mechanisms of NA cytotoxicity the interference with cellular replication is a 
common denominator between most NAs, but further activities also play a role. These 
include inhibition of RNA synthesis, deregulation of nucleotide pools by inhibition of 
ribonucleotide reductase (RnR), inhibition of nucleotide biosynthesis, induction of 
apoptosis, reduction of DNA methylation and induction of DNA damage (Consoli, 1998; 
McGinn and Lawrence, 2001; Galmarini, 2002; Ewald, 2008; Liu, 2012b).  
We wanted to focus our study on the effects of ara-A and ara-C and the fluorinated 
derivatives fludarabine and gemcitabine (Figure 1). In the following section the cellular 
metabolism and known modes of action of these NAs are summarized.  
 
Figure 1 Chemical structures of selected nucleoside analogs. Structures of deoxyadenosine and 
deoxycytidine and their analogs ara-A, fludarabine, ara-C and gemcitabine.  
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 Cellular metabolism and modes of action of NAs used in this 
study 
1.2.2.1 Ara-A 
Ara-A is a functional analog of deoxyadenosine. that is incorporated into DNA, but not 
RNA (Kufe, 1983). Ara-A differs from deoxyadenosine by having arabinose as sugar 
moiety instead of deoxyribose. Arabinose is an isomere of ribose in which the 2´ 
hydroxyl group on the furanosyl ring is in β instead α configuration (Hubeek I, 2006).  
Adenosine kinase has been implicated as the activating enzyme that performs the initial 
phosphorylation of ara-A within the cell, which is uncommon for NAs (Chan and Juranka, 
1981; Cass, 1983). However, ara-A has also been reported to be a minor substrate for 
dCK and deoxyguanosine kinase (Arner and Eriksson, 1995). Ara-A is quickly 
deaminated by adenosine deaminase (ADA) in cells or plasma resulting in fast 
deactivation (Lepage, 1975; Tanaka, 1984). 
Ara-A effectively inhibits DNA, but not RNA synthesis. In DNA synthesis ara-A is not a 
definitive chain terminator and most ara-A nucleotides are found in internucleotide 
linkages at lower concentrations, while the proportion of ara-A at terminal positions 
appears to increase with rising concentrations (Plunkett, 1974; Muller, 1975; Kufe, 1983; 
Ohno, 1989). It has been demonstrated, that ara-A inhibits the DNA polymerases α 
and β (Dicioccio and Srivastava, 1977). It is also a very potent inhibitor of DNA primase, 
which synthesizes RNA primers during replication and forms a complex with polymerase 
α (Kuchta and Willhelm, 1991). Additionally, ara-A has been shown to inhibit RnR, 
whereby it may modify the balance of nucleotide pools in the cells, which is expected to 
further contribute to inhibition of replication (Moore and Cohen, 1967; Chang and 
Cheng, 1980). 
 
1.2.2.2 Fludarabine 
The development of fludarabine resulted from the search for a deamination resistant 
derivative of ara-A (Montgomery and Hewson, 1969). Fludarabine is not a substrate for 
ADA and thus is metabolically more stable (Brockman, 1977). Fludarabine shares a 
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number of similarities with ara-A regarding its mode of action, but there are also some 
remarkable differences.  
An important difference exists regarding the activation of the two NAs. The initial 
phosphorylation steps of fludarabine and ara-A seem to be catalyzed by different 
enzymatic activities as cells deficient for dCK show strongly increased resistance 
against fludarabine while remaining relatively sensitive to ara-A (Dow, 1980; Cory and 
Cory, 1994). Thus fludarabine, in contrast to ara-A is mainly activated by dCK. 
Like ara-A, fludarabine is incorporated into DNA, but unlike ara-A fludarabine appears to 
be a veritable chainterminator (Huang, 1990). Also unlike ara-A, fludarabine is 
incorporated into RNA (Huang and Plunkett, 1991). Similar to ara-A, fludarabine does 
inhibit the DNA polymerases α and β, as well as DNA primase (White, 1982; Catapano, 
1993). Another mechanism that is likely to contribute to the impact of fludarabine on 
replication is inhibition of Ligase1, which has not been found for ara-A (Yang, 1992). 
Fludarabine has also been shown to inhibit RnR, but to be at least 10 fold as effective as 
ara-A in doing so (White, 1982). 
 
1.2.2.3 Ara-C 
Ara-C, like ara-A, is an arabinoside NA in which the deoxyribose sugar 
(deoxyribofuranose) has been replaced by a β-D-furanosylarabinoside ring (Figure 1). It 
is a structural analog of deoxycytidine. Like other NAs, it needs to be converted to an 
active metabolite upon cellular uptake.  
Transport into the cell is mainly achieved through hENT at plasma concentrations 
achieved during standard treatment (0.5 -1 µM), but mainly occurs by passive diffusion 
at the concentrations of around 100 µM that are achieved during high dose ara-C 
treatment (Early, 1982; Liliemark, 1985; Hubeek I, 2006). The initial step in activation of 
ara-C is phosphorylation by dCK. Through consecutive phosphorylation by mono- and 
diphosphate kinases, Ara-CMP is ultimately converted to the active metabolite ara-CTP.  
Ara-CTP is incorporated into DNA and causes strong inhibition of DNA synthesis. This 
inhibition is thought to be elicited by a mechanism of relative chain termination, since 
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most ara-CMP residues are found in internucleotide linkages (Graham and Whitmore, 
1970), although higher concentrations of ara-C seem to increase the proportion of ara-
CMP nucleotides in terminal positions (Ohno, 1988). Ara-CTP is a weak competitive 
inhibitor of DNA polymerase α and to a lesser extent of polymerase β (Matsukage, 1978; 
Miller and Chinault, 1982). Incorporation of ara-CMP into RNA is barely detectable 
(Kufe, 1980), but there are reports that show inhibition of RNA synthesis by ara-C (de 
Vries, 2006), which may take place by an inhibition of RNA polymerase without requiring 
incorporation (Chuang and Chuang, 1976). Unlike the other NAs used in this study, 
ara-C is not an inhibitor of RnR (Moore and Cohen, 1967). 
 
1.2.2.4 Gemcitabine 
Gemcitabine (2´2´-difluoro-2´-deoxycytidine or dFdC) is a halogenated cytidine analog 
(Hertel, 1988). It is different from most other halogenated NAs in that the fluorine 
substitutions are located on the sugar ring instead of the base. Fluorination renders 
gemcitabine substantially more resistant to deamination than ara-C (Hertel, 1990). 
Similar to other NAs dFdC has to be converted into active metabolites upon entry into 
the cell. The first and rate limiting step is phosphorylation performed by dCK. 
Subsequently gemcitabine is di- and triphosphorylated to dFdCDP and dFdCTP. 
dFdCTP is incorporated into DNA and to a lesser extent also into RNA by cellular 
polymerases (Vanhaperen, 1993). dFdCDP is a potent inhibitor of RnR (Heinemann, 
1990). The resulting depletion of deoxynucleotide pools contributes to replication 
inhibition by gemcitabine. It also represents a self-potentiating mechanism of this drug, 
as reduction of dCTP levels result in increased incorporation of gemcitabine into DNA. 
Another self-potentiating mechanism is inhibition of dCMP deaminase by dFdCTP, an 
enzyme capable of deactivating gemcitabine (Heinemann, 1992). A third self-
potentiating mechanism is present at high concentrations of dFdCTP, which lead to 
inhibition of CTP synthetase. This further contributes to dCTP depletion and the 
accompanying increase of dFdCTP incorporation. Once a gemcitabine nucleotide is 
incorporated into DNA only a single further nucleotide is added to the chain, then 
elongation stops (Huang, 1991). The proofreading function of DNA polymerase ε is 
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essentially unable to remove the incorporated dFdCMP. This mode of disruption of DNA 
synthesis has been termed “masked chain-termination” (Plunkett, 1995). 
The intracellular half-life of Gemcitabine is exceptionally long compared to most other 
NAs (Plunkett, 1995). Long half-life, the unusual mode of chain termination and the 
multiple self-potentiating mechanisms of Gemcitabine may partially explain why it is 
more effective in solid tumors than many other NAs (Shewach DS, 2006). 
 
 Radiotherapy and the effects of Ionizing radiation  
 Tumor and normal tissue response to IR 
Radiotherapy uses IR to efficiently eradicate tumor cells in a localized, non-invasive way 
that also allows the treatment of growths that are difficult to resect. A critical parameter 
limiting the use of radiotherapy is the risk for the occurrence of acute or late side effects 
like erythema and edema or fibrosis in normal tissue. The incidence and severity of such 
side effects depends on radiation dose and the radiosensitivity of the irradiated normal 
tissue. There is a strong correlation between the turnover rate of an irradiated tissue and 
its radiosensitivity (Begonie, 1906). Fast growing tissues like mucosa are very 
radiosensitive, while tissues with low mitotic rates like the central nervous system or 
skeletal muscles are less radiosensitive.  
Similarly, rapidly dividing tumor cells also show higher susceptibility towards killing by IR 
than the surrounding healthy tissue which, depending on the location, usually consists 
mainly of mitotically inactive, terminally differentiated cells (Hall and Giaccia, 2006). This 
connection between growth rate and radiosensitivity forms one of the fundamentals of 
radiotherapy.  
Despite this growth rate dependent difference in radiosensitivity, the total doses that are 
required for curative therapy are so high that they would lead to intolerably high normal 
tissue damage, if administered as a single dose. This was a major problem in the 
beginnings of radiotherapy, and side effects were often severe. Reduction of these side 
effects was and is the main reason to break down the total radiation dose into smaller 
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portions, so called fractions (Connell and Hellman, 2009). Modern external beam 
radiotherapy is given almost exclusively as fractionated radiotherapy. Indeed, the risk for 
side effects can be substantially reduced by fractionation. However, even under these 
conditions side effects are not completely abolished, and the probability of occurrence 
strongly depend on the type of tissue in the radiation field (West and Barnett, 2011). 
Decades of extensive radiobiological research and experiences with fractionation have 
led to the formulation of some key principles, the so called four Rs of radiotherapy 
(Withers, 1975), which try to rationalize the advantages gained by fractionation with 
several distinct, but potentially cooperative mechanisms: repair, redistribution, 
repopulation and reoxygenation.  
Repair refers to the capacity of cells to repair so called sub-lethal damage (SLD) 
between fractions of radiation, which improves their chance of survival. This “R” is the 
factor that led to the initial development of fractionated irradiation schemes, since they 
allow delivery of total doses that would intolerably damage surrounding healthy tissue 
when given as a single dose. It is usually assumed that normal cells repair SLD better 
than tumor cells, resulting thus in a net benefit for the patient.  
Redistribution of irradiated cells in the cell cycle also occurs between fractions. When 
tumor tissue is irradiated, cells are hit in all phases of the cell cycle. Cells show strong 
variations in their radiosensitivity depending on the cell cycle phase they are in. 
Commonly the radioresistance increases during S-Phase and is lowest for cells in M-
Phase (Tamulevicius, 2007). There is evidence that these differences are related to cell 
cycle dependent regulation of the activity of different DSB repair pathways (Rothkamm, 
2003; Tamulevicius, 2007). Upon irradiation cells in sensitive phases of the cycle are 
killed preferentially. Surviving cells in resistant phases progress through the cell cycle 
and reach more sensitive phases, where they can be eradicated more efficiently by the 
subsequent dose fraction.  
Besides redistribution of tumor cells, the allowed intervals between fractions may give 
normal tissues and tumors time to refill their ranks. Inactivation of cells during 
radiotherapy is often compensated by an increase in the mitotic activity of the tumor. 
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This repopulation has to be taken into account and potentially counteracted to ensure 
success of radiation therapy.  
While position in the cell cycle is a cell intrinsic determinant of radiosensitivity, a well-
known cell extrinsic factor for a cell´s susceptibility to killing is the oxygenation status. 
Hypoxic regions of tumors are known to be more resistant to radiation than regions that 
lie close to blood vessels and are therefore well oxygenated. This phenomenon is known 
as the oxygen effect. A popular explanation for this effect is the Oxygen fixation 
hypothesis (Ewing, 1998; Bertout, 2008) that postulates that Oxygen di-radicals can act 
as a fixating agent for DNA lesions induced by IR. After irradiation, cells in better 
oxygenated regions of the tumor will be killed preferentially. Cells located more distant 
from blood vessels can now move in into more oxygen rich regions and become 
oxygenated - or alternatively new blood vessels can form. This development leads to 
reoxygenation of formerly hypoxic cells enabling more efficient killing of cells during later 
fractions. 
The correlation of mitotic activity and susceptibility to killing, as well as the four “Rs” can 
help to explain many of the effects of IR in fractionated radiotherapy – both the beneficial 
action on tumor cells and the partial protection of normal tissue. However, 
radiosensitivity does not only differ between tissues types, but there is also variability 
between the same tissues from different patients and between different tumors of the 
same or similar type (Deacon, 1984; Tucker and Thames, 1989). In cases where growth 
rate and architecture of tissues or tumors under study are similar, differences in 
radiosensitivity have to derive from other factors. These individual differences are 
referred to as intrinsic radiosensitivity (Roberts, 1999; West and Barnett, 2011). Intrinsic 
cellular radiosensitivity has been shown to be an important factor underlying cell killing 
by IR and the radioresponse of tumors (Fertil and Malaise, 1981; Deacon, 1984; Steel, 
1989; Tucker and Thames, 1989; Gerweck, 2006). 
 
 Repair of potentially lethal damage 
In the context of radiobiology cell death refers to the mitotic inactivation of treated cells. 
The sensitivity of cells to killing by IR can be assessed in vitro in clonogenic colony 
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formation assays (Hall and Giaccia, 2006). In these experiments the reproductive 
potential of cells is assessed at the single cell level. Loss of this potential can be realized 
via different routes including mitotic catastrophe, senescence, autophagy, apoptosis or 
necrosis (Balcer-Kubiczek, 2012). The contribution of these mechanisms or pathways to 
cell killing differs among cells and depends on factors like cell type and radiation dose 
(Puck and Marcus, 1956; Held, 1997). Apoptosis as an immediate response to radiation 
(interphase death) for example plays a decisive role only in a small number of cellular 
systems, e.g. lymphocytes (Ross, 1999). Mitotic catastrophe is considered to be a main 
route to cell death after IR in most systems, but may not be a genuine pathway of cell 
death itself. Instead cells running into mitotic catastrophe may eventually die, i.e. cease 
to proliferate, by any of the other pathways mentioned above (Galluzzi, 2012). 
Analysis of cells exposed to increasing doses of IR yield characteristic survival curves 
(Figure 2). Various treatments or conditions can result in modification of the 
radiosensitivity of cells in this assay, e.g. the oxygenation status (see above). Post-
treatment conditions that can modify the survival of irradiated cells are assumed to exert 
their effects through either repair or fixation of damage that is only potentially lethal 
(Phillips and Tolmach, 1966) (Little, 1969; Iliakis, 1988a). 
A classic experiment can be performed with cells in the plateau, or stationary phase, of 
growth. When these cells are irradiated they can be plated as single cells in fresh growth 
medium either immediately after irradiation (immediate plating) or at increasing periods 
of time after irradiation (delayed-plating). Plating in fresh, serum supplemented growth 
medium results in the re-entrance of cells into the cell cycle and their progression 
through S-Phase, which is also a prerequisite for colony formation. Delayed plating 
occasionally has a profound impact on the survival of cells. Cells that are plated 
immediately after irradiation exhibit the lowest survival levels. If plating is delayed for 
longer times (e.g. 6-24h) the cells display more radioresistance (Figure 2). This 
phenomenon is ascribed to the repair of potentially lethal damage (PLD). Incubation of 
cells in their resting state apparently allows the repair of some PLD which is inhibited 
when cells are stimulated to reenter the cell cycle by immediate plating. 
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This experimental setup can be used to test a condition or treatment, e.g. incubation 
with a drug, for its potential to interfere with the repair of PLD by its ability to prevent the 
increase in survival normally associated with delayed plating. A variety of treatments has 
been identified that are able to inhibit repair of PLD. Notably, these include NAs like 
ara-A (Figure 2). When this approach is used, repair of PLD and its inhibition is 
measured in non-cycling cells. However, PLD repair also occurs in actively cycling cells 
and is assumed to contribute to the cell cycle dependent fluctuations in radiosensitivity 
to killing (Iliakis and Nusse, 1983b; Stamato, 1988). Similarly, differences in the intrinsic 
radiosensitivity of cells can be interpreted as differences in their capability to repair PLD. 
The precise molecular nature of the lesion/s underlying PLD remains to be fully 
characterized. 
 
Figure 2 Repair of potentially lethal damage. Survival curves of plateau-phase cells plated either 
immediately (IP) or after prolonged incubation in the plateau-phase (DP) after irradiation. Also shown 
is the survival of cells treated with ara-A at concentrations that cause maximum fixation of PLD 
during incubation in plateau-phase before delayed plating,  
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In order to understand the repair or fixation of which type of lesion/s may underlie 
phenomena like the fluctuations of radiosensitivity during the cell cycle, intrinsic cellular 
radiosensitivity and PLD repair it is necessary to take a look at the physical mechanisms 
of damage induction by IR and the associated cellular responses on a molecular level. 
 
 Basic physics of the interaction of IR with biological matter 
Damage to the DNA is the source for the prominent biological effects that can be 
observed after exposure to IR. These effects include mutation, chromosome aberration, 
neoplastic transformation, mitotic inactivation and cell death. IR is particularly efficient in 
inducing lesions that lead to the formation of chromosome aberrations. Excellent 
correlations have been found for the induction of chromosome aberrations and cell 
killing as well as the repair of chromosome breaks and PLD repair (Carrano, 1973; Virsik 
and Harder, 1980; Cornforth and Bedford, 1987). 
Ionizing radiation (IR) is highly energetic radiation that is characterized by its potential to 
expel electrons from atomic shells or chemical bonds. The different types of IR that exist 
can be categorized into particulate and electromagnetic radiation. Particulate IR includes 
α (Helium nuclei) and β (electrons) radiation, as well as any other particle that carries 
sufficient kinetic energy to ionize other atoms (e.g. accelerated neutrons, protons or 
heavy Ions). X-rays and γ-rays represent the electromagnetic forms of IR. Since all 
experiments in this work were exclusively carried out with X-rays we will focus mostly on 
this form of radiation. 
X-rays consist of high energy photons that can ionize atoms as a consequence of 
interactions with orbital electrons. At photon energies that are used in radiation therapy 
(200 keV to 25 MeV) a process called Compton scattering is the predominant interaction 
process in soft tissue (Hall and Giaccia, 2006). When this type of interaction takes place, 
only part of the photon’s energy is absorbed by the interacting electron, resulting in 
expulsion of the electron from its shell. The remaining energy is carried away by a 
scattered photon. Electrons that have been liberated by interaction with a photon travel 
through the surrounding medium and can cause further ionizations. Those electrons (as 
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well as those produced by further interactions) are often referred to as secondary 
electrons, despite the fact that they represent the product of the primary ionization event. 
Secondary electrons account for the vast majority of ionizations caused by 
electromagnetic IR, which is thus considered as indirectly ionizing radiation. Since most 
of the energy is deposited in a disperse pattern, X-rays are also considered to be a 
sparsely ionizing radiation. This is in contrast to the pattern of energy deposition of 
radiation types like alpha particles or neutrons, which produce dense ionization tracks 
(Figure 3). 
A measure for the density of ionizations generated by a particular form of radiation is 
provided by the physical quantity: linear energy transfer (LET [keV/µM]). Thus, sparsely 
ionizing radiations are often also referred to as low LET and densely ionizing radiations 
as high LET radiation. However, secondary electrons induced by X- or γ-rays lose 
energy during the interactions along their track. With decreasing velocity the interaction 
probability of such electrons increases. This causes an increase in LET associated with 
clustering of ionizations especially at the ends of their tracks (Goodhead, 1994). 
 
Figure 3 DNA damage induction by low and high LET radiation tracks.  Ionization events caused by 
IR localize along radiation tracks and can induce clustered damage at the DNA. With increasing LET the 
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probability for DNA damage clustering increases. Large dots represent ionizations and small dots 
represent excitations along the radiation track. The Monte Carlo simulated tracks are drawn on the same 
scale as the DNA. (modified from (Schipler and Iliakis, 2013))  
 Mechanisms of DNA damage induction and types of DNA lesions 
induced 
Ionization of atoms that take part in a molecular bond can result in the formation of free 
radicals. Radicals are highly reactive, short lived chemical species characterized by an 
unpaired valence electron. Production of radicals can take place directly in the target 
molecule (i.e. the DNA), which would be considered as direct effect. However, since a 
cell is composed of water to approximately 70% (Alberts, 2008) the majority of radicals 
generated initiate from H2O (e.g. hydroxyl radicals). Consequently the majority of DNA 
damage induced by sparsely ionizing radiations is due to the indirect effect exerted by 
water produced free radicals. Due to the short life time of free radicals the probability of 
interaction with DNA is only significant when the radical forms in close proximity to the 
DNA molecule. The spectrum of chemical modifications induced in the DNA by radiation 
is highly divers and includes oxidative damage to bases and sugars, cross-links between 
bases or between DNA and proteins and breaks in the sugar phosphate backbone. 
Breakage of the sugar phosphate backbone on both strands of the double helix within a 
couple of nucleotides will lead to the formation of a double-strand break (DSB). 
Accumulation of ionizations in small volumes, as it occurs at the end of secondary 
electron tracks, increases the likelihood of the induction of multiple damages in short 
sequence stretches. Such sites of accumulated damage are being referred to as multiply 
damage sites or clustered DNA damage. Clustering of ionizations increases the 
probability of induction of two or more single-strand breaks (SSB) in close proximity, 
thereby increasing the chances for the generation of a DSB. However, DSB are not a 
uniform class of damage. Instead the term subsumes a variety of chemically different 
entities, which will be briefly reviewed in the next paragraphs. 
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Figure 4 Types of DSB with different levels of complexity A) DSB induced by a RE with a 5`-phosphate 
and a 3`-OH group. B) DSB induced by IR frequently comprise a 3` phosphoglycolate and a 5’-OH. C) DSB induced 
by IR that comprises also other types of lesions like base damages or base loss in close proximity to the DSB. D) 
Clusters of multiple DSBs. Two examples are shown: On the left, a single radiation track induces two DSBs in the 
linker regions of a nucleosome leading to loss of the nucleosome. On the right, a higher order packaging of 
nucleosomes is illustrated. Chromatin loops can be severed by a single radiation track if hit appropriately. (modified 
from (Schipler and Iliakis, 2013)) 
 
 Different types of DSB and damage complexity 
The simplest type of DSB that can be envisaged is the one induced by a restriction 
endonuclease (Figure 4 A). No further damage is involved and the ends of the DSB are 
equipped with intact 3´-OH and 5´-phosphate groups that can readily be religated. 
However, this type of clean break cannot be expected to be found after exposure to IR. 
Instead, DSB induced by IR usually contain modified ends, e.g. 5´-OH and 3´-
phophoglycolate groups, as illustrated in Figure 4 B. In addition, for a proportion of DSB 
induced by IR further types of damage are to be expected in the vicinity of the break 
(Figure 4 C). DSB in conjunction with additional DNA lesions are usually referred to as 
complex DSB. An additional level of complexity can be added by clustering of multiple 
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DSB, which may lead to loss of nucleosomes or entire chromatin domains (Schipler and 
Iliakis, 2013). The list of different DSB types presented here is by no means complete 
and is further complicated by the existence of indirect DSB that can develop from IR-
induced non-DSB lesions by enzymatic processing or thermal evolution (Singh, 2009; 
Singh, 2013). Computational modelling yields distinct ratios for various DSB types as a 
function of radiation quality. In general, with increasing LET of radiation the complexity of 
damage induced in the DNA increases (Nikjoo, 1999; Friedland, 2012). Importantly, 
cellular survival decreases with increasing LET (Figure 5). These observations create a 
close link between DSB, damage complexity and cell killing. 
 
Figure 5 Survival curves for cultured cells of human origin  Human cells were exposed to 250 kV X-
rays, 15 MeV neutrons and 4 MeV α-particles. Survival curves obtained with neutrons and alpha rays 
have steeper slopes and a smaller initial shoulder than curves generated with x-rays. (modified from (Hall 
and Giaccia, 2006)) 
DSB threaten the integrity of chromosomal DNA and undermine the fundamental 
principle of DNA repair as both strands of the helix are disconnected and no intact 
strand is available for repair. In contrast, SSB or base damages don´t compromise the 
continuity of the DNA molecule and the complementary strand of the double helix can 
serve as repair template. Although conceptually the repair of DSB is particularly difficult, 
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actually recognition and repair of DSB is in higher eukaryotic cells faster and more 
efficient than of many other DNA lesions (Eriksson, 2007; Schipler and Iliakis, 2013) 
(see also Figure 6). Cells have evolved elaborate mechanisms to correct and repair 
DSB. However, complex DSB consisting of multiple different types of damage pose 
particularly demanding challenges to the cellular repair machinery. The involvement of 
several steps of processing and the potential participation of multiple pathways of DNA 
repair is likely to be associated with a higher risk of accidents. It is now widely believed 
that the induction of complex DSB is a key aspect of IR, underlying the effective 
induction of chromosomal aberrations and cell killing (Goodhead, 1994; Schipler and 
Iliakis, 2013). The chemical nature of a DSB and its complexity may also be factors 
participating in the determination of repair pathway choice. In the following paragraphs 
the key events of the cellular response to DSB induction will be described 
 
Figure 6 Repair kinetics of different forms of DNA damage  Shown is the kinetics of removal of SSBs, 
DSBs, 6–4 photoproducts (6–4PP), cyclobutane pyrimidine dimers (CPD) from CHO-AA8 cells. Kinetics of 
N7-meG comes from measurements in human lymphocytes. (from (Schipler and Iliakis, 2013)) 
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 Cellular responses to DSB 
 DSB detection and signaling- The DNA damage response 
Induction of a DSB initiates a cascade of posttranslational protein modifications (PTMs) 
that signal to the cellular repair and cell cycle control machineries (Grabarz, 2012). The 
events elicited by this DNA damage response (DDR) include changes in chromatin, in 
gene expression, the relocation of a large number of proteins, the regulation of DNA 
repair and the activation of cell cycle checkpoints (Bekker-Jensen and Mailand, 2010). 
The molecular components of the DDR can be categorized into damage sensors, 
transducers, mediators and effectors. The recruitment and activation of factors involved 
in DDR follows a hierarchical order beginning with the recognition of DSB. Candidates 
for the function of primary damage sensors are the MRE11-RAD50-NBS1 complex 
(MRN), the KU70/KU80 heterodimer (KU) as well as the Poly(ADP-ribose) polymerases 
1 (PARP1) (Wang, 2006b; Polo and Jackson, 2011). All of these proteins and 
complexes are capable of binding to DSB ends and are among the first proteins that 
recruited to the breaks (Polo and Jackson, 2011) (Figure 7). The MRN complex can 
tether DSB ends by binding with its globular domains comprised of the dimerized RAD50 
and MRE11 subunits (Lavin, 2007; Williams, 2008). KU is highly abundant in the cell and 
displays extraordinarily high affinity for dsDNA end. PARP1 becomes directly activated 
by binding to DNA breaks and start to poly(ADP-ribosylate) substrate proteins (D'Silva, 
1999; Kun, 2002). Any of those putative damage sensors is also strongly implicated in 
other processes related to DNA repair, e.g. DNA end-resection (MRN), non-homologous 
end-joining (KU) and SSB repair (PARP). Most models in the literature ascribe the role 
of the major DSB sensor to MRN, although KU and PARP1 arrive earlier at breaks and 
MRN recruitment is modulated by PARP1 (Haince, 2008; Polo and Jackson, 2011).  
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Figure 7 Recruitment kinetics of proteins involved in the DDR Sequential recruitment of DDR factors to SSBs 
and DSBs generated by laser microirradiation. (from (Polo and Jackson, 2011)) 
 
On the next hierarchical level, the role of the signal transducers is taken by three 
members of the family of phosphatidylinositide 3-kinase related kinases (PIKKs). Among 
those the ataxia telangiectasia mutated kinase (ATM) has emerged as a master kinase 
in IR induced DDR signaling. ATM is activated in response to DSB in a MRN dependent 
manner (Uziel, 2003). In its inactive form ATM persists as a dimer in the cell, which 
dissociates upon intermolecular autophosphorylation at Serine 1981 (pS1981) in 
response to DSB (Bakkenist and Kastan, 2003). The DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) is another member of the PIKK family that becomes 
activated in response to DSB. Together with KU it forms the DNA dependent protein 
kinase (DNA-PK) that plays a central role in the non-homologous end-joining pathway of 
DSB repair. It is capable of phosphorylating a number of important targets involved in 
DSB signaling, repair and chromatin structure, but possesses a substantially smaller 
substrate spectrum than ATM (Stiff, 2004; Tomimatsu, 2009). ATM and Rad3 related 
kinase (ATR) is a further PIKK involved in the DDR. ATR becomes not directly activated 
by DSB, but by single-stranded DNA (ssDNA). In conjunction with its partner ATRIP it 
binds to ssDNA coated with replication protein A (RPA). Thus, ATR activation in 
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response to DSB requires the resection of 5” strand of the dsDNA at the end of the 
break. Resection of DSB ends again is tightly regulated and highly depending on the cell 
cycle phase, as is explained in more detail below (1.4.2.3). 
A number of mediator proteins help to maintain and amplify the signaling that is initiated 
by the transducer kinases. One of the first posttranslational modifications in response to 
a DSB is phosphorylation of the histone variant H2AX, on Serine 139. This 
phosphorylation can be mediated by ATM and DNA-PKcs and likely also by ATR (Stiff, 
2004; Ward, 2004; Wang, 2005c). In its phosphorylated form the histone variant is 
termed γH2AX (Rogakou, 1998). γH2AX spreads to both sides of the DSB covering the 
region around the break up to a length of a few megabases (Nakamura, 2010). It 
provides a binding platform for the mediator of DNA damage checkpoint protein 1 
(MDC1) (Stucki, 2005). MDC1 constitutively interacts with the MRN complex (Spycher, 
2008) and can also interact with ATM. Thereby, MDC1 binding to γH2AX leads to 
accumulation of these factors around DSB and contributes to stabilization and 
amplification of the damage signal. Phosphorylation of MDC1 by ATM also leads to the 
recruitment of the E3 Ubiquitin Ligase RNF8, which elicits ubiquitylation of a number of 
targets, including the histones H2A and H2AX. This in turn leads to the recruitment of 
RNF168, another E3 Ligase that mediates the polyubiquitylation of H2A (Bohgaki, 
2010). Together these ubiquitylations have been implicated in the recruitment of BRCA1 
and 53BP1, factors that play important roles in DSB repair pathway choice by regulating 
the resection of DSB ends (Stewart, 2009; Bunting, 2010; Escribano-Diaz, 2013).  
The multiple PTMs and accumulations of proteins at damage sites that are part of the 
DDR can be visualized by immunofluorescence staining and microscopy. Staining with 
antibodies against γH2AX, MDC1, ATM-pS1981, 53BP1 and many other proteins 
involved in the DDR and DSB repair reveals a pattern of focal protein accumulations in 
the nuclei of cells after exposure to IR. Measurement of induction and decay of these IR 
induced foci (IRIF) has been used extensively to investigate mechanisms and kinetics of 
DSB signaling and repair. 
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Figure 8 Simplified schematic of the cellular response to DSB  Induction of a DSB triggers a complex 
cascade of events that results in signaling to the cellular DNA repair machinery and cell cycle checkpoint 
control. (modified from (West and Barnett, 2011)) 
 
One of the central functions of DDR is to cause cell cycle arrests that prevent cells with 
damaged genomes from progressing into subsequent phases. The pathways that elicit 
these arrests or delays in the progression through the cycle are called checkpoints. The 
main effectors of cell cycle checkpoints are the checkpoint kinases CHK1 and CHK2. 
ATM and Chk2, as well as ATR and CHK1 form two signaling modules that primarily 
coordinate checkpoint activation in response to DNA damage (Reinhardt and Yaffe, 
2009). Both pathways converge on members of the CDC25 family of phosphatases. 
Inactivating phosphorylations placed on CDC25 by CHK1 and CHK2 prevent the 
removal of inhibitory phosphorylations on CDK/cyclin complexes that are critical for cell 
cycle progression. In addition, CHK2 phosphorylates p53 in response to DNA damage 
thereby contributing to the stabilization of this protein and the development of a G1 
arrest (Chehab, 2000). Activation of p53 can also trigger the activation of apoptotic 
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pathways; however apoptosis plays an important role as a response to IR only in some 
cell systems (see below). The action of CHK1 on the other hand can arrest cells at the 
G2/M border via phosphorylation of CDC25C. DNA damage checkpoints prevent cells 
with excessive genetic damage from progressing through the cycle and thereby 
contributing to genomic stability. By halting cells in the current phase of the cell cycle, 
checkpoints provide time to the cellular repair machinery to deal with existing DNA 
lesions. In the following paragraphs the pathways of DSB repair are briefly described. 
 
 Mechanisms of DSB Repair in Eukaryotes 
1.4.2.1 A short overview of DSB repair pathways 
It is important to note that DSB and other DNA damages don´t occur only as a product of 
exogenous insults like IR, radiomimetic drugs or topoisomerase inhibitors. The genome 
of a cell is in constant need for maintenance and repair due to attack by byproducts of its 
own metabolism, thermodynamic degradation of DNA or replication accidents. In 
addition DSB can be induced in a programmed manner by the cell as part of scheduled 
processes like the generation of antibody diversity (V(D)J recombination) or meiotic 
recombination. As a consequence eukaryotic cells have developed highly effective 
mechanisms for the management of DSB. Classically, the spectrum of DSB repair 
mechanisms is divided into two main categories: non-homologous end-joining (NHEJ) 
and homologous recombination repair (HRR). NHEJ operates throughout the cell cycle 
and rejoins the free ends of DSB with fast kinetics (Mao, 2008). NHEJ frequently 
introduces sequence alterations at the joints it generates. The chemical nature of DSB 
induced by IR usually necessitates some processing in order to generate ligatable ends 
(see Figure 4). In the case of repair by NHEJ loss or gain of bases at the molecular 
junction is the consequence of this processing. HRR on the other hand uses the intact 
sequence on a sister chromatid as template to faithfully restore the sequence around the 
break. The requirement of HRR for the availability of already replicated, homologous 
sequences restrict this repair pathway to the S- and G2- phases of the cell cycle. Since 
this type of repair involves search for homology, more extensive processing and 
synthesis, as well as the resolution of intermediary structures it is considered a slow 
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process in comparison to NHEJ. More recently other repair pathways, with varying 
fidelity and requirements for homology, have emerged diversifying the simplistic 
classification outlined above. Most notably, alternative pathways of NHEJ acting as 
backup (B-NHEJ) for the classical, DNA-dependent protein kinase (DNA-PK) dependent 
pathway of NHEJ (D-NHEJ), have been described. Next to different modes of HRR an 
additional homology directed repair process, single-strand annealing, exists as well, 
which uses intra-molecular homologies to seal DSB.  
Although there is common consent that the majority of breaks are handled by D-NHEJ if 
this pathway is not compromised, an important contribution of HRR to the repair of DSB 
and the maintenance of genomic stability is undisputed as well. Importantly, there is a 
large body of evidence that suggests that HRR is the mechanism that underlies the S-
Phase dependent radioresistance that can be observed in proficient cell lines (Iliakis and 
Nusse, 1983a; Wang, 2003b; Wang, 2004a). How the decision is made for a particular 
DSB to be repaired by one of the available pathways remains largely unknown, but may 
involve factors like lesion complexity or radiation dose. The most important DSB repair 
pathways and sub-pathways are described in more detail below.  
 
1.4.2.2 D-NHEJ 
D-NHEJ is considered to be the dominant pathway of DSB repair in mammalian cells, in 
contrast to yeast, where the dominant repair pathway is HRR (Mansour, 2008; Mao, 
2008; Weterings and Chen, 2008). As indicated by its designation, it is dependent on the 
DNA-PK complex. This consists of the KU70/KU80 heterodimer (KU) and the large 
DNA-PK catalytic subunit (DNA-PKcs). Unlike most other factors involved in D-NHEJ, 
DNA-PKcs is not found in yeast and many other lower eukaryotes and is also absent in 
prokaryotes. This makes it tempting to speculate, that the development of the extremely 
fast and efficient form of NHEJ that is found in higher eukaryotes today was made 
possible by this evolutionary new protein. KU is a highly abundant protein in mammalian 
cells that binds with strong affinity to free DNA ends. Binding of KU to DNA ends results 
in the recruitment of DNA-PKcs (Mladenov and Iliakis, 2011). This in turn leads to 
phosphorylation of multiple targets upon formation of the active holoenzyme, including 
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DNA-PKcs itself (Figure 9). These phosphorylations are an important step for the 
progression of the NHEJ process, and autophosphorylation of DNA-PKcs is believed to 
elicit conformational changes that allow for further steps to take place. Various factors 
like the polymerases µ and λ (Pol µ, Pol λ), the Artemis nuclease, terminal 
deoxynucleotidyl transferase (TdT) and polynucleotide kinase (PNK) are implicated in 
processing of DSB ends prior to rejoining by D-NHEJ (Mladenov and Iliakis, 2011). End 
processing by D-NHEJ usually stays limited as it only serves the cause of creating 
ligatable ends. Thus the extent of loss or addition of bases at junctions formed by D-
NHEJ is usually relatively small (Lieber, 2010). The final ligation step is carried out by 
DNA Ligase IV (LIG4) aided by its interaction partners XRCC4 and XLF/Cernunnos 
(Figure 9).  
Since D-NHEJ lacks a built-in mechanism to preserve the original sequence around the 
break site it is usually regarded as an error-prone repair process. Disregarding this error 
proneness, D-NHEJ is not an adverse process for the cell. On the contrary D-NHEJ is 
highly important for survival after irradiation and plays a crucial role in maintaining 
genome integrity and stability (Burma, 2006). Several arguments are conceivable to 
explain how it could have been advantageous for cells of higher eukaryotes to let an 
error prone repair pathway evolve to become the dominant mechanism of DSB repair. 
One might be that for large vertebrate genomes, which are rich in non-coding and 
repetitive sequences, there is a net-benefit in having an extremely fast pathway of DSB 
rejoining that quickly removes breaks before other accidents may occur, even if it comes 
at the cost of an elevated but manageable mutation rate. It is also possible that this 
beneficial role of D-NHEJ arises from suppression of other, more error prone pathways. 
Indeed, despite the conceptual capacity of D-NHEJ to rejoin unrelated ends it has been 
reported that components of the D-NHEJ pathway actively participate in suppressing 
chromosomal translocations (Simsek and Jasin, 2010). 
Other nomenclature like “classical” or “canonical” NHEJ (cNHEJ) have been brought 
forward to name this repair pathway and discriminate it from alternative B-NHEJ 
pathways. In this work the term D-NHEJ will be used to refer to this pathway.  
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Figure 9 Schematic overview of key factors and steps of D-NHEJ  D-NHEJ efficiently restores 
genomic integrity without ensuring sequence restoration. Association of Ku to DNA ends facilitates the 
recruitment of DNA-PKcs, a major kinase activated by DNA ends and contributing to the efficiency of this 
repair pathway. DNA-PKcs promotes end-processing by the Artemis nuclease and subsequent rejoining of 
broken DNA ends by the LigIV/XRCC4/XLF complex. (from (Mladenov and Iliakis, 2011)) 
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1.4.2.3 HRR 
HRR is the other main pathway of DSB repair in mammalian cells (Liang, 1998). In 
contrast to D-NHEJ, HRR by design faithfully restores the sequence to its original state. 
To achieve this goal it has to recover this information from an intact template molecule, 
which in the case of mitotic HRR is the sister chromatid. Intact sister chromatid 
sequences only start to become available with progression of DNA replication during S-
phase. Thus, contrary to D-NHEJ HRR is a highly cell cycle dependent process. This 
dependence is not only determined by the presence of sister chromatids themselves, but 
is also tightly regulated through multiple PTMs that prevent crucial steps of HRR to 
occur outside its appropriate time window (Heyer, 2010; Mladenov, 2013). For HRR to 
commence an essential step is the creation of a long single-stranded 3´-overhang that 
can be used to find homology in an annealing based process. This 3´-overhang is 
created through nucleolytic resection of the 5´-end of the break (Symington and Gautier, 
2011). Resection of DNA ends is tightly regulated in a cell cycle phase dependent 
manner and is restricted to the S and G2 phase (Huertas, 2010). Thereby the regulation 
of end-resection is likely to be one of the main determinants of the cell cycle specific 
constrain of HRR mentioned earlier (Ira, 2004). A key mechanism of the control of end 
resection is the balance between the actions of two proteins antagonizing each other: 
53BP1 and BRCA1 (Bunting, 2010).  
The opposing roles of these two proteins are impressively illustrated by a phenotype of 
“synthetic viability” in mice. Mice with a certain BRCA1 mutation display mid-gestational 
lethality. When these mice are placed in a 53BP1 deficient background this lethality is 
rescued (Cao, 2009). It has been shown that 53BP1 inhibits end resection, via its 
effector RIF1, thereby inhibiting HRR (Bunting, 2010; Escribano-Diaz, 2013). BRCA1 on 
the other hand promotes end resection, thereby favoring HRR over D-NHEJ (Bouwman, 
2010; Bunting, 2010). This end resection promoting activity depends on interaction of 
BRCA1 with CtIP and the MRN complex (Chen, 2008). This interaction in turn is 
regulated by phosphorylation of CtIP on Serine 327, which is executed by CDKs in the S 
and G2 phase (Yu and Chen, 2004). Thus, in G1 53BP1 prevents end-resection, 
prohibiting HRR. However, when cells progress into S and G2 the phosphorylation of 
CtIP bestows BRCA1 with the power to alleviate the inhibition exerted by 53BP1 and to 
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stimulate end resection. Although important, the phosphorylation of CtIP is not the only 
mechanism that supports end-resection in S and G2, but is complemented by a plethora 
of further cell cycle dependent PTMs of various proteins (Mladenov, 2013). Once a 
stretch of single-stranded DNA (ssDNA) has formed it will be coated with the hetero-
trimeric replication protein A complex (RPA). Coating with RPA prevents further 
degradation and formation of intramolecular secondary structures (Eggler, 2002). 
However, for HRR to progress RPA has to be displaced by RAD51, the central 
recombinase protein in HRR. This process is mediated by the BRCA2 (breast cancer 2, 
early onset) protein (Yang, 2005; San Filippo, 2008). RAD51 forms a helical 
nucleoprotein filament with ssDNA that is capable of searching for homologous 
sequences and invasion of another double-stranded DNA (dsDNA) molecule 
(Raderschall, 1999; Aly and Ganesan, 2011). Besides core factors like RAD51 and 
BRCA2 many other factors participate in or facilitate these intricate reactions. These 
include the members of the RAD52 epistasis group (RAD50, RAD52, RAD54, MRE11), 
the RAD51 paralogs (RAD51B, C, D and XRCC2 and XRCC3) and CtIP the mammalian 
Sae2 homolog (San Filippo, 2008; Huertas and Jackson, 2009; Heyer, 2010). Strand 
invasion leads to formation of a structure called the displacement loop (D-loop). The 3´-
end of the invading strand serves to prime DNA synthesis using the homologous 
sequence as template. Afterwards, depending on several factors, repair by homologous 
recombination can take several routes:  
In the synthesis dependent strand annealing (SDSA) sub-pathway the invading strand is 
simply disengaged from the donor duplex after DNA synthesis is completed and re-
anneals with the complementary strand on the opposing side of the break. Gaps are 
filled-in by another round of DNA synthesis and the remaining nicks are finally ligated 
(Figure 10). 
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Figure 10 Steps and outcomes of homology directed repair pathways.  Protein names refer to the 
budding yeast Saccharomyces cerevisiae (blue). Where different in human, names (brown) are given in 
brackets. For proteins without a yeast homolog, brackets for human proteins are omitted. Broken lines 
indicate new DNA synthesis and stretches of heteroduplex DNA. Abbreviations: BIR, break-induced 
replication; dHJ, double Holliday junction; LOH, loss of heterozygocity; SDSA, synthesis-dependent strand 
annealing; SSA, single-strand annealing. (modified from(Heyer, 2010)) 
 
In the double Holliday junction sub-pathway the second end of the DSB is captured by 
the displaced strand and elongated using the latter as a template. After DNA synthesis is 
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completed on the originally invading strand it is ligated with the 5´-prime end at the 
opposite side of the break. In this way a complex structure called a double Holliday 
junction (dHJ) is formed. Nucleolytic incision is required to resolve this structure and 
several enzymatic activities, like the Bloom’s helicase (BLM) and the Mus81/Eme1 have 
been implicated in this process. Resolution of a dHJ can be achieved in several ways 
and can yield crossover or non-crossover products (Figure 10). DNA synthesis as it 
occurs during SDSA or dHJ HRR is limited to a few hundred bases, in contrast to BIR 
where much longer sequences are synthesized de novo. 
Recently, in a collaborative effort of our laboratory with the group of Thanos Halazonetis, 
it could be demonstrated that the BIR pathway is important for genomic stability under 
conditions of DNA replication stress (Costantino, 2014). In yeast BIR has been 
characterized as the pathway that repairs one-ended DSB arising when replication forks 
collapse. This frequently occurs in cells that suffer from replication stress, as it is 
prevalent in cancer as well. A one-ended DSB cannot be repaired by a joining 
mechanism. Instead in BIR the break end is used to prime new long range DNA 
synthesis up to the end of the chromosome after strand invasion (Malkova, 2001; Davis 
and Symington, 2004; Malkova, 2005)(Figure 10). In this way sequences of 100 kB or 
more can be synthesized in yeast. BIR requires most essential replication factors as well 
as the non-essential Polδ subunit Pol32/POLD3 (Wang, 2004c; Lydeard, 2007; Lydeard, 
2010). Still, DNA synthesis during BIR does not seem to include assembly of a 
conventional replication fork. Instead, DNA is replicated in a conservative manner, by a 
migrating bubble mechanism accompanied by continuous lagging strand synthesis 
(Donnianni and Symington, 2013; Saini, 2013). In yeast this mechanism has been 
associated with extensive loss of heterozygosity (LOH), formation of non-reciprocal 
translocations, inversions and tandem duplications (Smith, 2007; Payen, 2008; Ruiz, 
2009; Mizuno, 2013). We could show that in a human model of replication stress these 
rearrangements are induced and that their frequency is reduced after silencing of the 
essential BIR factor POLD3 (Costantino, 2014).  
It is intriguing that HRR, while being the principal pathway in bacteria and lower 
eukaryotes and also the only truly faithful DSB repair process available, seems to have 
been pushed to the background by the emergence of D-NHEJ in higher eukaryotes. A 
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possible rationalization for this observation would be that HRR is not such an error-free 
process as it may appear at first glance. While it is true that HRR is the only process that 
can reliably accomplish the faithful restoration of sequence at complex DSB, there is 
also potential danger associated with this process. The human genome contains a high 
amount of shorter and longer repetitive sequences. These include so-called segmental 
duplications or low copy repeats, which can serve as targets for non-allelic homologous 
recombination (NAHR). The presence of such sequences may have made it favorable to 
exert a tighter control about homology directed repair. Indeed several syndromes exist 
that arise due to NAHR during meiosis (Liu, 2012a). NAHR is believed to be restricted to 
gametogenesis in mammals. However, this may be a consequence of the cell cycle 
specific regulation of HRR. If HRR was unleashed in G1/G0 cells, it would have to resort 
to the use of either the homologous chromosome or dispersed sequence duplications as 
recombination substrates. The first would result in LOH, the latter in NAHR (Carr and 
Lambert, 2013). 
HRR has gained a lot of attention as a target for radiosensitization recently (Mladenov, 
2013). A number of compounds that interact more or less directly with the DNA repair 
machinery or checkpoint and cell cycle control mechanisms (Asaad, 2000; Bohm, 2006; 
Morgan, 2010; Takagi, 2010; Meike, 2011; Prevo, 2012), as well as multiple treatments 
with less obvious connections to this repair pathway have been shown to elicit 
radiosensitization by inhibition of HRR (Chinnaiyan, 2005; Noguchi, 2006; Adimoolam, 
2007; Murakawa, 2007; Li, 2008; Choudhury, 2009). 
 
1.4.2.4 B-NHEJ 
To date the description of back-up mechanisms of NHEJ remains incomplete, although 
an increasing number of proteins is emerging that may play roles in non-homologous 
DSB repair processes in the absence of D-NHEJ. Other nomenclature than B-NHEJ has 
been proposed to describe these processes, including alternative end-joining (A-EJ), 
alternative non-homologous end-joining (A-NHEJ) or microhomology mediated end-
joining (MMEJ). B-NHEJ has been initially described based on the observation that 
mutant cell lines deficient in components of the main D-NHEJ machinery - although 
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severely impaired in the fast rejoining of DSB - are still capable of repairing DSB and 
eventually rejoin almost all breaks after prolonged repair times (Nevaldine, 1997; 
Kabotyanski, 1998; Wang, 2001b; Wang, 2003a; Iliakis, 2004). Defects in HRR did not 
influence residual repair suggesting that another mechanism of NHEJ, acting as a back-
up for D-NHEJ, was at work (Wang, 2001a).  
Later studies showed the participation of alternative pathways of NHEJ in physiological 
processes, like the generation of antibody diversity through V(D)J recombination 
(Verkaik, 2002; Corneo, 2007), or in class switch recombination (Soulas-Sprauel, 2007; 
Yan, 2007), when the classical DNA-PKcs dependent NHEJ was inactivated.  
There is evidence that B-NHEJ has an increased preference for the usage of short 
sequence homologies (so called microhomologies) for the formation of joints (Roth and 
Wilson, 1986; Bogue, 1997; Kabotyanski, 1998), but it is not absolutely dependent on 
them (McVey and Lee, 2008; Fattah, 2010; Mansour, 2010). Typically, homologies <5bp 
sometimes <10bp are defined as microhomologies. It has been reported that 
microhomology mediated B-NHEJ events benefit from resection of DNA ends (Xie, 
2009; Bothmer, 2010; Lee-Theilen, 2011; Symington and Gautier, 2011). This is not 
surprising considering that resection would be a prerequisite for detection and annealing 
of homologous sequences. Nevertheless, many B-NHEJ mediated junctions harbor 
large deletions without showing microhomology signature, even when microhomology 
would have been available. This suggests that end-resection plays a more general role 
in B-NHEJ than to purposefully reveal microhomologies. The presence and usage of 
microhomologies however could facilitate ligation of ends by holding them together.  
It is possible that two or more B-NHEJ sub-pathways exist, microhomology dependent 
and independent ones, which fulfill end-joining tasks in the absence of other functional 
repair. Disregarding possible dependency on microhomology, repair by B-NHEJ has a 
characteristic tendency to cause large scale chromosomal alterations. Translocations 
and extensive deletions are found frequently when repair is carried out by B-NHEJ 
(Soulas-Sprauel, 2007; Yan, 2007; Robert, 2009; Boboila, 2010; Simsek and Jasin, 
2010). Thus, B-NHEJ now is considered to be a major contributor to chromosome 
aberration formation and genomic instability (Mladenov and Iliakis, 2011; Symington and 
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Gautier, 2011; Mladenov, 2013). This places B-NHEJ not only in the center of cell killing 
during radiotherapy but also at the heart of carcinogenesis (Greaves and Wiemels, 
2003; Edwards, 2008).  
B-NHEJ can potentially act throughout the cell cycle, but does display remarkable 
variations in its efficiency depending on the position in the cycle. In G2 for example B-
NHEJ is enhanced (Wu, 2008a; Wu, 2008b). This might be explainable with increased 
end-resection activities during G2 that facilitate B-NHEJ. In growth inhibited plateau 
phase or serum starved cells on the other hand B-NHEJ is strongly reduced (Windhofer, 
2007; Singh, 2011). Although B-NHEJ is observable best on a D-NHEJ deficient 
background acting as a backup for this pathway, its association with end resection 
makes it easy to imagine that it also takes advantage of abortive HRR events 
(Symington and Gautier, 2011; Dueva and Iliakis, 2013).  
B-NHEJ can be best observed when the major beneficial repair processes are impaired 
globally genetically or by chemical inhibition. Nevertheless it is likely that B-NHEJ can 
also occur in repair proficient background locally at sites of repair accidents, possibly 
also accounting for a majority of chromosomal translocations found in repair proficient 
cells. Candidates for proteins involved in B-NHEJ include LIG3 (Wang, 2005b; Simsek, 
2011), LIG1 (Boboila, 2012), Histone 1 (Rosidi, 2008), PARP1 (Wang, 2006b; Robert, 
2009; Wray, 2013), MRE11 (Xie, 2009) and CtIP (Zhang and Jasin, 2011). 
1.4.2.5 SSA 
Single-strand annealing (SSA) is another homology directed cellular DSB repair process 
besides HRR (Figure 10). In contrast to HRR, SSA does not favor homologous 
sequences on other DNA molecules, but preferentially on the same molecule where the 
DSB occurred (Ivanov, 1996; Symington, 2002). Similar to HRR it requires extensive 
resection to reveal those homologies, but unlike HRR the long 3´-ssDNA is not used for 
initiation of repair synthesis (Fishman-Lobell, 1992; Sugawara and Haber, 1992). 
Instead two homologous stretches of sequence are annealed, tails/flaps are removed 
and gaps are filled in (Symington, 2002). This inevitably leads to the loss of the 
intervening sequences, which may be hundreds of base pairs long. Thus SSA is a highly 
mutagenic process with the propensity to cause large deletions. Worse still, due to the 
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presence of vast numbers of dispersed repetitive elements like LINES and SINES in 
mammalian genomes SSA can also cause translocations (Elliott, 2005; Weinstock, 
2006). SSA is strongly suppressed by HRR and if core components of this faithful 
homology directed repair pathway, like RAD51 or BRCA2, are inactivated the frequency 
of SSA event multiplies 4-8 fold (Tutt, 2001; Stark, 2004; Mansour, 2008; Manthey and 
Bailis, 2010). Similar to HRR, SSA shows strong cell cycle dependence, possibly due to 
the cell cycle regulated efficiency of end resection activities (Frankenberg-Schwager, 
2009; Trovesi, 2011). Important proteins implicated in SSA in mammalian cells are 
RAD52, the ERCC4/XPF-ERCC1 endonuclease and RPA (Symington, 2002; Stark, 
2004; Al-Minawi, 2008) . 
 
Figure 11 Schematic overview of key factors and steps of B-NHEJ.  The enzymatic activities implicated in 
B-NHEJ are shown together with their possible contributions in the process. (modified from (Mladenov and Iliakis, 
2011)) 
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 The role of DSB in cell killing and cancer induction by IR 
 The DSB as cancerogenic lesion 
Only the breakage and rejoining of double-stranded DNA can eventually account for the 
gross chromosomal abnormalities that can be induced by ionizing radiation and which 
are also a common hallmark of cancer. There are certain chromosomal translocations 
that are known to be potent inducers of carcinogenesis, e.g. the t(9;22) translocation – 
also known as Philadelphia chromosome - that is found in >95% of patients with chronic 
myeloid leukemia (CML)(Greaves and Wiemels, 2003; Nambiar and Raghavan, 2011). 
This highlights the important role of DSB, not only for the killing of cells, but also for 
carcinogenesis. Still, although IR is a mutagenic agent that induces DSB, base damages 
and other lesions that can drive cancer development, it is the potentially lethal 
consequences of the DSB that make IR a valuable tool in cancer therapy. 
 
 The DSB as lethal lesion 
Complex DSB as a product of IR are potent inducers of cell death. Although base 
damages and SSB are induced at a much higher frequency by IR than DSB, their 
contribution to the cytotoxicity of IR is far less than that of DSB (Iliakis, 1991; Foray, 
1997a; Nikjoo, 1999). It has been shown that a single unrepaired DSB can be sufficient 
to kill an eukaryotic cell (Frankenberg, 1981). The importance of DSB in cell killing is 
also highlighted by the pronounced radiosensitivity of cells with defects in DSB 
processing that is found in several human syndromes or mutant cell lines (Jeggo and 
Kemp, 1983; Joubert, 2008; Mladenov, 2013). However, there is not a clear general 
correlation between DSB induction and rejoining (as measured by physical methods) 
and cell killing respectively survival. While cell lines that show defects in the rejoining of 
DSB are radiosensitive, not all radiosensitive cell lines have clear defects in the rate with 
which they rejoin DSB. A better correlation exists with the induction of chromosomal 
aberrations. So how can the particularly detrimental effects of the DSB be explained? 
DSB can result in the loss of vital genetic material in subsequent cell divisions if they 
remain un-rejoined, while rejoining of the wrong DNA ends can result in chromosomal 
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aberrations like translocations and chromosome or chromatid fusions that may cause 
cell death or lead to carcinogenesis (Bryant, 1988; Obe, 1992; Ferguson and Alt, 2001). 
Therefore the DSB can with high certainty be assumed to be the lesion underlying the 
formation of chromosomal aberrations and - via this route - cell killing (Bender, 1974; 
Natarajan, 1980; Radford, 1985; Iliakis, 2004). 
 
 Evidence connecting DSB repair to cellular 
radiosensitivity and PLD 
It is known that the main genetic determinants of cellular sensitivity to IR are genes 
whose products are involved in the detection and repair of DSB, or those that participate 
in the signaling and control of cell cycle progression in response to DNA damage 
(checkpoints) (Jeggo and Lavin, 2009b). These genes include ATM (Foray, 1997b), ATR 
(Wang, 2004b), CHK1 (Wang, 2005a), BRCA1&2 (Foray, 1999), LIG4 (Plowman, 1990; 
Badie, 1995), MRE11 (Matsumoto, 2011), NBS1 (Carney, 1998), RAD50 (Waltes, 2009), 
RAD51 (Liu, 2011), RNF168 (Stewart, 2007; Stewart, 2009), XRCC2&3 (Cui, 1999), 
Artemis (Moshous, 2001), DNA-PKcs (Hendrickson, 1991) and KU (Tzung and Rünger, 
1998) (reviewed in (Jeggo and Lavin, 2009a; Foray, 2012)). The presence of core 
components of both major DSB repair pathways in this list indicates that HRR, as well as 
NHEJ play important roles in conferring radioresistance to the cell. Thus, both pathways 
present as potentially promising targets for cell radiosensitization (Yoshihisa Matsumoto, 
2013). 
DSB are also the best candidate for the lesion constituting PLD due to their cytotoxic 
effects. Pathways of DSB repair can be envisioned to account for repair, as well as for 
fixation of PLD. The former occurring when the correct ends of DSB are rejoined with 
high fidelity, the latter when repair of DSB either entirely fails, or when misrejoining 
occurs that results in the formation of lethal chromosomal aberrations. These 
considerations are reinforced by observations that implicate NHEJ and HRR in PLD 
repair and the cell cycle dependent fluctuations in the sensitivity to IR.  
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XR-1 cells for example are deficient in XRCC4, a component of D-NHEJ. These cells 
are extremely sensitive to IR in G1, but only moderately sensitive in S/G2. Furthermore, 
they don´t appear to repair PLD in G1/G0, but show substantial repair of PLD in S/G2 
that operates with a halftime of approximately 5h (Stamato, 1988). In the parental cell 
line on the other hand, much of the PLD repair occurs in G1 and repair halftimes are 
about 1h (Stamato, 1988). The cell cycle dependence and kinetics of PLD repair in the 
mutant and parental cell line here reflect exactly what would to be expected, if DSB 
constituted PLD and repair was carried out by NHEJ and HRR. In the mutant only the 
slow HRR pathway, which is restricted to S/G2, would be available for repair. In the 
parental cell line the fast NHEJ pathway, which dominates repair throughout the cell 
cycle would be capable of repairing most of the PLD. 
Further evidence is provided by the hamster cell line irs-1, which is deficient for the 
RAD51 paralog XRCC2. In irs-1, the S-phase dependent increase in radiosensitivity 
usually observed in hamster-cells is abolished (Cheong, 1994). Similarly treatment with 
caffeine, which exerts an inhibitory effect on HRR, flattens the fluctuations of 
radiosensitivity throughout the cycle in cells that are proficient for this pathway (Beetham 
and Tolmach, 1984; Asaad, 2000). This list could be considerably extended with various 
other examples of mutant cell lines and treatments demonstrating the dependence of 
radiosensitivity during the cell cycle and PLD repair on the repair of DSB (Sonoda, 2006; 
Tamulevicius, 2007). 
Taken together, a large body of evidence suggests that individual differences in cell-
intrinsic sensitivity to IR, the fluctuations in radiosensitivity during the cell cycle and the 
repair of PLD depend largely on the ability of a cell to detect and repair DSB (Roberts, 
1999; Joubert, 2008; West and Barnett, 2011). Thus, pathways of DSB repair present 
promising targets for the modulation of cellular radiosensitivity to killing for the 
optimization of radiotherapy (Yoshihisa Matsumoto, 2013). 
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 Synergistic interactions between IR and nucleoside 
analogs 
A number of NAs have been reported to show synergistic action with IR in vitro (Dewey 
and Humphrey, 1965; Iliakis, 1989a; Iliakis, 1989b; Gregoire, 1994; Shewach, 1994; 
Buchholz, 1995; Meike, 2011). Some of these drugs have been evaluated as 
radiosensitizers in clinical trials (Goffman, 1991; Miser, 1992; Bartelink, 1997; Aguilar-
Ponce, 2004; Nitsche, 2008) and others already belong to the standard of care as 
concurrent treatments for some diseases (Vallerga, 2004; Gurka, 2013; Lee, 2013). 
Despite their great clinical promise the mechanisms of radiosensitization by many NAs 
remain poorly understood. In the following the NAs used in this study are described with 
respect to their potential radiosensitizing activities. 
Early studies could show that ara-A is a particularly effective inhibitor of PLD repair 
(Iliakis, 1980; Iliakis and Bryant, 1983; Iliakis and Ngo, 1985; Chavaudra, 1989; Iliakis, 
1989b; Little, 1989). In comparative studies with other inhibitors of replication and DNA 
synthesis ara-A consistently showed the strongest inhibitory effect on the repair of PLD 
(Iliakis and Bryant, 1983; Iliakis, 1989b). In the studies cited above plateau phase 
cultures were used for the generation of the results. Reports about radiosensitization by 
ara-A in actively cycling populations are scarcer (Iliakis and Nusse, 1983b; Chavaudra, 
1989; Mustafi, 1994). Ara-A has also repeatedly been reported to inhibit the repair of 
chromosomal breaks (Bryant, 1983; Mozdarani and Bryant, 1987; Iliakis, 1988b; 
MacLeod and Bryant, 1992; Okayasu and Iliakis, 1993; Bryant, 2004). Intriguingly, the 
number of exchange type aberrations was observed to increase at the same time in 
some studies (Bryant, 1983; Mozdarani and Bryant, 1987). Taken together, this 
suggests that ara-A interferes with pathways of DSB repair that are involved in the repair 
of PLD and chromosomal breaks. 
Radiosensitization by fludarabine has been demonstrated in numerous in vitro studies 
(Gregoire, 1994; Laurent, 1998; Nitsche, 2008) and also been tested in first clinical 
studies (Gregoire, 2002; Nitsche, 2012). Radiosensitization by fludarabine was found not 
to coincide with inhibition of DSB repair measured by pulsed field gel electrophoresis 
(PFGE) (Gregoire, 1998). 
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Ara-C is generally not recognized as a radiosensitizer and there are no clinical studies 
assessing such a potential. However, there are some reports that show a comparatively 
weak inhibition of PLD repair by ara-C (Iliakis and Bryant, 1983; Nakatsugawa, 1984; 
Iliakis, 1989b). 
The in vivo radiosensitizing potential of Gemcitabine has been tested extensively in 
preclinical studies (Shewach, 1994; Lawrence, 1996; Latz, 1998; Rosier, 1999; Pauwels, 
2003) and confirmed in numerous clinical trials (Eisbruch, 2001; Aguilar-Ponce, 2004; 
Evans, 2008). Concurrent chemo radiation with gemcitabine is currently considered as 
standard treatment for locally advanced pancreatic cancers in North America (Gurka, 
2013). Like for fludarabine, radiosensitization by gemcitabine was found not to coincide 
with inhibition of DSB repair measured by (PFGE) (Gregoire, 1998). 
Previous reports and preliminary data generated in the beginning of this study 
suggested that radiosensitization elicited by ara-A exceeds the effects of fludarabine, 
ara-C and gemcitabine. Thus, we chose to use ara-A as a model compound in most of 
our experiments to study NA mediated radiosensitization and to investigate the 
mechanisms that underlie its superior sensitization characteristics. 
 
2 Aims and scope of this work 
Improving the treatment of cancer belongs to the most important and most challenging 
tasks of modern medicine. The diversity of malignant entities and the variety of possible 
steps that can lead to carcinogenic transformation make solid cancers a highly 
heterogeneous group of diseases. The combination of different treatment modalities is 
one of the most promising current approaches to achieve improvements in cancer 
treatment for a broad range of patients. Radiotherapy is one of the most efficient means 
to eradicate cancer cells. However, some cancers are relatively radioresistant and even 
when tumors can be treated successfully, surviving cells are often responsible for 
relapses. Combining IR with drugs that sensitize targeted cancer cells to killing can 
significantly improve the outcome of radiotherapy.  
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NAs represent a large group of anticancer drugs, several members of which have been 
shown to possess radiosensitizing potential. Aim of the present study was to elucidate 
the mechanisms of radiosensitization by NAs using as a model compound ara-A, due to 
its superior radiosensitizing properties. 
The DSB is the most detrimental IR-induced lesion, whose misrepair underlies cell killing 
and likely also ara-A radiosensitization. Therefore, we studied in detail the effects of ara-
A on the main pathways of DSB repair: HRR, NHEJ and B-NHEJ, placing particular 
emphasis on cell cycle specific effects. To this end, we employed advanced methods of 
microscopy, flow cytometry and various cell biological and biophysical techniques. This 
approach led to the generation of a wealth of data that allowed the development of a 
mechanistic model of ara-A radiosensitization. This model invokes the selective 
inhibition of the error-free DSB repair pathway HRR and the parallel activation of the 
error-prone DSB repair pathway B-NHEJ by ara-A. This information also formed the 
basis for a comparative analysis of the mode of action of selected other NAs. 
The efficiency of concurrent chemo-radiotherapy can greatly benefit from increased 
knowledge about mechanisms of action of radiosensitizers. We hope that the 
information generated as part of the present thesis will assist in the identification and 
selection of drugs able to maximize the radiation response of tumors and the 
optimization of treatment schedules. 
 
3 Materials and Methods 
 Materials 
Table 3.1: Laboratory Apparatuses 
Laboratory Apparatus Model Manufacturer 
Cell counter Multisizer™ 3 Beckman Coulter Inc. 
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Cell Sorter Epics Altra Beckman Coulter Inc. 
Centrifuge Multifuge 3 S-R Heraeus 
Centrifuge Avanti J-20XP Beckman Coulter Inc. 
Centrifuge Tabletop GS-6R Beckman Coulter Inc. 
Elutriation Centrifuge Beckman J2-21M centrifuge Beckman Coulter Inc. 
CO2- incubator Hera Cell 240 Heraeus 
Confocal Microscope TCS-SP5 Leica Microsystems 
Dry blotting system iBlot Invitrogen 
Flow Cytometer Coulter XL-MCL Beckman Coulter Inc. 
Flow Cytometer Gallios Beckman Coulter Inc. 
Imaging scanner Typhoon 9400 GE Healthcare 
Infrared imaging system Odissey LI-COR 
Laboratory microscope Inverted phase contrast  Olympus 
Laminar Flow Hood Hera safe Heraeus 
Liquid Scintillation 
counter 
TriCarb1900 TR Packard 
Magnetic stirrer MR Hei-Mix L Heidolph 
Microtiter Pipettes Rainin  
Mini centrifuge Biofuge fresco Heraeus 
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Table 3.2: Chemicals 
Molecular Imager  VersaDoc  Bio-Rad 
Electroporation device Nucleofector I Lonza AG  
pH-Meter WTW InoLab 
Photometer Nanodrop Thermo Scientific 
Photometer UV-2401 PC Shimadzu 
Pipet Aid Express Falcon 
Rocky Shaker 3D Peter Oehmen 
SDS PAGE equipment Mini Protean Bio-Rad 
X-ray tube Isovolt 320HS 
General Electric-
Pantak 
Chemical Provider 
1-β-D-arabinofuranosylcytosine Sigma-Aldrich, Steinheim, Germany 
2-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany 
2´-deoxy-2´,2´-difluorocytidine LC Laboratories, USA 
9-β-D-arabinofuranosyl-2-fluoro-adenine Metkinen, Finland 
9-β-D-arabinofuranosyladenosine TCI America, USA 
Aphidicolin SERVA, Heidelberg 
Boric acid Roth, Karlsruhe, Germany 
BSA [Bovine serum albumin fraction V] Roth, Karlsruhe, Germany 
Bromophenol blue Sigma-Aldrich, Steinheim, Germany 
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Coomassie brilliant blue R 250 SERVA Electrophoresis GmbH, Heidelberg, Germany 
Crystal violet Merck, Darmstadt, Germany 
DAPI Sigma-Aldrich, Steinheim, Germany 
Dichlorodimethylsilane Merck, Darmstadt, Germany 
DMSO [Dimethyl sulfoxide] Sigma-Aldrich, Steinheim, Germany 
DMEM [Dulbecco’s Modified Eagle Medium] Gibco™, Invitrogen, Karlsruhe, Germany 
DTT [Dithiothreitol] Roth, Karlsruhe, Germany 
EtOH [Ethanol] Sigma-Aldrich, Steinheim, Germany 
EtBr [Ethidium bromide] Roth, Karlsruhe, Germany 
EDTA [Ethylenediaminetetraacetic acid] Roth, Karlsruhe, Germany 
FBS [Fetal bovine serum] 
Biochrom, Berlin, Germany; 
Gibco™, Invitrogen, Karlsruhe, Germany 
FBS [Fetal bovine serum] PAA, Coelbe, Germany 
FBS [Fetal bovine serum] Gibco™, Invitrogen, Karlsruhe, Germany 
HEPES Roth, Karlsruhe, Germany 
Hydroxyurea Sigma-Aldrich, Steinheim, Germany 
Isopropanol Sigma-Aldrich, Steinheim, Germany 
KCl Roth, Karlsruhe, Germany 
KH2PO4 Roth, Karlsruhe, Germany 
KOH Roth, Karlsruhe, Germany 
LMA [Low melting agarose] Roth, Karlsruhe, Germany 
Mc Coy’s 5A medium Sigma-Aldrich, Steinheim, Germany 
Methanol Sigma-Aldrich, Steinheim, Germany 
MgCl2 Merck, Darmstadt, Germany 
NaCl Roth, Karlsruhe, Germany 
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NaHCO3 Roth, Karlsruhe, Germany 
NaH2PO4 Roth, Karlsruhe, Germany 
Na2HPO4 Roth, Karlsruhe, Germany 
NLS [N-lauroyl sarcosine] Merck, Heidelberg, Germany 
Non-fat dry milk Roth, Karlsruhe, Germany 
NU7441 Tocris Bioscience, Ellisville, MO, USA 
Paraformaldehyde Honeywell Specialty Chemicals GmbH, Seelze, Germany 
Penicillin Sigma-Aldrich, Steinheim, Germany 
Phenylmethanesulfonylfluoride Roth, Karlsruhe, Germany 
Phosphoric acid Roth, Karlsruhe, Germany 
Poly-L-lysine Biochrom AG, Berlin, Germany 
ProLong® Gold antifade reagent Invitrogen, Karlsruhe, Germany 
PI [Propidium iodide] Sigma-Aldrich, Steinheim, Germany 
Protease from S. griseus Sigma-Aldrich, Steinheim, Germany 
Protease inhibitor cocktail Sigma-Aldrich, Steinheim, Germany 
Puromycin Sigma-Aldrich, Steinheim, Germany 
RIPA buffer Thermo Scientific, Schwerte, Germany 
RNase A Sigma-Aldrich, Steinheim, Germany 
Scintillation Cocktail UniSafe1 (Zinsser Analytic) 
SEAKEM LE® Agarose Lonza 
SeeBlue plus2 pre-stained protein ladder Invitrogen, Karlsruhe, Germany 
SDS [Sodium dodecyl sulfate] Roth, Karlsruhe, Germany 
Streptomycin Calbiochem, Invitrogen, Karlsruhe, Germany 
Tetramethylethylenediamine Sigma-Aldrich, Steinheim, Germany 
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Table 3.3: Software 
Trichloric acid Roth, Karlsruhe, Germany 
TRIS [Tris(hydroxymethyl)aminomethane] Roth, Karlsruhe, Germany 
Tris-HCl Roth, Karlsruhe, Germany 
Triton X-100 Sigma-Aldrich, Steinheim, Germany 
Trypsin Biochrom AG, Berlin, Germany 
Tween 20 Roth, Karlsruhe, Germany 
Software Provider Use 
ImageQuant™ 
5.0  
GE Healthcare Life Sciences, 
USA  
Quantification PFGE Gels 
SigmaPlot® 11.0  Systat Software, USA  
Graphic Presentation, Curve 
fitting 
ImarisXT® 6.0  Bitplane Scientific Software, Switzerland  
Immunofluorescence analysis ( 
Foci) 
Microsoft Excel 
2010®  Microsoft Corp., USA  
Data analysis and calculations 
WincycleTM  Phoenix Flow Systems, USA  Cell cycle analysis 
Kaluza 1.2 
Beckman Coulter Inc., 
USA 
Flow Cytometry analysis (Gallios) 
EXPO32TM 
MultiComp V1.2 
Beckman Coulter Inc., 
USA 
Flow Cytometry analysis (XL-
MCL/ALTRA) 
Adobe® Creative 
Suite® 5.5  
Adobe Systems Inc., USA  
Illustrations, presentation, 
cropping 
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 Methods 
 Cell culture 
3.2.1.1 Cell lines and passage 
A549 human non-small cell epithelial lung carcinoma cells (American Type Culture 
Collection; CCL-185TM; positive for p53) were maintained in McCoy´s 5A medium. Stably 
transfected U2OS human Osteosarcoma cell lines (kindly provided by Jeremy Stark, 
Ph.D.; Beckman Research Institute of City of Hope, Duarte, CA) carrying different 
reporter substrates (279A/EJ2-GFP; 280A/EJ5-GFP; 282C/DR-GFP; 283C/SA-GFP) for 
the repair of I-SceI induced DSB were cultured in McCoy´s 5A medium containing 2 
µg/ml puromycin. HCT116 human colon carcinoma cell lines were cultured in McCoy´s 
5A medium. The following HCT116 cell lines were used in these studies: HCT116 
(HCT116 WT), as well as HCT116 Lig4−/− (HCT116 Lig4) (Fattah, 2010) and HCT116 
DNA-PKcs−/− (HCT116 DNA-PK) (Ruis, 2008) derivative knockout Mouse embryonic 
fibroblasts (MEF) were cultured in Dulbecco´s modified Eagle medium DMEM. The 
following MEF cell lines were used in these studies: p53-/-/Lig4+/+ (MEF Lig4+/+), p53-/-
/Lig4-/- (MEF Lig4-/-) (kind gift of Dr. F. Alt; (Frank, 2000)). CHO cell lines were cultured in 
DMEM. All growth media were supplemented with 10% fetal bovine serum (FBS) as well 
as 100 µg/ml penicillin and 100 µg/ml streptomycin. All cell lines were grown as 
monolayer cultures and incubated at 37°C in a humidified atmosphere containing 5% 
CO2 and 95% air. For passaging or collection of cells for experiments, dishes were 
washed with phosphate buffered saline (PBS) and trypsinized at 37°C for 3-5 min using 
a solution of 0.05% Trypsin. Human cell lines were passaged after 3 to 4 days, while the 
faster growing rodent cell lines were passaged every second day. Intervals between 
passages were kept regular and fixed cell numbers of cells were plated for a given cell 
ApE A plasmid 
editor V1.17 
Freeware, M.W. Davis 
Sequence 
viewing/editing/alignments  
EndNote X4 Thomson Reuters Literature Bibliography 
Materials and Methods 
____________________________________________________________________________________________________________________________________________ 
47 
 
line and interval. Cell numbers were determined by counting in a Beckman Coulter Cell 
counter (Multisizer™ 3). Confluence was avoided during passage and all cells used in 
experiments were in the exponential phase of growth unless stated otherwise 
(experiments with plateau phase or serum deprived cells). Cell cycle distribution of cells 
in passage was regularly checked by flow cytometry after staining with propidium iodide. 
 
Table 3.4: Cell lines 
 
3.2.1.2 Induction of a plateau-phase like growth state by serum deprivation 
In a number of experiments we purposefully did not use cell cultures in the exponential 
phase of growth, but cultures that retained only very low levels of proliferative activity. In 
regular cultures this growth state is attained when cells are grown for a prolonged period 
of time without medium change. Growth factors that drive the entry of cells into the cell 
cycle are introduced into the culture medium by addition of FBS. Those factors become 
gradually depleted by cellular uptake. When growth factor levels become too low, cells 
exit the division cycle. This state is also referred to as G0 (in analogy to the gap phases 
of the cell cycle) or quiescence. It is not to be confused with terminal differentiation, as it 
is reversible upon stimulation with growth factors.  
Cell line name species Cell type 
A549 Homo sapiens Alveolar adenocarcinoma 
HCT116 WT Homo sapiens Colon carcinoma 
HCT116 LIG4-/- Homo sapiens Colon carcinoma 
HCT116 DNA-PKcs-/- Homo sapiens Colon carcinoma 
U2OS 280A Homo sapiens Osteosarcoma 
U2OS 282C Homo sapiens Osteosarcoma 
U2OS 283C Homo sapiens Osteosarcoma 
U2OS EJ-DR Homo sapiens Osteosarcoma 
MEF Mus musculus Embryonal fibroblasts 
MEF Lig4-/- Mus musculus Embryonal fibroblasts 
DRaa40 Cricetulus griseus Ovarian
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In many cell lines growing into a plateau phase is accompanied by a high accumulation 
of cells with G1 DNA content. This however is not a universal phenomenon, as 
especially cancer cell lines can be either relatively independent of growth factor 
regulation, or capable of their own growth factor production and secretion. Plateau 
phase cultures are preferable as model system over exponential cultures for a number 
of questions, as the vast majority of cells in an adult human body is in a resting, post-
mitotic state. Also in tumor tissue usually not all cells are continuously, actively dividing 
(Moore and Lyle, 2011). 
 
Figure 12 Growth curve of A549 cells.  A549 cells were plated at a density of 0.2*106 in 5 ml per petri 
dish (60mm diameter) at day 0 (d0). Cells were counted every 24h and samples were fixed for later 
analysis of DNA content by PI staining. Red histograms show the result of PI flow cytometry. Black dots 
and line: Cell number/dish as determined by counting in a Beckmann Coulter cell counter.  
When cells are grown into the plateau phase, small deviations in the initial cell number 
can cause substantial differences in the time when cells reach this phase. For reasons 
of accumulation of metabolic end products and dead cell remnants however, it is 
desirable to use cells that are in the early plateau phase. The variations mentioned 
above make it difficult to obtain cell populations with the same plateau state quality at a 
fixed time point (e.g. equal cell cycle distribution).  
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Since the plateau phase state derives from growth factor exhaustion, a plateau phase-
like growth state can also be induced by depriving an exponentially growing culture from 
growth factors. Besides being time saving, such an approach creates defined conditions 
and ensures higher reproducibility. We employed a protocol that involved growing cells 
for 2 days under standard conditions for exponential culture. After 48h, medium 
containing serum was removed and replaced by medium without serum (i.e. free of 
growth factors). After 24h of serum deprivation cells were used in the respective 
experiments. Cells were continuously kept in serum free medium throughout the whole 
experiment. All experiments with non-cycling populations in this work were performed 
using this serum deprivation protocol. For this reason, the terms plateau phase cells and 
serum deprived cells are used interchangeably here. 
 
3.2.1.3 Cell cycle analysis by Propidium iodide staining 
Propidium iodide (PI) is a DNA intercalating dye that exhibits strongly increased 
fluorescence when bound to nucleic acids. It is not cell membrane permeable and binds 
to DNA as well as RNA. Thus, for measurements of DNA content, cells have to be 
permeabilized and treated with RNAse. Cells are fixed and permeabilized by 
resuspension in cold EtOH 70% (4°C). After fixation cells can be stored at 4°C for a 
prolonged time. Before measurement cells are spun down, EtOH is aspirated and the 
pellet is resuspended in PI staining buffer (PBS, 40µg/ml PI, 62µg/ml RNAse) and 
incubated for 15 min at 37°C in a water bath. For cell cycle determination routinely 1x104 
cells were measured per sample. 
 
 Flow cytometry 
Flow cytometry analysis of cells exhibiting a fluorescent signal, also known as 
fluorescence activated cell sorting or in short FACS, is a method to rapidly measure high 
numbers of cells in a single cell suspension. Sample cells are driven into a capillary, 
hydro-dynamically focused and transported within a sheath stream through the light path 
of an excitation laser. Emission light of excited fluorophores and scattered incident light 
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are collected by photomultiplier tubes (PMT) that amplify the signal. Scattered incident 
light provides information about size and granularity of cells (forward and side scatter). 
Incident light is selectively removed by a long pass filter (typically 488 nm LP) before 
reaching the PMTs assigned for fluorescence signal detection. 
Flow cytometry analysis of cells was done using a Beckman Coulter XL-MCL flow 
cytometer equipped with an Argon ion laser (488 nm) and a Beckman-Coulter Gallios 
flow cytometer equipped with a solid state laser (488 nm). Analysis of experiment 
repeats was always performed with the same flow cytometer. Emission of green 
fluorescent protein (GFP) was measured using a 525 nm bandpass filter when 
measured alone, or a 510 nm bandpass filter when measured together with DsRed2. 
Emission of yellow fluorescent protein (YFP) was measured using a 550 nm bandpass 
filter and emission of dsRed2 was collected using a 610 nm bandpass filter. Propidium 
iodide (PI) was routinely measured with a 620 nm bandpass filter. Data acquired with the 
XL-MCL flow cytometer were analyzed in the EXPO32TM MultiComp V1.2 software. Data 
acquired with the Gallios flow cytometer were analyzed in the Kaluza 1.2 software. 
Detector settings (PMT gain) were chosen according to the application. Compensation 
was not required for most measurements. In experiments with multiple fluorochromes 
exhibiting emission overlap (GFP/YFP and GFP/dsRed2) compensation was done using 
monochrome control samples. 
 
 X-Irradiation 
X-irradiation of cells was performed using an X-ray tube (General Electric-Pantak) 
operated at 320kV, 10 mA with a 1.65 mm aluminium filter. The distance of the X-ray 
tube to the irradiation table was adjusted according to the cell culture vessel format used 
in the experiment. This adjustment was done in order to achieve homogenous coverage 
of the target area by the radiation field. 60 mm and 30 mm diameter petri dishes were 
irradiated at a distance of 50 cm, while cells grown on 100 mm petri dishes were 
irradiated at a distance of 75 cm. Rotation of the irradiation table during exposure 
compensated for the intensity variations within the radiation field, ensuring homogenous 
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irradiation. The dose rate at 50 cm was ~2.7 Gy/min, and at 75 cm ~1.3 Gy/min. 
Radiation dose was confirmed at regular intervals using Fricke’s chemical dosimetry. 
 
 Transfection of nucleic acids 
The term transfection describes the introduction of nucleic acids into cells by non-viral 
methods. The most common approaches employed for the transfection of cells are 
usage of Lipid based transfection reagents (e.g. Lipofectamine), cationic Polymers (e.g. 
Polyethylenimin) or electroporation based methods (e.g. Nucleofection). In this work 
NucleofectionTM was exclusively used for the transfection of cells. Depending on the type 
of experiment 1x106 - 6x106 cells were used per transfection reaction. No differences in 
transfection efficiency could be observed for cell numbers up to 8x106 cells/reaction 
(highest cell number tested) with Plasmid DNA, or in knockdown efficiency up to 12x106 
cells/reaction (highest cell number tested) for the transfection of siRNAs. Cells were 
collected for nucleofection by trypsinization and pelleted for 5 min at 1500 rpm. The 
supernatant was aspirated and the pellet resuspended in 100 µl of custom nucleofection 
buffer (80 mM NaCl, 5 mM KCl, 12 mM Glucose, 25 mM HEPES, 20mM MgCl2, 0.4 mM 
Ca(NO3)2, 40 mM Na2HPO4/NaH2PO4) and transferred in an electroporation cuvette. 
Nucleofection program was chosen according to the cell line (Table 3.5). After 
transfection cells were taken up in pre-warmed (37°C) growth medium, plated out and 
returned to the incubator. Measurements were taken, depending on the experimental 
system, after 24h, 48h or 72h hours using flow cytometry. 
Table 3.5: Nucleofector Programs 
Cell type Nucleofector Program 
A549 X-05 
U2OS X-01 
CHO U23 
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Table 3.6: siRNAs 
siRNA Target Sequence Provider 
GFP-22 CGG CAA GCT GAC CCT GAA GTT CAT Qiagen 
Luciferase GL2 AAC GTA CGC GGA ATA CTT CGA Qiagen 
Hs_BRCA2_7 TTG GAG GAA TAT CGT AGG TAA Qiagen 
Hs_RAD52_6 TGG GCC CAG AAT ACA TAA GTA Qiagen 
Hs_RAD51_7 AAG GGA ATT AGT GAA GCC AAA Qiagen 
 
 Repair-outcome-specific chromosomal reporters 
DRaa-40 were obtained from Maria Jasin, Ph.D. (Memorial Sloan Kettering Cancer 
Center, New York, USA). These cells were derived from the CHO cell line AA8 by stable 
integration of the DR-GFP reporter construct (Pierce, 1999). 
A panel of four stably transfected human U2OS cell lines was obtained from Jeremy 
Stark, Ph.D. (Beckman Research Institute of City of Hope, Duarte, USA) and used to 
assay the influence of several drugs on the repair efficiency of distinct pathways of DSB 
repair (Pierce, 1999; Stark, 2004; Bennardo, 2008; Bennardo, 2009; Gunn and Stark, 
2012). These assays are based on the reconstitution of a reporter gene by repair of an 
endonuclease induced chromosomal DSB. Each of the four U2OS cell lines used within 
this study carries a different reporter construct stably integrated into their genomes. 
Each of those constructs contains one or two recognition sites for the homing 
endonuclease I-SceI that has no naturally occurring target sites within mammalian 
genomes. None of those constructs generates a signal without having been processed 
for DSB repair resulting in a specific recombination outcome. Expression of I-SceI from a 
plasmid vector results in the creation of a DSB at its cutting site. Although this DSB may 
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be repaired by any pathway of DSB repair, only repair events that result in the 
restoration of a functional EGFP expression cassette are detected. 
The DR-GFP construct (integrated into U2OS 282C, DRaa40 an EJ-DR) consists of two 
non-functional, direct repeat EGFP Sequences. The first consists of a modified eGFP 
gene with an I-SceI site containing a premature stop codon (SceGFP), the second is a 
3´- truncated modified EGFP ORF (iGFP). Repair via HRR (more specifically short tract 
gene conversion) results in the generation of a functional EGFP-ORF from DR-GFP 
(Figure 17 A & Figure 20 A). 
The SA-GFP construct (integrated into U2OS 283C) harbors two direct repeats of 
truncated EGFP-ORFs. The first of the two repeats is truncated at the 3´-end (5´-GFP) 
the second is truncated at the 5´-end (3´-GFP) and contains an I-SceI site. Signal 
generation through HRR repair of this construct is prevented by a premature stop codon 
at the 3´-end of the first ORF (5´-GFP). Upon repair by SSA a functional EGFP gene is 
reconstituted (Figure 21 A). 
The EJ5- GFP construct consists of a CAG promoter (chicken beta-actin promoter with 
CMV enhancer) that is separated from a full length GFP open reading frame by a 
puromycin (Puro) gene (Figure 22 A). The Puro gene is flanked by two I-SceI sites in 
tandem orientation. DSBs induced by I-SceI in this construct can be directly repaired 
using the proximal ends, thus restoring the two original I-SceI sites. Alternatively, it is 
possible that the intervening DNA is lost and rejoining occurs between the distal ends, 
which results in the loss of the Puro gene and one or both of the I-SceI sites. GFP 
expression is only possible when distal ends are joined and the CAG promoter is 
brought into proximity of the GFP gene.  
U2OS EJ-DR cells were obtained from the Lab of Ranjit S. Bindra, MD, Ph.D. (Smilow 
cancer hospital, Yale, USA) (Bindra, 2013). These cells were used to examine the 
influence of NAs on the general mutagenicity of DSB repair. The EJ-RFP system 
functions after a different principle than the three constructs described above. The EJ-
RFP system consists of two integration cassettes that are randomly introduced at 
different locations in the genome (Figure 23 A). One cassette consists of a tetracycline 
repressor gene under the control of a constitutively active promoter. The TetR gene 
Materials and Methods 
____________________________________________________________________________________________________________________________________________ 
54 
 
contains a recognition site for the I-SceI endonuclease. The other cassette is a DsRed 
gene containing several TetR binding sites. Under non inducing conditions TetR is 
expressed and binds to its binding sites in the DsRed gene, resulting in suppression of 
gene expression. Upon expression of I-SceI a DSB can be induced in the TetR gene. If 
this DSB is repaired without any sequence alterations, TetR continues to be expressed. 
If repair of the DSB results in loss of sequence or a frame shift no functional TetR 
protein will be expressed. As a consequence, cells that have undergone mutagenic 
repair will eventually develop red fluorescence. EJ-DR cell also contained an integration 
of the DR-GFP construct. However, since measurements of the EJ-RFP signal had to be 
taken 4 days after transfection, data that concomitantly accrued from the DR-GFP 
integrate did not yield meaningful information with regard to short term NA treatment 
promptly after transfection (see Discussion 5.3.3 and Figure 37). 
I-SceI expression in the U2OS cells was achieved by transient transfection of pCMV-
3xNLS-ISceI (Figure 17 A). Transfection was performed by nucleofection. After 
transfection, cells were allowed to re-attach for 1.5 h or 3h before drug treatment. Drug 
treatment lasted for 4 h unless indicated otherwise. Cells were collected and measured 
by flow cytometry 24 h after transfection unless indicated otherwise. FACS data was 
analyzed in the Kaluzaa 1.2 software and the percentage of GFP positive cells was 
determined. Results are expressed as percent repair efficiency of I-SceI transfected 
controls (no drug treatment). Variations in transfection efficiency could be excluded, as 
all cells used in one experiment were transfected together in a single reaction and 
subsequently distributed to several dishes before drug treatment. 
 
 Clonogenic survival assay 
Clonogenic survival assays determine the reproductive integrity of cells. To allow the 
formation of isolated colonies arising from a single founder cell, test cells have to be 
plated at low density. To this end cells were plated from a single cell suspension aiming 
for 30-150 colonies/dish. With increasing expected cell killing (i.e. higher doses of IR or 
increasing drug concentrations) the number of plated cells was increased. In this work 
clonogenic survival assays were used to investigate the radiosensitizing effects of ara-A 
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and other drugs. A549 cells were grown for 2 days and collected in the exponential 
phase of growth at the day of the experiment. Survival data obtained at different doses 
of IR and drug treatment with different concentrations was always normalized to the 
survival of non-irradiated (0 Gy) cells treated with the same drug concentration. Two 
slightly different protocols were followed for these treatments: 
Protocol I: Cells were plated with the respective concentrations of ara-A and immediately 
irradiated without significant pre-incubation with the drug (Figure 14 A). 
Protocol II: Cells were plated and allowed to attach for 1.5-2 hours. Drugs were added 
and cells were pre-incubated for a defined period of time before irradiation (Figure 14 B, 
Figure 16 C, Figure 30 B). Length of pre-treatment was either 15 min (Figure 16 C) or 40 
min (Figure 14 B and Figure 30 B), depending on the design and scale of the respective 
experiments. Within a set of experiments pre-treatment times were always identical. 
There were no significant differences between results obtained with the two protocols or 
different length of pre-treatment. In all cases the medium containing ara-A was removed 
4 h after irradiation, the cells were washed twice with medium and then supplied with 
fresh growth medium containing 10% FBS. The cells were kept at 37 °C, 5% CO2 for 9-
10 days and then stained for counting (1% crystal violet in 70% EtOH). Colonies that 
comprised 50 or more cells were scored. Curves were fitted to data using the linear-
quadratic model. 
 
 Pulsed-field gel electrophoresis 
Pulsed-field Gel electrophoresis (PFGE) is a method that allows the physical separation 
of large pieces of DNA within a gel matrix. Conventional constant field agarose gel 
electrophoresis allows the efficient separation of DNA fragments of 100-200 base pairs 
(bp) up to approximately 50 kbp. PFGE overcomes this size limit by applying an 
alternating electrical field and allows the resolution of DNA molecules up to 10 Mbp 
(Gardiner, 1991; Gurrieri, 1999). In this work asymmetric field inversion gel 
electrophoresis (AFIGE), a PFGE variation, was used to investigate the repair of DSB in 
irradiated cells. To this end, cells were embedded in low melting agarose (LMA), cut into 
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equally sized cylindrical pieces (plugs), lysed, loaded on a gel and subjected to the 
alternating electrical field for 40h. The amount of DNA that was able to escape the plug 
and migrate into the gel during the run provides a measure of DSB present in the 
assayed population.  
DSB are induced in a linear fashion proportionally to the dose of IR. However, DNA 
release in PFGE can vary depending on cell line and cell cycle status of the used 
culture. To create a standard curve a dose response (DR) was determined within each 
experiment. Cells were collected, pelleted and resuspended in cold serum-free HEPES-
buffered medium at a concentration of 6 x 106 cells/ml. This cell suspension was mixed 
with an equal volume of pre-warmed (50°C) serum-free medium containing 1% low 
melting agarose (LMA) to a final concentration of 3x106 cells/ml and poured into round 
glass capillaries for polymerization. The solidified agarose with the cell suspension was 
subsequently cut into plugs containing approximately 1.5 x 105 cells/plug. DR plugs were 
placed in 60 mm petri dishes containing 3.5 ml cold HEPES-buffered serum-free 
medium and X-irradiated on ice. X-ray doses used for DR curves were either from 5 Gy 
– 20 Gy in steps of 5 Gy, or from 10 Gy to 40 Gy in steps of 10 Gy. Irradiated plugs were 
immediately placed in cold lysis buffer (10 mM Tris, 50 mM NaCl, 100 mM EDTA, 2% N-
lauryl sarcosine, pH 7.6, 0.2mg/ml protease), and incubated at 4°C for 30 min before 
placing them at 50°C for 18h.  
For the evaluation of DSB repair kinetics after IR attached cells were irradiated on ice 
(unless stated otherwise) with 20 Gy of X-rays. After irradiation cold medium was 
replaced by fresh pre-warmed growth medium (42 °C) to avoid time lag due to 
prolonged warm up of chilled medium. In drug treatment experiments the replacement 
medium contained the same concentrations as pre-treatment medium. After each repair 
time interval cells were collected by trypsinization, embedded in agarose plugs and 
lysed as described above. After lysis, plugs were washed for 1 h at 37°C in washing 
buffer (10 mM Tris, 100 mM EDTA, 50 mM NaCl, pH 7.6) and then treated with 0.1 
mg/ml RNase A for 1 h in washing buffer at 37°C. For determination of the background-
DNA-release, plugs were prepared from otherwise identically treated non-irradiated cells 
at different time points (typically 2h or 4h and 8h). 
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Plugs were loaded on 0.5% agarose gels (SeaKem® LE Agarose, Lonza) pre-stained 
with 0.7 μg/ml EtBr and gel slots were sealed with 1% Agarose. The gels were run in 0.5 
x TBE (45 mM Tris, pH 8.2, 45 mM Boric Acid, 1 mM EDTA) in Horizon 20x25 gel boxes 
with circulating, continuously cooled buffer to ensure a stable temperature of approx. 10 
°C during the whole run. 
The opposing electrical fields for AFIGE were provided by two power supplies (Bio-Rad) 
connected to a custom build switching unit. Run parameters were set to cycles of 50 V 
(1.25 V/cm) for 900 s in the direction of DNA migration (forward) alternating with cycles 
of 200 V (5.0 V/cm) for 75 s in the reverse direction for a total of 40 hours. Afterwards 
gels were scanned with a Typhoon 9400 imaging device (GE Healthcare) and analyzed 
using the ImageQuant™ 5.0 software (GE Healthcare). 
The fraction of DNA released (FDR) was calculated by dividing the signal of DNA 
released into the gel (lane) by the total signal (lane + plug). The FDR values of irradiated 
samples were corrected by the background values of non-irradiated control cells (see 
above). Using FDR values derived from the linear DR standard curves a dose equivalent 
(DEQ) in Gy was calculated for the repair kinetics (RK) data points. DEQ was plotted 
against repair time and curve fitting was performed in SigmaPlot 11.0 software using an 
exponential decay algorithm assuming a fast and slow component in the RK curves. 
 
 PFGE with sorted cell populations  
Experiments with cell populations sorted by flow cytometry generally followed the 
protocol for PFGE described above with some adjustments as laid out below. Due to the 
large number of cells required per repair time point, sorting is a time consuming 
procedure that only allows the processing of a few samples per day. Thus the cells that 
were collected at each time point on the day of the experiment were frozen for later 
sorting. Freezing was done by resuspending washed, pelleted cells in cold freezing 
solution A (5mM KH2PO4, 25mM KOH, 30mM NaCl, 20mM L (+) lactic acid, 5mM 
Dextrose, 0.5mM MgCl2, 200mM Sorbitol in Milli-Q H2O) and gently mixing this 
suspension with an equal volume of freezing solution B (Freezing solution A with 20% 
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DMSO). Cells were then transferred to -150 °C for snap freezing and storage. Controls 
were prepared before freezing and every following step of the procedure. For sorting, 
aliquots of cells were quickly thawed and suspended in cold growth medium. The 
thawed cells were stained with propidium iodide (PI) in a permeabilizing solution (PI 
40 µg/ml, Tris 0.1M, NaCl 0.1M, MgCl2 5mM, Triton X-100 0.05%) sorted according to 
DNA content in a Beckman-Coulter Epics Altra Flow Cytometer. Several measures had 
to be taken to optimize cell recovery. Cells were collected in tubes pre-coated with 
Dichlorodimethylsilane (Merck, 2% solution in 1,1,1-trichloroethane) into 0.5 ml of heat 
treated fetal bovine serum. Sheath fluid (phosphate-buffered saline, PBS) and collection 
tubes were continuously chilled (10 °C) during sorting. Numbers of deposited cells were 
reconfirmed with manual counting in a Rosenthal chamber. Plugs for PFGE were 
prepared as described above, with the exception that cell numbers of sorted populations 
were adjusted to contain 1 x 105 cells/plug for G1 populations, and 0.5 x 105 cells/plug 
for G2 populations - to ensure equal amounts of DNA per plug. 
 
 Immunofluorescence staining 
For immunofluorescence detection of Rad51 foci in A549 cells were grown for two days 
on glass coverslips in 30 mm petri dishes aiming for a total number of 500.000 cells per 
dish. Prior to irradiation cells were subjected to a 15 min pulse of 10 µM 5-ethynyl-2´-
deoxyuridine (EdU). This was done in order to enable identification of cells that were 
synthesizing DNA at the time of irradiation, i.e. S-Phase cells. Immediately before 
irradiation EdU was washed away and cells were supplied with fresh medium. Cells 
were irradiated with 4 Gy X-rays and kept at 37 °C for, 5% CO2 for 3h. After incubation, 
cells were briefly washed with PBS and fixed with 2% PFA for 15 min. Fixed cells were 
washed with PBS again and permeabilized with 0.5% Triton X-100 in 100 mM Tris, 50 
mM EDTA. After permeabilization cells were washed twice with 3% BSA. Incorporated 
EdU was stained with the Click-iT® EdU Alexa Fluor® 647 imaging kit according to 
manufacturer’s instructions. Click chemistry allows the addition of a fluorophore to EdU 
incorporated in DNA without the need for denaturation. A Click reaction is a copper-
catalyzed covalent reaction between an azide and an alkyne. In this application, the EdU 
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carries the alkyne and the Alexa Fluor® dye presents the azide (Salic and Mitchison, 
2008; Invitrogen, 2011). Briefly, a reaction cocktail was prepared containing Copper 
sulfate (CuSO4), Alexa Fluor® 647 azide and the buffer and additive provided in the kit. 
Cells grown on coverslips were placed on 100 µl drops of the reaction cocktail on 
Parafilm (Pechiney Plastic Packaging) for 30 min and protected from light. Afterwards 
cells were washed again in 3% BSA and then incubated for one hour in a blocking 
solution containing 0,2 % gelatin and 0,5 % BSA fraction V in PBS. Cells were then 
incubated with primary antibody (Ab) in blocking solution overnight, using mouse 
monoclonal IgG2b Rad51 14B4 (Genetex) and rabbit polyclonal IgG cyclin B1 H-433 
(Santa Cruz). Incubation with secondary Ab for one hour was performed the next day 
after triple washing with PBS. Rad51 was detected using Alexa 488 polyclonal goat anti-
mouse IgG and cyclin B1 was detected using a polyclonal Alexa 568 conjugated anti 
rabbit IgG antibody from goat (both Invitrogen). Finally the coverslips were incubated 
with 4’,6-diamidino-2-phenylindole (DAPI) for staining of DNA and mounted on 
microscopic slides with ProLong® Gold antifade reagent (Invitrogen). Slides were stored 
in the dark for at least 24h before analysis by confocal laser scanning microscopy. 
Immunofluorescence detection of various IRIF in serum deprived MEF Lig4-/- was 
performed using the same antibody staining protocols using antibodies and dilutions as 
stated in Table 3.7, but without labeling with EdU. 
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Table 3.7: Antibodies Immunofluorescence 
 SDS-PAGE 
Denaturing SDS-Polyacrylamide gel electrophoresis allows the separation of proteins 
according to their molecular weight in a unidirectional electrical field. Cellular protein 
extracts for SDS-PAGE were prepared using RIPA buffer with the addition of a protease 
inhibitor cocktail. SDS-PAGE gels consisted of a 5% stacking and a 10% resolving gel, 
which were cast into Bio-Rad mini gel stands. For loading 20-50 μg (depending on the 
protein to be detected) cell extracts were mixed 1:1 with 2x Laemmli Buffer, denatured for 5 
min at 96 °C and centrifuged briefly at 13000 rpm. For electrophoresis a constant voltage of 
100 V was set for 2 h. 
IF Primary Ab Host/ type specificity Dilution Provider 
Cyclin B1 Rabbit polyclonal Human 1:100 Santa Cruz 
Rad51 (14B4) Mouse monoclonal Human 1:400 Genetex 
gH2AX (pS139) Mouse monoclonal Human, mouse 1:200 Abcam 
53BP1 (H-300) Rabbit polyclonal Human, mouse 1:200 Santa Cruz 
pATM-S1981 
(10H11.E12) 
Mouse monoclonal Human, mouse 1:400 Cell Signaling
IF Secondary 
AB 
Host/ type Specificity 
 
Provider 
Alexa488  goat polyclonal Mouse IgG 1:400 Invitrogen 
Alexa568  goat polyclonal Rabbit IgG 1:400 Invitrogen 
Alexa633  goat polyclonal Rabbit IgG 1:400 Invitrogen 
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3.2.10.1 Western blot 
During Western blotting proteins are transferred from a SDS-polyacrylamide gel onto a 
nitrocellulose membrane. Transfer was performed using an iBlot® dry blotting system 
(Invitrogen). For transfer pre-assembled blotting stacks (Invitrogen) containing a 
nitrocellulose membrane were used. After transfer the membrane was incubated for 2 h 
in 5% non-fat dry milk in 1 x TBS-T (0.05% Tween20 in 1 x PBS). For immunodetection 
the membranes were incubated overnight at 4 °C with primary Ab. After washing three 
times for 10 min in PBS-T the secondary Ab was incubated for 1.5 h and the membrane 
was again washed three times in PBS-T prior to detection. The Odyssey® Infrared 
Imaging System from LI-COR Biosciences was used for detection and analysis. 
Table 3.8: Antibodies Western blot 
WB Primary Ab Host/ type specificity Dilution Provider 
BRCA2 (3E6) Mouse monoclonal Human 1:500 GeneTex 
Rad51 (Ab-1) Rabbit polyclonal Human 1:2000 Calbiochem 
Rad52 (F-7) Mouse monoclonal Human 1:500 SantaCruz 
Ku80 (H-300) Rabbit polyclonal Human 1:400 SantaCruz 
GAPDH (MAB374) Mouse monoclonal Human 1:10000 Millipore 
WB Secondary 
Antibody 
Host/ type Specificity 
Dilution 
Provider 
IRDye 800CW Goat polyclonal rabbit 1:10000 LI-COR 
IRDye 800CW Goat polyclonal mouse 1:10000 LI-COR 
IRDye 680LT Goat polyclonal mouse 1:10000 LI-COR 
IRDye 680LT Goat polyclonal rabbit 1:10000 LI-COR 
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 Confocal laser scanning microscopy (CLSM) and foci 
quantification 
CLSM was performed on a LEICA TCS-SP5 confocal microscope to generate high 
resolution three dimensional image data of the stained cells. A key feature of a confocal 
microscope is the pinhole in front of the optical detector, a photo multiplier tube (PMT), 
that blocks out emission light that originates from all other points within the sample (out-
of-focus light) but the points in the focal plane of the objective. Thus a considerable 
increase in optical resolution and contrast as compared to conventional fluorescence 
microscopy is achieved. In CLSM the sample is scanned by a focused laser beam that 
moves over the specimen in lines and only illuminates a small focal volume of the 
sample at any given time. Confocal scanning in steps of 0.5 µM along the Z-Axis 
through the whole specimen was performed to obtain a stack of optical sections (Z-
stack). These pictures were used to create a three-dimensional image of the spatial 
structure of the investigated specimen, which was saved as LIF file and used for foci 
analysis. For data presentation, image stacks were merged into a single two-
dimensional picture, the maximum intensity projection (MIP), and exported as TIFF files. 
For each slide at least 5 fields were analyzed, with an average of 120 S- and 20 G2-
phase cells per sample. Parameters and settings used for CSLM and foci analysis are 
summarized in Table 3.9. 
Foci were scored using the ImarisXT® 6.0 Software. For this purpose LIF files were 
loaded into the Imaris software and processed using embedded MatLab features. 
Fluorescent spots with a diameter above 0.5 µm and intensity above a set gray value 
threshold, which was kept constant within experiments, were identified as foci and 
grouped into object clouds within each nucleus. The threshold values were kept identical 
throughout all experiments. The number of foci within each single nucleus was recorded 
and average foci numbers were calculated. It was discriminated between cells in G1, S 
or G2 phase based on the staining of cyclin B1 and EdU incorporation. 
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Table 3.9: Microscope settings and parameters 
Hardware Type 
Microscope Leica TCS-SP5 
Objective HCX PL APO lambda blue; 63.0x1.4 OIL UV 
Acquisition parameter Mode 
Scan direction Bidirectional 
Zoom 1 
Speed 400 Hz 
Resolution 1024x1024 
Excitation laser Intensity setting 
405 nm 25 % 
488 nm 10 % 
561 nm 20 % 
633 nm 20 % 
Detector Range PMT voltage / Offset 
415 nm – 490 nm 700.8 / -4 % 
505 nm – 547 nm 636.0 / -3.5 % 
587 nm – 621 nm 750.2 / -4,9 % 
657 nm – 684 nm 600.6 / -2 % 
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Imaris parameter Value 
Minimal spot size  0.5 µm 
 
 
 In vivo replication assay 
Inhibition of cellular DNA synthesis by various drug treatments was assayed by 
incorporation of tritium labeled thymidine (3H-thymidine). A549 Cells were grown in 25 
cm2 flasks under standard tissue culture conditions (37 °C, 5% CO2) with caps loosely 
screwed on for 24 h. One day before the experiment caps were fastened and flasks 
transferred to a warm room (37 °C) with normal atmosphere for another 24 h. All further 
steps of the experiment were performed in the warm room, to avoid decrease of 
replicative activity caused by temperature fluctuations. Drugs were added 30 min prior 
addition of the 3H-thymidine pulse. Controls were treated with the respective solvent. 3H-
thymidine was added to the drug containing medium to a concentration of 0,5 µCi/ml. 
Radioactive medium was removed 20 min later, cells were washed with ice cold PBS 
and trypsinized. The collected cells were kept on ice until further processing. Cells were 
counted with the Multisizer™ 3 cell counter (Beckman coulter) for later normalization to 
allow comparisons between samples. Cells were sucked onto a glass microfibre filter 
(WhatmanTM, GF/A, 25 mm) using a vacuum manifold. Trichloroacetic acid was added to 
the filters and incubated for approximately 5 min before being sucked through. The filters 
were washed with Millipore water and sucked dry. Subsequently the filters were 
transferred to the bottom of scintillation vials. To each vial 0.5 ml of 0.5 N NaOH were 
added and incubated overnight at 65oC. On the following day 0.5 ml 0.5 N HCl were 
added to each vial. Lastly, 10 ml of a scintillation cocktail (Unisafe 1, Zinsser Analytic) 
was added and the vials were mixed thoroughly using a vortex mixer. Measurements 
were taken in a Tri-Carb Liquid Scintillation Counter 1900 TR (Packard) 6 h to 24 h later. 
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4 Results 
 Inhibition of DNA replication in A549 cells 
One of the most prominent biological effects of ara-A in mammalian cells is inhibition of 
DNA replication. To determine the concentrations required to achieve effective inhibition 
at this endpoint we performed DNA replication assays with A549 lung carcinoma cells.  
Figure 13 Measurement of DNA replication by 3H-thymidine incorporation in A549 cells. A) Effect of 
ara-A treatment on DNA replication. Data points show the mean and standard deviation (s.d.) of three 
independent experiments. B) Effect of aphidicolin treatment on DNA replication. Data points show the 
mean and standard deviation (s.d.) of three independent experiments. C) Effect of hydroxyurea (HU) 
treatment on DNA replication. Data points show the mean and standard deviation (s.d.) of three 
independent experiments. Bold text in each graph indicates the IC50 values for DNA replication inhibition. 
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We also compared the inhibition of replication exerted by ara-A in this assay to the 
inhibition by two non-NA replication inhibitors. Specifically, we used hydroxyurea (HU), a 
small molecule known to inhibit RnR, and aphidicolin, an inhibitor of DNA polymerases 
(α,δ & ε).Replication was assayed by incorporation of tritium labeled thymidine (3H-
thymidine). Inhibitors were added 30 min prior to a 20 min pulse treatment with 3H-
thymidine. Subsequently cells were lysed and incorporation of 3H-thymidine was 
measured in a liquid scintillation counter.  
Figure 13 shows the results obtained with the replication inhibitors normalized to 
controls incubated without drug. The concentration at which 50% of the maximum 
inhibition of replication was achieved (IC50repl) was determined. Figure 13 A shows the 
inhibition of DNA replication by ara-A in A549 cells. An IC50repl of 6.25 µM was 
determined. Aphidicolin proved to be the most effective inhibitor of DNA replication in 
our experiments with an IC50repl of 0.027 µM (Figure 13 C). Much higher concentrations 
of HU were required to achieve comparable inhibition of replication (IC50repl= 45 µM; 
Figure 13 D).  
 
 Radiosensitization of cycling A549 cells by ara-A 
Having established the effectiveness of ara-A in our cell system, we next investigated 
the potential of ara-A to sensitize cycling A549 cells to IR. Cells were routinely 
maintained in the exponential phase of growth. For experiments, A549 cells were grown 
for 2 days and collected by trypsinization while still in the exponential phase of growth. 
Cells were plated at numbers (estimates from available survival data) aiming for 30-150 
colonies/dish after exposure to pre-defined radiation doses. Two slightly different 
protocols for survival assays with drug treatment and irradiation were applied within this 
work (protocols I and II; see Materials and Methods), that vary with regard to cell 
attachment time and drug pre-incubation before irradiation. Both protocols yielded 
comparable results. Figure 14 A (protocol I) shows strong radiosensitization of A549 
cells by 250 µM, 500 µM and 1000 µM of ara-A that increased with increasing drug 
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concentration. At concentrations of 500 µM and above a shoulderless survival curve was 
obtained.  
 
Figure 14 Effect of ara-A on the radiosensitivity to killing of A549 cells.  A) Exponentially growing 
A549 cells were exposed to the indicated doses of ara-A for 4 h after IR. Plating efficiency (PE) was 0.68, 
0.55, 0.42 and 0.29 for cells exposed to 0, 250, 500, and 1000 µM, respectively. Black circles represent 
cells treated with 0 µM ara-A, green circles cells treated with 250 µM ara-A, red circles cells treated with 
500 µM ara-A and blue circles cells treated with 1000 µM ara-A. The results shown represent the mean 
and standard error calculated from three independent experiments, each including double determinations. 
B) Comparison of radiosensitization by 4h post-irradiation treatment with ara-A and other DNA replication 
inhibitors in exponentially growing A549 cells. Red circles, ara-A (500 µM); green circles ara-A (250 µM); 
light blue triangles, HU (2000 µM); dark blue diamonds, aphidicolin (6 µM); black squares, control (no drug 
treatment). The results shown represent the mean and standard error calculated from three independent 
experiments, each including double determinations. 
 
Sensitizer enhancement ratios (SER) were calculated for radiosensitization by ara-A. 
Two different approaches were employed for this calculation: 1. SER was determined at 
at a fixed dose of 2 Gy by dividing the fraction of surviving cells (SF2) without drug 
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treatment by that measured with ara-A treated cells. 2. SER was determined at a fixed 
cell survival of 37% (the survival fraction at which statistically each cell within a 
population has received on average one lethal hit) by dividing the corresponding 
radiation dose of untreated cells to that of treated cells. The SER calculated for 500 µM 
ara-A was 3.7 based on SF2 and 2.9 based on 37% survival (Table 1).  
 
Table 4.1: Quantification of ara-A mediated radiosensitization. Sensitizer enhancement ratios (SER) 
were calculated for the survival of A549 cells at 2 Gy (SF2), as well as for the radiation dose where cell 
survival was 37% (37%sv). 
 Conc. Ara-A 
SER 
(SF2) 
SER 
(37%sv) 
250 µM 2.0 1.9 
500 µM 3.7 2.9 
1000 µM 7.9 3.8 
 
 
This observation was in agreement with earlier results showing radiosensitization of 
rodent and human cell lines (in the plateau and the exponential phases of growth, 
respectively) by treatment with ara-A. Since ara-A effectively inhibits DNA replication we 
inquired whether radiosensitization by ara-A may be attributable to inhibition of this 
cellular function alone. To answer this question we compared radiosensitization elicited 
by post-irradiation treatment with ara-A with the radiosensitizing effects of HU and 
aphidicolin (Figure 14 B; Protocol II, 40 min pre-incubation). Since these compounds 
inhibit DNA replication with widely different efficiencies we used the IC50repl values as 
orientation for the comparison of the radiosensitizing effect. We observed that 
aphidicolin at 6 µM (~220-fold IC50repl) did not sensitize cells to IR at all. In contrast, ara-
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A at 250 µM (40-fold IC50repl) and 500 µM (80-fold IC50repl) caused marked 
radiosensitization of A549 cells. HU at 2000 µM (~45-fold IC50repl) did cause 
radiosensitization in these cycling cells, but the effect was only modest compared to the 
effect of ara-A. From this result we concluded that effects beyond DNA replication 
inhibition must underpin the radiosensitizing effect of ara-A, which should be more 
specific than global inhibition of DNA replication. We hypothesized that the drug 
somehow interferes with the repair of IR-induced DSB. Although inhibition of DNA 
synthesis alone appears not to be sufficient to explain the radiosensitizing effect of ara-
A, it may well play a role in the interference with DSB repair. Pathways of HRR are the 
only DSB repair mechanisms known to involve extensive DNA synthesis. Thus, we 
decided to first investigate possible interactions of ara-A with HRR. 
 
 Impact of ara-A treatment on HRR 
 Inhibition of IR induced RAD51 foci formation by ara-A 
Rad51 is the central recombinase in HRR that forms a nucleoprotein filament on the 
resected DNA ends during the repair process. Accumulation of Rad51 at sites of DSB 
can be visualized by immunofluorescence staining as discrete foci. These foci form and 
decay with characteristic kinetics upon exposure of cells to IR. Scoring of Rad51 foci is 
widely used as a surrogate marked of HRR function. We applied this method to 
investigate possible interference of ara-A with HRR. 
We used exponentially growing A549 cells and selected a radiation dose (4 Gy) and 
time point of observation (3 h) known to produce maximum numbers of Rad51 foci 
(previous unpublished work from our group). In addition to Rad51 staining, we included 
additional staining protocols allowing the assignment of each cell in a particular phase of 
the cell cycle. Expression of cyclin B1 is regulated differentially throughout the cell cycle: 
Expression starts in S-phase and continues in G2. However, staining with cyclin B1 is 
not sufficient for a reliable assignment of cells in G1, G2 and S cells. Expression of 
cyclin B1 is weak in early- to mid-S phase cells, but remains high between late-S and G2 
phase. Therefore, to improve the discriminatory power of our assay we also included 
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incorporation and staining of EdU. EdU is an analog of thymidine that was recently 
developed as an alternative for BrdU for the detection of S-phase cells in a proliferating 
cell population (Cappella, 2008). EdU like BrdU is incorporated into DNA without 
inhibiting DNA replication. However, for detection of BrdU, DNA must be denatured in 
order to grant the required antibodies access to the incorporated BrdU nucleotides. 
Detection of EdU on the other hand is based upon a chemical reaction whereby a 
fluorophore is coupled covalently to the incorporated nucleotide without the need for 
DNA denaturation. Together, EdU and Cyclin B1 staining allowed for an unambiguous 
assignment of each analyzed cell in a phase of the cell cycle. EdU positive cells were 
identified as being in S-phase at the time of irradiation and were analyzed either during 
S-phase or in the subsequent G2–phase of the cell cycle. Cells that were positive for 
cyclin B1 but negative for EdU were scored as being in G2 during the time of irradiation 
and remaining in G2 in the following repair time interval. Cyclin B1 and EdU negative 
cells were scored as being in G1 at the time of irradiation. G1 cells were not scored in 
the context of the present set of experiments, as G1 cells fail to develop Rad51 foci after 
IR (Figure 15 A).  
Our labeling strategy allowed us to stringently discriminate G1, S and G2 phase cells 
from each other and allowed us to analyze a large number of S-phase cells (385 
(+/-106); n= 3). However, the number of G2 cells that could be analyzed was relatively 
small (61 (+/-19); n= 3). This is mainly due to two factors: First, in an exponentially 
growing culture of A549 cells, the number of cells in G2 is typically only about a quarter 
of the number of cells in S. Second, in our experiments cells were fixed 3h after 
irradiation, a time during which a large proportion of cells that were in G2 could have 
entered mitosis without irradiation. However, irradiation with a dose of 4 Gy is expected 
to induce a G2 block that would prevent most G2 cells from progressing into mitosis. 
Nevertheless, more cells may have escaped the G2/M checkpoint activation than 
expected. This could explain why we did not only find 4 times more S-phase cells, but 
about 6 times more. 
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Figure 15 Inhibition of Rad51 foci formation in A549 cells by ara-A. Cells were fixed and stained 3 h 
after exposure of exponentially growing A549 cells to 4 Gy X-rays and treatment with different 
concentrations of ara-A. To label cells in S-phase, cultures were exposed to an EdU pulse (15 min) just 
before irradiation. Late-S and G2-cells were identified by staining for Cyclin B1. A) Split channel 
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representation of confocal microscopy immunofluorescence images. Micro molar indications above the 
individual blocks show the respective ara-A concentration. The left column of each block shows an overlay 
of DAPI (blue), EdU (white), Cyclin B1 (red) and Rad51 (green) staining. The middle column shows an 
overlay of DAPI (blue) and Rad51 (green) staining. The right column shows Rad51 staining alone (green). 
B) Number of Rad51 foci scored in S-phase (green circles and line) and G2-Phase cells (red circles and 
line) as a function of ara-A concentration. Mean foci number and s.e.m. from 3 independent experiments 
are shown. Each S-phase data point represents a total of 384 (±105) cells (~130 S-phase cells were 
analyzed for each concentration in every experiment). Each G2 data point represents of 61 (±19) cells on 
average in 3 independent experiments (~20 G2-phase cells were analyzed for each concentration in every 
experiment). C) Comparison of the concentration dependency of survival of A549 cells at 2 Gy (post-
irradiation treatment with ara-A for 4 h) and Rad51 foci suppression in A549 by ara-A. Curves were 
derived from the data presented in Figure 14 and Figure 15 B. 
Quantitative analysis of immunofluorescence images revealed a marked reduction in the 
number of Rad51 foci in ara-A treated cells irradiated during the S-phase (Figure 15 B; 
green circles). Half maximum inhibition of Rad51 foci formation was about 165 µM ara-A 
and Rad51 foci formation almost ceased above 500 µM. The ara-A concentration- 
Rad51 foci-effect relationship is very similar to that of radiosensitization to killing at 2 Gy, 
which implies a cause-effect relationship between these two endpoints (Figure 15 C). 
Higher concentrations of ara-A appeared to be required in G2 to reduce the number of 
Rad51 foci to similar levels like in S-phase cells. Nevertheless, the reduction of Rad51 
foci formation in ara-A treated G2-phase cells followed a similar trend. At concentrations 
above 250 µM a strong reduction was observed in the number of Rad51 foci and more 
than 50% inhibition was achieved at 1000 µM ara-A (Figure 15 B; red triangles and line). 
We concluded therefore that ara-A must exert a strong inhibitory effect on HRR. Figure 
15 C shows the normalized number of Rad51 foci (S + G2) and the normalized survival 
at 2 Gy, both plotted against the ara-A concentration. The curves show an almost 
identical course in dependence of drug concentration, suggestive of an underlying 
cause-effect relationship. 
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 Proficiency in HRR is a prerequisite for radiosensitization by 
ara-A 
Results obtained by scoring Rad51 foci prompted us to hypothesize that inhibition of 
HRR may constitute an important mechanism of radiosensitization by ara-A. If inhibition 
of HRR was a major mechanism of radiosensitization, sensitization of cells already 
deficient for HRR should be reduced as compared to HRR proficient cells. Maximum 
suppression of HRR would theoretically be achieved in the absence of Rad51 (see also 
Figure 19). Since knockout of Rad51 is lethal in mice as well as in human cell lines, we 
attempted to induce a transient deficiency in HRR by RNAi mediated knockdown of 
Rad51. In order to enable direct comparisons with the already available cell survival 
measurements (see above), we used A549 cells to carry out these knockdown 
experiments. We used the same siRNA against Rad51 used in the DR-GFP experiments 
and as a negative control a siRNA against GFP. Cells were grown for 48 h before 
transfection with the respective siRNA. After transfection cells were cultured for another 
24h before collection and processing for plating and irradiation for colony formation. 
Cells were left for 1.5h to attach before addition of ara-A. Cells were pre-incubated with 
the drug for 45 min before irradiation and the drug was washed away 4h later (Protocol 
II). Cellular levels of Rad51 protein were monitored by western blotting and proved to be 
reduced by more than 90% after transfection of the corresponding siRNA (Figure 16 A). 
Plating efficiency (PE) of cells transfected with siRNA targeting GFP was equal to that 
commonly found for untreated A549 cells. Furthermore, cells transfected with this control 
exhibited normal radiosensitivity to killing and were radiosensitized by ara-A to the same 
extend as untransfected cells in previous experiments. 
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Figure 16 Requirement of HRR for the radiosensitization by ara-A.  A) Detection of RAD51 protein in 
A549 cells 48h after transfection with either control (siGFP) or Rad51 (siRad51) siRNAs. GAPDH was 
used as a loading control. Detection of RAD51 and GAPDH was performed simultaneously using 
secondary antibodies with two different infrared dyes. Rad51 protein was reduced by more than 90% 
through RNAi. B) Plating efficiencies (PE) of siRNA transfected A549 cells. Cells transfected with the 
control siRNA exhibit the same PE typical for untransfected A549 cells. Cells transfected with siRad51 
showed a decreased PE of about 20%. Bars show mean and s.d. from 3 independent experiments. C) 
Radiosensitivity of siRNA transfected cells treated with different concentrations of ara-A. Dotted lines: 
Cells transfected with siGFP. Solid lines: Cells transfected with siRad51. Black circles and curves: No ara-
A treatment. Green diamonds and curves: Treatment with 250 µM ara-A. Red squares and curves: 
Treatment with 500 µM ara-A. Plots show mean and s.d. of 3 independent experiments. 
This confirmed that the transfection procedure itself had no significant impact on the 
viability and radiosensitivity of cells. On the other hand, we found that the PE of cells 
transfected with siRNA against Rad51 was reduced (20% +/- 6% vs. 72% +/- 6) (Figure 
16 B). This was not unexpected, as cells deprived of key HRR factors have been shown 
to display reduced PE (Feng, 2011; Liu, 2011; Short, 2011; Jensen, 2013). Importantly, 
cells treated with siRNA against Rad51 were significantly more radiosensitive than the 
corresponding controls. This is in agreement with the radiosensitive phenotype shown 
by others after Rad51 knockdown and confirms that cells retaining their ability to form 
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colonies after transfection of Rad51 siRNA do not represent an untransfected 
subpopulation (Liu, 2011; Short, 2011). In Rad51 depleted cells treatment with ara-A 
failed to further increase the radiosensitivity at most irradiation doses (Figure 16 C). Only 
at the highest radiation dose used in these experiments (5 Gy) we observed a significant 
(p= 0.006) radiosensitization by ara-A. However, the shape of the survival curve and the 
observed increase in radioresistance makes it likely that this radiosensitization derived 
from a small subpopulation that retained more HRR function than the bulk of cells. We 
concluded that HRR proficiency is a pre-requisite for efficient ara-A mediated 
radiosensitization. 
 
 Effects of ara-A on homology directed repair in reporter gene 
assays 
4.3.3.1 Effects of ara-A on HRR 
Several cellular reporter gene systems exist that claim to provide a measure for the 
activity of specific DSB repair pathways. To further investigate inhibition of HRR by 
ara-A we employed cell lines bearing stable integrations of a repair reporter construct 
that is designed to detect events that can arise due to the activity of the SDSA sub-
pathway of HRR. This construct, DR-GFP, consists of two modified GFP gene 
sequences oriented as direct repeats (hence the name DR-GFP; see Figure 17 A). The 
first of the two sequences is a full length GFP gene (SceGFP), which is disrupted by an 
I-SceI site and a premature Stop-codon. It is followed by a 3´ truncated inactive copy of 
GFP (iGFP). Functional GFP cannot be expressed from any of the two GFP gene 
sequences in the construct. Upon expression of the I-SceI endonuclease a DSB is 
introduced in the SceGFP gene. If this DSB is repaired by HRR using iGFP as donor 
sequence, the I-SceI site and the premature Stop-codon in the SceGFP gene will be 
replaced by functional GFP sequences. Such a gene conversion event results in the 
reconstitution of a functional GFP gene. Cells that have undergone this form of repair 
can be easily detected by flow cytometry due to the resulting GFP fluorescence.  
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A CHO cell line, Draa40, carrying the DR-GFP construct was immediately available to 
us. Initial experiments were carried out using the following experimental protocol: CHO 
cells were transfected with the I-SceI expression plasmid (pCMV3xNLSI-SceI; Figure 
17 A) using electroporation (Nucleofector; Lonza), which requires cell trypsinization and 
the generation of a suspension with high cell concentration. After transfection cells were 
plated with normal growth medium and incubated for 3h at under standard culture 
conditions to allow for reattachment of cells and the expression of I-SceI. Three hours 
later, ara-A was added and the cells were maintained with the drug for an additional 4h. 
At the end of the treatment time interval, drug-containing medium was removed and 
cells were washed and supplemented with fresh growth medium. Cells were collected 
24h after transfection for analysis by flow cytometry (Figure 17 B). 
Using this protocol we first investigated the concentration-dependent effects of ara-A on 
HRR. Ara-A is significantly more toxic to CHO than to human cells. Therefore we chose 
500 µM ara-A to be the upper concentration limit. We found a strong correlation between 
increasing ara-A concentration and decreasing proportion of cells developing green 
fluorescence, indicating inhibition of HRR (Figure 17 C). 
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Figure 17 Suppression of HRR in DRaa40 cells harboring the DR-GFP reporter. A) Schematic of the 
stably integrated DR-GFP reporter construct and the I-SceI expression plasmid used to induce DSB in 
transfected cells. B) Representative flow cytometry dot plots of DRaa40 cells treated with different 
concentrations of ara-A. GFP was measured in fluorescence channel 1 (FL1). For better depiction of the 
positive populations, the GFP signal was plotted aginst signal recorded in FL3, for which no stain is 
included and in which cells showed very low autofluorescence. C) Graphical representation of HRR 
efficiency as a function of ara-A concentration (treatment 3h-7h after transfection) in DRaa40 cells. Data 
points show the mean and s.d. from 3 independent experiments.  
 
At 500 µM ara-A suppressed HRR by about 70% (Figure 17 B&C). We next sought to 
determine whether there is a temporal relationship between HRR inhibition and the 
position of the treatment time window. We performed experiments in which we 
compared the effect of the default 3-7h post-transfection treatment to equal duration 
treatments applied at later times after transfection. We found that inhibition was 
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significantly weaker (p= 0.002) when the treatment was initiated 7h after transfection, 
and not present when treatment started 20h post transfection (Figure 18). 
 
Figure 18 Time dependence of the effect of ara-A in DRaa40 cells (DR-GFP).  A) Effect of a shift of 
the 4h treatment window to later times after transfection. Cells were treated with 500 µM ara-A for 4h. 
X-axis categories indicate the time of treatment start after transfection of the I-SceI plasmid. Data shown 
represent the mean and s.d. from three independent experiments.  
 
When the human osteosarcoma cell line U2OS 282C, which also carries the DR-GFP 
construct, became available to us, we switched to this more relevant human cell system. 
The switch to a human system also gave us the opportunity to validate the assay by 
silencing of various factors implicated in HRR with siRNAs designed to target human 
transcripts. As a negative control we used a siRNA against Luciferase (Ctrl). Cells were 
transfected with siRNA using nucleofection and incubated for 24h under standard 
culturing conditions before transfection with the I-SceI expression vector. Another 24h 
later (48h after siRNA transfection) cells were collected and analyzed by flow cytometry. 
The efficiency of the knockdowns was confirmed at the protein level by western blotting 
(Figure 19 and (Costantino, 2013)). Knockdown of both, BRCA2 and Rad51, lead to a 
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strong and highly significant reduction of HRR in this system (Figure 20 B). Silencing of 
Rad51, as expected, had the strongest effect reducing the frequency of gene conversion 
events by more than 98 % (p= 0.00004). Silencing of BRCA2, which is known to play an 
important role in loading Rad51 onto ssDNA, resulted in a decrease of HRR events by 
almost 80 % (p= 0.017). Rad52 is a crucial factor for HRR in yeast, but is not essential 
for this process in human cells, probably due to a functional redundancy with BRCA2 
(Feng, 2011). Accordingly, Rad52 knockdown is associated with a reduction of HRR by 
only approximately 25 %, but which was still significant (p= 0.049) (Figure 19 B). 
 
Figure 19 Knockdown of components of HRR in U2OS 282C cells (DR-GFP). A) Detection of protein 
levels by western blot. (Transfection and sampling were conducted by Simon Magin; gel runs, blotting and 
detection by Dr. Emil Mladenov). Upper left panel: RNAi of Rad52; knockdown>90%. Ku80 was used as 
loading control. Upper right panel: RNAi of BRCA2; knockdown~65%; loading control Ku80. Lower panel: 
RNAi of Rad51; knockdown 87%; loading control GAPDH. B) Quantification of GFP positive cells 24h after 
I-SceI-plasmid transfection and 48h after siRNA transfection. Bars show mean and s.d. of multiple 
experiments. Ctrl n=4; Rad52 n=5; BRCA2 n=3; Rad51 n=6. 
 
Having confirmed the validity of U2OS 282C cells as a test system for HRR, we 
proceeded to test the effects of ara-A on HRR in human cells. Based on additional 
experimentation for optimization (Figure 35) we slightly modified the treatment protocol 
used in previous experiments and preponed drug-addition to 1.5h after transfection of 
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the I-SceI expression plasmid. After 4h of incubation with ara-A the medium was 
removed, cells were washed twice and supplied with fresh medium. Cells were analyzed 
by flow cytometry 24h after transfection.  
Figure 20 Inhibition of HRR by ara-A in U2OS 282C cells.  A) Top: Schematic of DR-GFP construct 
present as single copy in this cell line. Bottom: representative flow cytrometry dot plots of samples treated 
with different concentrations of ara-A. B) Titration of ara-A effect on HRR as measured 24h after 
transfection with the I-SceI expression plasmid. Data points represent mean and s.d. from 3-5 
independent experiments. 
Incubation of U2OS 282C with ara-A for 4h resulted in a clear, concentration dependent 
decrease of the frequency of gene conversion events (Figure 20 A&C). These results 
confirmed the observations made with immunofluorescence staining of IR induced 
Rad51 foci. We concluded that ara-A exerts a strong inhibitory effect on HRR. 
 
4.3.3.2 Effects of ara-A on SSA 
Besides HRR, SSA is the other homology directed process for the repair of DSB. SSA 
repairs DSB by the intramolecular annealing of homologous sequences (see 
Introduction). Thus, there is no conceptual requirement for the presence of a sister 
chromatid or de novo synthesis of DNA. SSA frequently leads to the creation of large 
deletions and must be considered a highly error prone rejoining process. To investigate 
potential effects of ara-A on SSA we employed another repair reporter system. 
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The SA-GFP construct consists of two consecutive truncated GFP-ORFs separated by 
2,7kb (Figure 21 A). The two sequences share 266nt of homology (Gunn and Stark, 
2012). The first ORF (5´-GFP) is truncated at its 3´-end the second (3´-GFP) is truncated 
at its 5´-end and harbors an I-SceI site. Signal generation after repair by HRR is 
hampered by a premature stop codon at the 3´-end of the first ORF (5´-GFP). Upon 
repair by SSA a functional GFP gene is reconstituted.  
We obtained a U2OS cell line (283C) which carries this construct stably integrated into 
its genome. First we wanted to evaluate this system in a similar manner as we did for 
the DR-GFP cell line 282C. The protein repertoire required for SSA in mammalian cells 
has not been very well characterized, but it is known that a functional HRR pathway 
strongly suppresses SSA events (Tutt, 2001; Stark, 2002). Therefore we decided to 
knock down the same set of proteins involved in HRR that was used in the evaluation of 
DR-GFP in U2OS 282C. Efficiency of knockdowns was equivalent to those achieved in 
U2OS 282C cells (compare Figure 19 A). 
Consistent with the reported suppression of SSA by HRR, knockdown of the key HRR 
factors BRCA2 and Rad51 resulted in an increase in the frequency of SSA events in our 
experiments by about 400% and 500% respectively (Figure 21 B). Knockdown of Rad52, 
which had only shown mild effects on HRR, resulted in a reduction of SSA by 
approximately 55%. This suggests a more important role for Rad52 in SSA than in HRR 
in human cells and is in line with findings by other groups (Stark, 2004). Together these 
results seemed to confirm the validity of the SA-GFP system in U2OS 283C cells. We 
investigated the effects of ara-A on SSA using the same treatment plan as in 
experiments with the DR-GFP construct in 282C cells. 
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Figure 21 Effects of ara-A on SSA mediated repair in U2OS 283C cells (SA-GFP).  A) Schematic of 
the SA-GFP construct. B) Effect of knockdown of several HRR factors on the SSA mediated repair of SA-
GFP. Knockdown of BRCA2 and Rad51 lead to a dramatic increase in the proportion of GFP positive 
cells. C) Representative FACS plots of samples treated with different concentrations of ara-A measured 
24h after transfection with the I-SceI expression plasmid. D) Titration of the effect of ara-A on SSA 
mediated repair, measured by flow cytometry 24h after transfection of the I-SceI expression plasmid. The 
dashed red line is a reproduction of the curve showing the effect of ara-A on HRR from Figure 20 C. Data 
points represent mean and s.d. from 3 independent experiments. E) Increase of SSA at higher 
concentrations of ara-A is dependent on inhibition of HRR. In cells that have been rendered deficient for 
HRR by RNAi of Rad51 no increase in SSA occurs at higher concentrations. Cells were transfected with 
siRNA for 48h and I-SceI was expressed for 24h prior to analysis. Data is normalized to the respective 
control without ara-A treatment. Circles and solid line: Cells silenced for Rad51. Squares and dashed line: 
Cells only transfected with I-SceI expression plasmid 24h prior to analysis. Plot represents data from one 
experiment. 
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Interestingly, we found that after an initial reduction of the efficiency of SSA at ara-A 
concentrations up to 150 µM, the frequency of GFP positive cells increased again at 
higher concentrations of ara-A (Figure 21 C&D) leading to full recovery at around 1500 
µM ara-A. We speculated that this recovery of SSA at higher concentrations resulted 
from relieve of suppression mediated by Rad51 dependent HRR. We tested this 
hypothesis by silencing of Rad51 before subjecting U2OS 283C cells to ara-A treatment 
(Figure 21 E). As predicted, knockdown of Rad51 before induction of the DSB resulted 
again in a strong increase of repair by SSA compared to cells that were only transfected 
with the I-SceI expression plasmid (compare Figure 21 B). For better comparability 
values from Rad51 knockdown cells and cells left untreated before I-SceI expression 
were normalized to their respective controls (Figure 21 E). No recovery of SSA at higher 
concentrations was observed in cells deprived of Rad51, but SSA could still be reduced 
by about a third (Figure 21 E). This confirmed that the observed increase of SSA at 
higher concentrations of ara-A stemmed from the concomitant inhibition of HRR. 
Furthermore this result indicated that only a fraction of SSA events is sensitive to 
inhibition by ara-A, while about two thirds of SSA events are not. 
 
 Impact of ara-A treatment on NHEJ 
 Non-homologous rejoining of distal ends in paired DSB 
Taken together the above results suggested an important role of HRR inhibition in the 
ara-A-mediated radiosensitization of cycling cells. However, a large amount of data from 
earlier studies showed strong inhibition of the repair of potentially lethal damage (PLD) 
by ara-A in non-cycling plateau phase cultures. Since the cell types used in most of 
these studies show extensive accumulation of cells with G1-DNA content in the plateau 
phase of growth, PLD inhibition in these populations cannot be explained by invoking 
inhibition of HRR. Therefore we inquired whether there may be other DSB repair 
pathways that are inhibited by ara-A.  
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The above results obtained with the SA-GFP construct indicated that mutagenic repair 
pathways may benefit from ara-A treatment under certain circumstances. SSA 
represents a homology dependent mode of mutagenic repair that results in the 
introduction of large deletions. Stark and colleagues have developed a reporter 
construct, EJ-5GFP, that also allows the measurement of non-homologous rejoining 
events associated with extensive deletions. The EJ5-GFP construct (integrated into 
U2OS 280A) consists of an intact EGFP ORF which is separated from its promoter by 
an interspersed puromycin resistance gene (Puro). In its uncut form only Puro is 
expressed. The Puro gene is flanked by two I-SceI sites. Upon cleavage at these sites 
rejoining can take place either between the proximal ends, leaving Puro in its place, or 
between the distal ends (distal end joining), resulting in excision of Puro and enabling 
expression of EGFP (Figure 22 A). This construct was stably integrated in U2OS cells 
resulting in the creation of the derivative cell line U2OS 280A. 
The fidelity of the DNA-PK dependent pathway of NHEJ (D-NHEJ) is known to be higher 
than that of B-NHEJ, which is also frequently associated with large sequence losses. 
Therefore, we used chemical inhibition of DNA-PKcs to test if the EJ5-GFP can be used 
as an assay for the fidelity of NHEJ. NU7441 is a specific inhibitor of DNA-PKcs and 
induces a strong DSB repair defect in D-NHEJ proficient cells (Figure 38). Cells 
transfected with the I-SceI expression plasmid were treated with increasing 
concentrations of NU7441 for 6h after transfection. The proportion of GFP positive cells 
increased with increasing concentration reaching a plateau at approximately 5 µM 
(Figure 22 B). Perturbation of D-NHEJ by inhibition of DNA-PKcs resulted in an increase 
from 12% GFP positive cells in the untreated control to more than 20% in cells treated 
with 5 µM or more of Nu7441. We concluded that the use of distal over proximal ends in 
the repair of I-SceI induced tandem DSBs is indicative of compromised D-NHEJ, which 
is compensated for by B-NHEJ.  
We proceeded to also perform experiments similar to those carried out with U2OS cells 
carrying the DR-GFP and SA-GFP constructs. We found that a 4h treatment with ara-A 
resulted, after a small decrease at lower concentrations (50 µM and 150 µM), in a 
concentration dependent increase in the proportion of GFP positive cells in the U2OS 
280A cell line (Figure 22 C&D). This increase was found to be significant at all 
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concentrations above 250 µM (p<0.05). At 2000 µM ara-A, joining of distal ends 
increased to 130% (+-22%) of controls. Figure 22 D also shows the results obtained with 
the DR-GFP and SA-GFP constructs as dashed lines.  
 
Figure 22 Effect of ara-A on the joining of distal ends in U2OS 280A (EJ5-GFP).  A) Schematic of the 
EJ5-GFP construct. B) Effect of DNA-PKcs inhibition on the joining of distal ends. Cells were rendered 
deficient in D-NHEJ by treatment with the DNA-PKcs inhibitor Nu7441 for 6h. The inhibition resulted in a 
strong increase in the frequency of distal–end joining. Plot represents data from one experiment. An 
experiment with different treatment schedule yielding qualitatively equivalent results is presented in the 
appendix (Figure 39). C) Representative dot plots of U2OS 280A cells treated with different concentrations 
of ara-A. Flow cytometry was performed 24h after transfection of the I-SceI expression plasmid. D) 
Titration of the effect of ara-A on the use of distal ends for the repair of a DSB. Blue circles and line 
represent the mean and s.d. of three independent experiments with U2OS 280A cells and ara-A. The 
dashed red line shows the effect of ara-A on HRR and has been transferred from Figure 20 C. The 
dashed green line shows the effect of ara-A on SSA and has been transferred from Figure 21 D. 
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Taken together the results obtained with these DSB repair reporter constructs indicated 
that ara-A elicits a clear inhibition of the faithful HRR pathway, while mutagenic repair 
pathways like the rejoining of distal DSB ends or SSA appear to be favored and show 
enhancement. 
 The effect of ara-A on mutagenic repair in the EJ-RFP system  
The EJ5-GFP construct allows the detection of a very specific repair event by NHEJ that 
results in the elimination of the intervening sequence between two I-SceI sites. This can 
be interpreted as an indicator for the tendency of a cell to perform mutagenic repair. 
However, the repair events that result in signal generation in this reporter system 
represent only a very small part of the spectrum of possible mutagenic NHEJ events.  
A repair reporter system that allows the detection of the majority of mutagenic events 
was developed by Bindra et al. (Bindra, 2013) and stably integrated into U2OS cells. 
The resulting cell line was named U2OS EJ-DR. The EJ-RFP system consists of a 
tetracycline repressor gene and an independent DsRed gene containing several TetR 
binding sites (Figure 23 A). Expression of the DsREd gene is constitutively repressed. 
The TetR gene contains an I-SceI site that is cut upon expression of I-SceI in the cells. If 
the resulting DSB is repaired with mutagenic consequences the TetR gene is disrupted 
and a DsRed signal can develop. This requires clearance of the remaining TetR protein 
and subsequent expression of the DsRed gene. In addition maturation of DsRed protein 
requires more time than the maturation of GFP proteins (Magin, 2013). These factors 
are reflected by the slow kinetics of appearance of red fluorescent signal in the cell 
population (Figure 37 A&B). DsRed positive cells starts to appear 3 days after 
transfection of the I-SceI plasmid and after 4 days a robust population had built up 
(Figure 37 A&B). Thus, measurements using this system could not be performed after 
24h as in the other reporter cell lines, but had to be carried out 96h after transfection. 
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Figure 23 Effect of ara-A on mutagenic DSB repair pathways in U2OS EJ-DR cells.  A) Schematic of 
the EJ-RFP system. B) DsRed expression in EJ-DR cells 96h after transfection. Non-transfected cells (no 
I-SceI) have a substantial background of DsRed positive cells. Transfection of I-SceI causes an increase 
in the portion of DsRed positive cells (I-SceI + 0µM). Treatment with ara-A increased the fraction of DsRed 
positive cells significantly (p< 0.05) above 250µM (I-SceI 500µM-2000µM). Y-Axis was limited to a fixed 
value to allow better comparison of the fraction of positive cells. Equal amounts of cells were measured for 
each sample (1.5*104). C) Effect of ara-A treatment on mutagenic end-joining in EJ-DR cells 96h after 
transfection of the I-SceI expression plasmid. Measured values were corrected for background and 
normalized to the corrected control (0µM). Data points represent mean and s.d. from three independent 
experiments. 
Unlike the other reporter cell lines introduced so far the EJ-DR cells possessed a 
significant background, i.e. cells with fluorescent signal without induction of I-SceI 
(between 1.5%-5% of the total population; Figure 23 B). Therefore, measured values 
were corrected by the background detected in untransfected cells and normalized to the 
number of DsRed positive cells in the control (I-SceI transfected without drug treatment). 
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We observed that in cells that were treated with ara-A for a four hour period after 
transfection, the proportion of cells showing red fluorescence was elevated (Figure 
23 C). With rising concentrations of ara-A the amount of mutagenic repair of the I-SceI 
induced DSB appeared to increase. At a concentration of 2000 µM the corrected portion 
of DsRed positive cells was 250% of the control (Figure 23 C). 
 
 Effect of ara-A on DSB repair kinetics in D-NHEJ proficient cells 
Results from experiments involving the SA-GFP, EJ5-GFP and EJ-RFP constructs 
suggested that treatment with ara-A induces a shift towards more mutagenic modes of 
DSB repair. While for SA-GFP the responsible repair pathway is clear (SSA), for 
EJ5-GFP and EJ-RFP interpretation is less unequivocal. However, results obtained with 
Nu7441 in U2OS 280A cells prompted us to hypothesize that signal generation in the 
EJ5-GFP construct is indicative of B-NHEJ activity. We asked whether this shift towards 
mutagenicity and putative promotion of B-NHEJ, as well as inhibition of HRR would be 
reflected in the kinetics of DSB repair in cells treated with ara-A. 
PFGE is a method that allows the physical detection of DSB in DNA. The amount of 
DSB and the kinetics of their repair are measured in the pooled total DNA of irradiated 
cell populations. The method is described in detail under Materials and Methods. Briefly, 
cells are embedded in small agarose blocks (plugs), which are loaded onto agarose gels 
that are subjected to an alternating electrical field for long run times (40 hours). DSB 
reduce the molecular weight of DNA and generate DNA fragments that can migrate from 
the plug into the gel. Higher molecular weight chromosomal DNA remains trapped within 
the plug. 
To obtain a measure for the amount of DSB present in a sample, the fluorescence signal 
generated by the stained DNA that leaves the plug and enters the lane is divided by the 
total signal of the same sample (plug + gel lane signal). This ratio is termed the fraction 
of DNA released (FDR). A linear relationship exists between FDR and radiation dose 
(Figure 24 B). Dose response curves (DR) are generated with samples that are 
irradiated with different doses of X-rays, but are not allowed to repair before processing. 
The DR data is used to express the FDR of cells that were allowed to repair as radiation 
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dose equivalents (DEQ). In this way repair kinetics (RK) are obtained that start (0 h) with 
a total DSB load equivalent to the initially delivered radiation dose (here 20 Gy). In repair 
proficient cells the kinetics of repair, as seen by the decline in DEQ, is biphasic. A fast 
component repairs ~80% of DSB within 0.5h-1h after irradiation and is followed by a 
second one that removes the remaining DSB within 4h-8h after IR. 
It is well known that some pathways of DSB repair operate with varying efficiencies 
depending on the growth state and phase of the cell cycle. HRR for example can only 
operate during the S an G2 phase, while B-NHEJ is known to be inhibited in the plateau 
phase of growth but enhanced in G2 (Wu, 2008b; Singh, 2011) (see Introduction). Thus, 
it is possible that repair pathway specific effects of ara-A would be masked by the 
distribution of cells over all phases of the cell cycle when using asynchronous samples.  
To overcome this complication we combined FACS with PFGE. In this way we could 
analyze populations highly enriched in G1 or G2 phase cells (Figure 24 A). Separate DR 
curves were prepared for asynchronous, G1 and G2 cells. G1 and G2 phase cells show 
a higher FDR per Gy than asynchronous cells (Figure 24 B). This is due to the S-phase 
cells present in the asynchronous population, which are known to display a lower FDR 
per Gy due to replication associated DNA structures (Latz, 1996; Dewey, 1997).  
Treatment with 1 mM ara-A did not change the kinetics of DSB repair in asynchronous 
cells (Figure 24 C). Excellent purities were achieved for cells sorted in G1 and G2 from 
exponentially growing cultures. For G1 cells an enrichment of 95.8% +/- 2.0% and for 
G2 cells an enrichment of 81.1% +/- 6% was achieved. These purity levels were 
maintained for all populations sorted at the different repair time points; the cell cycle 
analysis is shown in the right panels of Figure 24 C, D and E. Neither G1 nor G2 cells 
showed inhibition of DSB repair after incubation with 1 mM ara-A. 
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Figure 24 DSB repair by PFGE in sorted G1 and G2 A549 cells. A) Outline of the experimental work-
flow. B) Dose response (DR) curves for the induction of DSBs in sorted G1- and G2-phase cells, as well 
as in the asynchronous populations. Black circles, asynchronous cells; red circles, sorted G1 cells; green 
circles, sorted G2 cells. In the upper left corner an image of a typical DR on a PFGE gel is shown. C) 
Results for the asynchronous cell population. Left panel: DSB repair kinetics measured in the presence (1 
mM; dashed line), or absence (0 mM; solid line) of ara-A. Right panel: Representative flow cytometry 
histograms of cell populations collected at different times after IR. D) As in C for cells sorted in G1-phase. 
E) As in C for cells sorted in the G2-phase. All graphs depict the mean and s.d. from 6-8 determinations 
from 2 independent experiments. FDR = fraction of DNA released; DEQ = Dose equivalent. 
 
The careful approach and the accuracy of the obtained results allowed us to exclude 
confounding factors of PFGE technology as the reason why inhibition of DSB repair after 
incubation with ara-A could not be detected. D-NHEJ, unlike HRR and B-NHEJ, is 
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believed to operate with unaltered efficiency in G1, S and G2. Moreover, D-NHEJ is 
commonly regarded to be the dominant pathway of DSB repair throughout the cell cycle. 
If the great majority of DSB is repaired by D-NHEJ under the conditions employed for 
PFGE, interference of the drug with one of the remaining repair pathways or a partial 
shift to other pathways may be missed. This interpretation is supported by the 
observation that HRR mutants show in similar experiments no DSB repair defect, 
despite their increased radiosensitivity to killing (Wang, 2001a; Iliakis, 2004). 
Furthermore it is not clear if a shift to B-NHEJ in D-NHEJ proficient cells would 
necessitate a slowdown of repair. 
 Effect of ara-A on DSB repair in D-NHEJ deficient cells 
Since we couldn´t detect any effect of ara-A on the kinetics of DSB repair in D-NHEJ 
proficient cells we inquired if the same was true for D-NHEJ deficient cell lines. The 
activity of B-NHEJ becomes dominant in cells where core components of the classical, 
DNA-PKcs dependent pathway are dysfunctional or not present. Repair of DSB that is 
observable in these cells is chiefly carried out by B-NHEJ (Dibiase, 2000; Perrault, 
2004). We reasoned that in these cells alterations of the activity of B-NHEJ may be more 
apparent. 
For this purpose we utilized the human colorectal cancer cell line HCT116 (WT) and its 
two derivative knockout mutants HCT116 Lig4-/- and HCT116 DNA-PKcs-/-. We 
performed experiments with exponentially growing as well as with serum deprived cells. 
B-NHEJ is known to be suppressed under the latter condition (Singh, 2011) and we 
were curious to see if there might be differential effects. For serum deprivation we 
employed the protocol as described in Material and Methods (3.2.1.2). Briefly, cells were 
grown for 2 days. Then medium containing serum was removed and replaced by 
medium without serum. Another 24h later, cells were used in the experiment, during 
which they were continuously kept without serum. We used a treatment with 500 µM of 
ara-A for all cell lines. Cells were treated until they were collected at the respective time 
points for further processing. 
In exponentially growing cells ara-A treatment did not alter the repair kinetics of the WT, 
but enhanced the repair of DSB in Lig4 knockout cells (Figure 25 A). Repair in ara-A 
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treated Lig4-/- cells was increased by a dose equivalent of 5 Gy compared to the 
untreated Lig4-/- cells at 0.5h, but progressed with similar kinetics afterwards, keeping a 
constant gap (delta DEQ= 4-5 Gy) (Figure 25 A). Ara-A treated DNA-PKcs knockout 
cells repaired quicker initially, but repair progressed faster in the untreated DNA-PKcs-/- 
cells between 1h and 4h (Figure 25 A). At 8h treated and untreated DNA-PK cs-/- cells 
had the same amount of residual DSB. Interestingly the curves of ara-A treated Lig4-/- 
and DNA-PKcs-/- cells were fully congruent (Figure 25 A).  
 
Figure 25 Enhancement of DSB repair in D-NHEJ deficient human cells. A) Top Panel: Exponentially 
growing HCT116 wild type (WT), Ligase 4 knockout (Lig4-/-) and DNA-PKcs knockout (DNA-PKcs-/-) cells 
were irradiated with 20 Gy X-rays and left to repair without or with 500 µM ara-A. The amount of DSB was 
determined by PFGE. Black circles and solid line: HCT116 WT without ara-A. Black triangles and dashed 
line: HCT116 WT treated with 500 µM ara-A. Red circles and solid line: HCT116 Lig4-/- without ara-A (0 
µM). Red triangles and dashed line: HCT116 Lig4-/- treated with 500 µM ara-A. Violet circles and solid line: 
HCT116 DNA-PKcs-/- without ara-A (0 µM). Violet triangles and dashed line: HCT116 DNA-PKcs-/- treated 
with 500 µM ara-A. Data Points represent mean and s.d. from triple determination from one experiment. 
Bottom Panel: Cell cycle distributions of the starting populations of the three used cell lines. B) As in (A), 
but for serum deprived cells. 
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Under conditions of serum deprivation, DSB repair kinetics of WT cells were minimally 
slower than in exponentially growing cells, but were not altered by ara-A treatment 
(Figure 25 B). In line with the expectations the repair of DSB by the two knockout cell 
lines was substantially decreased in serum deprived cultures due to suppression of B-
NHEJ (Figure 25 B). Treatment with 500 µM ara-A clearly increased the efficiency of B-
NHEJ in Lig4-/- cells (Figure 25 B). After 8h, ara-A treated cells had repaired 52% of the 
initial DSB load. Untreated Lig4 on the other hand still retained more than 75% of the 
initial DSB (delta DEQ= 6.8). The difference was smaller in DNA-PKcs knockout cells 
(Figure 25 B), but present in contrast to exponentially growing cells. After 8h ara-A 
treated DNA-PK cells only retained DSB corresponding to a DEQ of 5.7 Gy. Untreated 
DNA-PK cells on the other hand retained DSB corresponding to a DEQ of 10.1 Gy (delta 
DEQ= 4.4). 
PFGE experiments with HCT116 WT, Lig4-/- and DNA-PKcs-/- cells showed that ara-A 
modulates DSB repair in D-NHEJ deficient cells in the exponential phase of growth, as 
well as under serum deprivation. These results confirmed that ara-A treatment can 
positively regulate B-NHEJ. They also showed that promotion of B-NHEJ, compared to 
the untreated controls, was more pronounced when B-NHEJ was suppressed by serum 
deprivation. 
 
 Relieve of serum deprivation-induced inhibition of B-NHEJ by 
ara-A 
In the light of the above results obtained with HCT116 cells we progressed to another 
system that reproducibly provides very strong inhibition of B-NHEJ under conditions of 
serum deprivation. MEF with a knockout for both alleles of Lig4 (MEF Lig4-/ -) have been 
extensively used in our institute. Under serum deprivation they frequently showed an 
almost full lack of DSB repair. To confirm that these standard could be met within this 
line of investigation we aimed to reproduce these PFGE results. We used exponentially 
growing, as well as serum-deprived cultures of MEF Lig4-/- and the parental MEF Lig4+/+ 
for comparison. Exponentially growing Lig4-/- MEFs showed a pronounced DSB repair 
defect while the parental cells repaired efficiently (Figure  B). Still within 2h after 
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irradiation about 50% of the breaks were repaired in MEF Lig4-/- cells, reflecting the 
activity of B-NHEJ.  
Figure 26 DSB repair by PFGE in exponentially growing and serum deprived MEF. A) Cell cycle 
distributions determined by FACS. B) DSB repair kinetics of MEF Lig4-/- and MEF Lig4+/+ cells. Grey 
squares and line: Exponentially growing MEF Lig4+/+ cells. Black circles and line: Serum deprived MEF 
Lig4+/+ cells. Light red squares and line: Exponentially growing MEF Lig4-/- cells. Dark red circles and line: 
Serum deprived MEF Lig4-/- cells. Data points of MEF Lig4+/+ cells and exponentially growing MEF Lig4-/- 
cells represent mean and s.d. of triple determinations from one experiment. Data points of serum deprived 
MEF Lig4-/- represent mean and s.d. of 4 independent experiments with triple determinations each. 
A plateau phase like state could be induced very efficiently in these cells by serum 
deprivation and resulted in accumulation of cells with G1 DNA content (Figure  A). As a 
result of this, an almost complete inhibition of DSB repair was observed in serum 
deprived MEF Lig4-/- cells (Figure 26 B). In contrast serum deprivation did not 
significantly alter DSB repair kinetics in MEF Lig4+/+ cells (Figure 26 B).  
We found that exponentially growing MEF Lig4+/+ and MEF Lig4-/- cells were very 
sensitive to ara-A treatment, which lead to extensive cell death and unacceptably high 
levels of background at longer treatment times in PFGE experiments (Data not shown). 
Therefore we decided to only use serum deprived Lig4-/- cells for further experiments, 
where toxicity was not a problem (Figure 27 A; lower panel controls 4h). Cultures of 
serum deprived Lig4-/- MEFs were irradiated with 20 Gy X-rays and treated with 250µM 
ara-A or solvent and left to repair for different time intervals. As expected the untreated 
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cells showed impaired DSB repair (Figure 27 A). Astoundingly cells treated with 250 µM 
ara-A showed repair kinetics almost equal to repair in MEF Lig4+/+ cells (compare Figure 
27 A and Figure 26 B).  
 
Figure 27 Ara-A treatment reactivates DSB repair in serum deprived Lig4-/- cells.  A) Top: DSB repair 
kinetics measured by PFGE in serum deprived Lig4-/- cells. Cells were irradiated with 20 Gy and repair 
followed for 4h. Untreated cells hardly show any repair of DSB. Treatment with 250 µM enables efficient 
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repair which is almost complete after 4h. Data points represent mean and s.d. of triple determinations from 
one experiment. Bottom: Cell cycle distributions determined by FACS of cells stained for DNA content with 
PI. Treatment with ara-A did not cause any changes in the flow cytometry histograms. B) Titration of B-
NHEJ enhancement by ara-A. DSB repair kinetics measured by PFGE in serum deprived MEF Lig4-/- 
cells. Cells were irradiated with 20 Gy and repair followed for 4h. Cells were either left untreated (0 µM), or 
treated with 25 µM (blue symbols and line), 50 µM (green symbols and line), 125 µM (yellow symbols and 
line) or 250 µM (red symbols and line). Upper right corner of the graph: Cell cycle distribution of the 
starting population determined. Data points represent mean and s.d. of triple determinations from one 
experiment. 
 
This effect surpassed our expectations by far. We inquired whether lower concentrations 
of ara-A elicit similar effects. We found that ara-A concentrations between 25 µM and 
250 µM all strongly increased the efficiency of B-NHEJ (Figure 27 B). Interestingly all 
concentrations showed almost identical enhancement of DSB repair up to 30 min after 
irradiation. At later times, however, the effect clearly increased with rising concentrations 
(Figure 27 B). Yet, even 25 µM and 50 µM ara-A were sufficient to reduce residual DSB 
after 4h of repair by a factor of two compared to the untreated control (0 µM). After 
treatment with 125 and 250 µM respectively, cells had repaired 87.5% of the initial 
damage, while the untreated control had repaired only 23,5% (delta DEQ= 12,8). 
These results strongly supported the notion that ara-A treatment enhances B-NHEJ 
efficiency. Furthermore they suggested that ara-A interferes with the mechanism that 
suppresses B-NHEJ in the plateau phase of growth respectively under serum 
deprivation. 
 
 Analysis of IR induced foci in serum deprived MEF Lig4-/- 
To further investigate the effect of B-NHEJ enhancement by ara-A we employed 
immunofluorescence combined with confocal microscopy to analyze DSB repair at low 
radiation doses. We selected proteins and modifications involved in the DNA damage 
response with the property of forming IRIF upon exposure to IR. One post-translational 
protein (PTM) modification we studied was the phosphorylation of Serine 139 (S139) of 
the histone variant H2AX. This PTM is commonly used as a surrogate marker for DSB 
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and is also known as γH2AX. Foci of γH2AX form in large chromatin domains around 
DSB.  
Recruitment of the protein 53BP1 to the sites of DSB is another assay that has been 
regularly used to monitor the repair of DSB. Both of these markers can be used to 
assess the capability of a cell to repair DSB. 
Another protein modification occurring after IR is the phosphorylation of Serine 1981 
(S1981) of ATM (pATM). ATM is a central kinase in IR induced DNA damage signaling 
and requires this phosphorylation for activation. pATM accumulates at sites of DSB 
where it can also be detected as IRIF. We aimed to analyze the assembly and the 
kinetics of decay of foci formed by these proteins in serum deprived Lig4-/- MEFs. 
In cells that were not treated with ara-A, foci of γH2AX persisted virtually unchanged 
from 1h (49.0 (+/- 13.7)) up to 24h (45.2 (+/- 8.4)) after exposure to 1 Gy (Figure 28 A). 
However, serum deprived MEF Lig4-/- cells that were treated with 250 µM ara-A 
developed a pan-nuclear γH2AX staining that grew in intensity with time (Figure  B). 
After 4h 90% of cells exhibited pan-nuclear staining and 8h and later 100% of cells 
showed this staining pattern (Figure 28 D), which made a meaningful quantitative 
analysis of γH2AX foci impossible. Similarly, 98% of non-irradiated cells showed pan-
nuclear staining for γH2AX after 24h (Figure 28 C). However, the intensity of the staining 
in non-irradiated cells did not reach the glaring intensity found for irradiated cells treated 
with ara-A. Still, pan-nuclear γH2AX staining was not exclusively observed in ara-A 
treated cells. In untreated cells with or without irradiation an average percentage of 
16.3% (+/- 3.3%) of cells with pan-nuclear staining could be observed (Figure 28 A, 
C&D).  
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Figure 28 Quantification of γH2AX and 53BP1 foci in serum deprived Lig4-/- MEFs.  A) Serum 
deprived Lig4-/- MEFs exposed to 1 Gy and left without further treatment until fixation. Maximum intensity 
projection (MIP) representations of Z-stacks recorded by confocal laser scanning microscopy (CLSM) of 
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immunofluorescent (IF) stained fixed cell samples. Cells were stained for DNA with DAPI (blue, top row), 
with an antibody against γH2AX (green, middle row) and an antibody against 53BP1 (red, bottom row). 
Pictures of cells fixed after 1h (1st column), 4h (2nd column), 8h (3rd column) and 24h (4th column) are 
shown. B) Serum deprived Lig4-/- MEFs exposed to 1 Gy X-rays and treated with 250 µM ara-A until 
fixation. MIP representations of Z-stacks recorded by CLSM of IF stained fixed cell samples. Cells were 
stained for DNA with DAPI (blue, top row), with an antibody against γH2AX (green, middle row) and an 
antibody against 53BP1 (red, bottom row). Pictures of cells fixed after 1h (1st column), 4h (2nd column), 8h 
(3rd column) and 24h (4th column) are shown. C) Non-irradiated serum deprived Lig4-/- MEFs left without 
ara-A (left column) or treated with 250 µM ara-A (right column) for 24h. Samples were fixed at the latest 
time point (24h) together with irradiated cells. MIP representations of Z-stacks recorded by CLSM. Cells 
were stained for DNA with DAPI (blue, top row) and with an antibody against γH2AX (green, middle row). 
The bottom row shows an overlay of the DAPI and the γH2AX stain. D) Quantification of the proportion of 
cells with pan-nuclear γH2AX staining in cells left without ara-A after irradiation (0 µM; black circles and 
line) and treated with 250 µM ara-A (red circles and line). E) Quantification of 53BP1 foci per nucleus. 
Black circles and line: cells left without ara-A after irradiation (0 µM). Red circles and line: Cells treated 
with 250 µM ara-A after irradiation. Data points represent the mean of all cells (51 (+/-17) per time point) 
analyzed in one experiment. 
  
Foci of 53BP1 on the other hand were, when detectable, always present in the form of 
distinct, quantifiable dots in ara-A treated and untreated cells (Figure 28 A&B). The initial 
number of average 53BP1 foci per cell was very similar (11.4 and 10.1 foci per cell) 
under both conditions. In cells without ara-A, 53BP1 foci persisted up to 24h after 
irradiation with a tendency to even slightly increase (Figure 28 A&E). In contrast, in cells 
treated with 250 µM ara-A 53BP1 foci quickly disappeared (Figure 28 B&E). After 4h 
only about 1 focus per cell could be detected on average. After 24h the number had 
decreased to 0.25 foci per cell on average (Figure 28 E). Interestingly, pan-nuclear 
γH2AX staining and the formation of 53BP1 foci seemed not to be mutually exclusive per 
se, at least in untreated cells (compare Figure 28 A; 0 µM 8h: pan nuclear 
γH2AX staining in cell with clear and bright 53BP1 foci). Still, most cells exhibiting pan-
nuclear γH2AX staining showed fewer or no 53BP1 foci.  
Detection of pATM after irradiation with 1 Gy revealed bright, punctate nuclear foci 
(Figure 29 A&B). The initial number of pATM 1h after irradiation was virtually identical in 
ara-A treated (60.8 (+/-15.6)) and untreated cells (60.6(+/-12.7)) (Figure 29 C). In 
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untreated cells a slow decay of pATM foci was observable (Figure 29 C). After 24h cells 
retained approximately half of the initial foci (27.9 (+/-6.7)), which were still visible as 
clearly defined, bright spots (Figure 29 A&C). In cells that were treated with 250 µM ara-
A decay of pATM foci proceeded much faster, with approximately 50% of foci being lost 
after 8h (residual foci 8h: 27.3 (+/- 20.6)) (Figure 29 B&C). This resulted in complete 
disappearance of pATM foci 24h after irradiation (Figure 29 B&C). Cells that lost the 
discrete protein foci retained a weaker, diffuse nuclear staining (Figure 29 B). 
We concluded that the complete disappearance of 53BP1 and pATM foci with time in 
serum deprived MEF Lig4-/- cells, was indicative of complete repair of DSB. This 
supported data showing enhanced repair of those cells in PFGE experiments. Pan-
nuclear staining with γH2AX and to a lesser degree of pATM after treatment with ara-A 
require further investigation.  
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Figure 29 Quantification of pATM-S1981 Foci in serum deprived Lig4-/- MEFs.  A) Serum deprived 
Lig4-/- MEFs exposed to 1 Gy X-rays. Maximum intensity projection (MIP) representations of Z-stacks 
recorded by confocal laser scanning microscopy (CLSM) of immunofluorescent (IF) stained fixed cell 
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samples. Cells were stained for DNA with DAPI (blue, top row) and with an antibody against pATM-S1981 
(pATM; green, middle row). The bottom row shows a merged picture of the DNA and pATM stains. 
Pictures of cells fixed after 1h (1st column), 4h (2nd column), 8h (3rd column) and 24h (4th column) are 
shown. B) Serum deprived Lig4-/- MEFs exposed to 1 Gy X-rays and treated with 250 µM ara-A until 
fixation. MIP representations of Z-stacks recorded CLSM. Cells were stained for DNA with DAPI (blue, top 
row) and with an antibody against pATM-S1981 (pATM; green, middle row). The bottom row shows a 
merged picture of the DNA and pATM stains. Pictures of cells fixed after 1h (1st column), 4h (2nd column), 
8h (3rd column) and 24h (4th column) are shown. C) Quantification of pATM foci in irradiated cells with or 
without ara-A. Black circles and line: cells left without ara-A after irradiation (0 µM). Red circles and line: 
Cells treated with 250 µM ara-A after irradiation. Data points represent the mean of all cells (43 (+/-8) per 
time point) analyzed in one experiment. 
 
 Effects of other NAs on radiosensitivity and DSB repair 
 Effects on the survival of A549 cells 
The interesting results obtained with ara-A motivated us to expand our study to include 
other NAs. We decided to use fludarabine, ara-C and gemcitabine. Fludarabine, an 
adenosine analog, is a fluorinated derivative of ara-A. Ara-C is an analog of cytosine and 
gemcitabine the di-fluorinated derivative (Figure 1). Both of these compounds are 
significantly more cytotoxic than ara-A and fludarabine and effectively inhibit DNA 
replication at much lower concentrations (Figure 30 A and Figure 42). Fludarabine and 
gemcitabine have both been reported to possess radiosensitizing potential. Ara-C on the 
other hand is generally not regarded as a radiosensitizer. 
We performed survival experiments in A549 cells as described above for ara-A using a 
40 min pre-incubation and a 4h post-irradiation treatment (protocol II). From preliminary 
experiments we selected concentrations of the respective drug that yielded plating 
efficiencies no lower than 40% -50% of the control. This data had shown that in the case 
of ara-C, although only moderately toxic at doses below 100 µM, toxicity increased 
drastically at concentrations above 250 µM. Therefore concentrations below 100 µM 
were used. Two concentrations were tested for ara-C (10 µM and 50 µM) and 
gemcitabine (1 µM and 10 µM). Fludarabine, which had shown toxicity very similar to 
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ara-A, was used at the same concentration as the latter (500 µM). Predictions for PE 
reduction were met well by the results obtained (Figure 30 A).  
 
Figure 30 Comparison of radiosensitization by post-irradiation treatment with different NAs. A) 
Plating efficiencies for colony formation of exponentially growing A549 cells treated with different 
concentrations of NAs for 4h. Bars represent the mean of two independent experiments, each including 
double determinations. B) Survival of exponentially growing A549 cells after exposure to different doses of 
X-rays and the indicated concentrations of NA drugs for 4 h after IR. Red triangles, ara-A (500 µM); pink 
diamonds, fludarabine (F-ara-A; 500 µM); light blue triangles, ara-C (10 µM); dark blue triangles, ara-C (50 
µM); light green squares, dFdC (1 µM); dark green squares, dFdC (10 µM); black circles, control (no drug 
treatment). Survival data is normalized to the corresponding unirradiated controls (compare panel A). The 
results shown represent the mean of two independent experiments, each including double determinations. 
A third experiment using different concentrations yielded similar results. 
 
Treatment with 500 µM Ara-A resulted in a steep, shoulderless survival curve as 
expected (Figure 30 B). Fludarabine at the same concentration did sensitize the A549 
cells, but to a lesser degree than ara-A (Figure 30 B). Unexpectedly, treatment with ara-
C showed radiosensitization similar to fludarabine (Figure 30 B). There was only a very 
small increase in radiosensitization between treatment with 10 µM and 50 µM ara-C. We 
were surprised at first not to find radiosensitization by gemcitabine (Figure 30 B). 
However, an in-depth literature research revealed that results reporting 
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radiosensitization by gemcitabine generally use long pre-incubations (e.g. 16-32h) with 
the drug (Shewach, 1994; Rosier, 1999; Pauwels, 2003). On the other hand, studies that 
also test the effect of post-irradiation treatment don´t find radiosensitization (Shewach, 
1994). Thus, our finding is in accordance with the existing literature. 
We concluded that post-irradiation treatment with gemcitabine is not sufficient to induce 
radiosensitization in A549 cells. Ara-C had some radiosensitizing potential in our hands, 
albeit distinctly weaker than ara-A. Fludarabine also proved to be a weaker 
radiosensitizer than ara-A in A549 cells.  
 
 Effects on ara-C and fludarabine on HRR, SSA and distal NHEJ  
We decided to exploit the reporter assays, which we had used to measure the influence 
of ara-A on different pathways of DSB repair, to further evaluate the effects of ara-C and 
fludarabine, for which we had found radiosensitization as a post-treatment. We also 
included aphidicolin and HU as controls in these experiments. 
Both compounds inhibit replication, but show no or only weak radiosensitizing potential 
(compare Figure 13 B&C and Figure 14 B). HU inhibits replication in a range 
comparable to ara-A (IC50repl > 5 µM), while aphidicolin inhibits DNA replication at much 
lower concentrations, in a range comparable to that of ara-C (IC50repl < 0.3 µM).  
These controls were intended to confirm that transient inhibition of DNA replication alone 
was not sufficient to cause major changes in the read out of the reporter assays. 
Treatment conditions in these experiments were as described for ara-A above. 
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We started by testing the effects of fludarabine and ara-C on HRR using the U2OS 282C 
cells, which carry the DR-GFP construct. Fludarabine proved to be an effective inhibitor 
of HRR with a concentration-effect relationship very similar to ara-A (Figure 31 A). 
Incubation with HU, even at 2000 µM, on the other hand, had only a very small effect on 
HRR (Figure 31 A). Aphidicolin also failed to inhibit HRR in U2OS 282C cells. Treatment 
with ara-C showed substantial but comparatively weak inhibition, reducing HRR by 
almost 45 % at a concentration of 10 µM (Figure 31 B). Since neither HU nor aphidicolin 
inhibited HRR despite their strong effects on DNA replication, we concluded that 
inhibition of replication per se was not sufficient to suppress HRR. 
 
Figure 31 Effect of fludarabine and ara-C on HRR in U2OS 282C cells (DR-GFP).  
  
A) Effects of fludarabine (F-ara-A) and hydroxyurea (HU) on HRR. Blue circles and line: F-ara-A. Red 
squares and line: HU. Data points represent mean and s.d. from three independent experiments. B) 
Effects of ara-C and aphidicolin on HRR. Dark pink circlesand line: Ara-C. Plot shows the mean from two 
independent experiments Blue triangles and line: Aphidicolin. Data points represent mean and s.d. from 
three independent experiments. 
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Figure 32 Effect of fludarabine and ara-C on SSA in U2OS 283C cells (SA-GFP). 
A) Effects of fludarabine (F-ara-A) and hydroxyurea (HU) on SSA. Blue circles and line: F-ara-A. Red 
squares and line: HU. Data points represent mean and s.d. from three independent experiments. B) 
Effects of ara-C and aphidicolin on SSA. Dark pink squares and line: Ara-C. Blue triangles and line: 
Aphidicolin. Data points represent mean and s.d. from three independent experiments. 
We proceeded to test fludarabine and ara-C in the U2OS 283C cells, to investigate their 
effect on the efficiency of SSA. Fludarabine treatment again resulted in a response 
similar to that of ara-A. After an initial decrease of SSA mediated repair, there was an 
increase at higher concentration, which was again abolished at very high concentrations 
(Figure 32; Figure 31 A). In contrast to ara-A, fludarabine lead to an effective net 
increase of SSA at concentrations between 500 and 1000 µM. HU again showed only 
little effect (Figure 32 A) and similar behavior was observed for aphidicolin. This drug 
only had a small impact on SSA, reducing its efficiency to 88% (+/- 4%) of control at 6 
µM (Figure 32 B). Ara-C had a stronger effect, reducing SSA by more than 30% to 68% 
(+/- 11%) at 5 µM, but did not inhibit the pathway further at 10 µM (Figure 32 B). 
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Figure 33 Effect of fludarabine and ara-C on the joining of distal ends of two DSB (EJ5-GFP). A) 
Effects of fludarabine (F-ara-A) and hydroxyurea (HU) on distal-end joining. Blue circles and line: F-ara-A. 
Red squares and line: HU. Data points represent mean and s.d. from three independent experiments. B) 
Effects of ara-C and aphidicolin on distal-end joining. Dark pink squares and line: Ara-C. Blue triangles 
and line: Aphidicolin. Data points represent mean and s.d. from three independent experiments. 
 
We concluded this analysis with the EJ5-GFP construct in U2OS 280A to measure the 
joining of distal ends of DSB. The effects of HU and fludarabine on the joining of distal 
ends seemed negligible. However, there is a small trend for distal end-joining to 
increase at higher concentrations of fludarabine (Figure 33 A). Aphidicolin and ara-C 
also had only small effects on the readout of this assay. Aphidicolin caused a reduction 
of 8% in the rejoining of distal ends at 6 µM, while ara-C reduced the efficiency of this 
repair mode to 80% (+/- 1.8%) of the controls at 10 µM (Figure 31 B). 
 
We concluded that inhibition of DNA synthesis by HU and aphidicolin had no important 
effects on the overall efficiency of any of the repair pathways or modes tested with this 
panel of cell lines. The profile of fludarabine for the modulation of repair pathway 
efficiencies was similar to that of ara-A, albeit with a much less pronounced effect on the 
joining of distal ends and a more pronounced effect on SSA. Ara-C was different from 
fludarabine and ara-A, as it uniformly reduced all types of repair events in these reporter 
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assays. The reductions elicited by ara-C were quiet moderate, ranging from 20% - 40%, 
but consistent. 
 
 Effects on mutagenic repair in EJ-DR cells 
The differences in the action of fludarabine and ara-C on specific repair outcomes we 
had found were intriguing. We wondered how the individual drugs would influence the 
overall fidelity of DSB repair. To address this question we conducted experiments using 
the U2OS EJ-DR cell line. We used the same conditions as described for experiments 
with ara-A. In this series of experiments we increased the tested ara-C concentrations to 
100 µM, to investigate if we would find more pronounced effects at higher 
concentrations. Fludarabine caused an increase of mutagenic end joining to about 150% 
of the controls at concentrations above 500 µM (Figure 34 A). Ara-C on the other hand 
caused a small reduction (about 20%) of mutagenic repair (Figure 34 B). However, this 
reduction was significant only at 1 µM (p= 0.001). 
Figure 34 Effect of fludarabine and ara-C in U2OS EJ-DR cells (EJ-RFP).  
A) Effect of treatment with fludarabine (4h starting 1.5h after transfection) on mutagenic end-joining. Flow 
cytometry analysis was performed four days after transfection with the I-SceI expression plasmid. Data 
points represent mean and s.d. from 3 independent experiments. B) As in (A) but with ara-C. 
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We concluded that Fludarabine behaved similar to ara-A in I-SceI reporter assays, but 
showed some differences in the strength of effects on individual repair pathways. 
Notably, fludarabine had lesser potential to increase distal-end joining and the overall 
mutagenicity of repair. Ara-C on the other hand did not have a positive influence on any 
of the examined repair pathways. Instead it showed small to moderate reduction of all 
repair outcomes. 
 
 
5 Discussion 
 Design of this study and general considerations 
It was our aim to investigate mechanisms of radiosensitization by NAs using ara-A as a 
model compound. We focused on possible interactions of ara-A with pathways of DSB 
repair. A well- known characteristic of this deoxyadenosine analog is its inhibitory effect 
on mammalian DNA replication (Plunkett, 1974; Muller, 1975; Kufe, 1983; Ohno, 1989). 
Most of the results previously reporting radiosensitization by ara-A were generated using 
cultures in the plateau phase of growth  (Iliakis, 1980; Iliakis and Bryant, 1983; Iliakis 
and Ngo, 1985; Iliakis, 1989b; Little, 1989). Plateau-phase conditions conveniently 
circumvent complications frequently generated when treating an actively growing culture 
with substances that have cell cycle phase specific effects. In the case of an S-phase 
inhibitor these complications include S-phase specific cytotoxicity and changes in the 
cell cycle distribution that may modify the outcome of many types of experiments.  
Despite the difficulties in experimentation and the interpretation of data that are 
associated with the usage of asynchronous cell populations, we decided to use 
exponentially growing cells for a large part of this work. One rational for this decision 
was that also within a tumor, cells can be found distributed in all phases of the cell cycle. 
A second important reason was that we wanted to investigate the effects of this drug on 
all known pathways of DSB repair. Since the activity of some repair pathways, especially 
HRR, but also B-NHEJ, underlie cell cycle dependent control mechanisms the use of 
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proliferating cultures was without alternative (Shrivastav, 2008; Escribano-Diaz, 2013). 
However, it was essential for us to have controls that allowed us to differentiate between 
effects that were primarily due to inhibition of replication and other, not directly 
replication linked effects. For this reason we included two non-nucleoside replication 
inhibitors in our studies. Aphidicolin is a tetracyclic fungal metabolite that inhibits the 
DNA polymerases α, δ and  ε by direct binding (Ikegami, 1978; Ohashi, 1978). 
Hydroxyurea (HU) is a hydroxylated analog of urea that acts by inhibiting the enzyme 
ribonucleotide reductase (RnR), which results in deregulation and depletion of 
deoxynucleotide pools (Chapman and Kinsella, 2011). Ara-A on the other hand can be 
incorporated into DNA and inhibits the DNA polymerases α  and  β,  as well as the 
enzymes primase and RnR (Dicioccio and Srivastava, 1977; Chang and Cheng, 1980; 
Kuchta and Willhelm, 1991). 
 
 Inhibition of replication and sensitization of cycling cells 
The two control compounds and ara-A all have different, albeit partially overlapping, 
modes of action and are effective as replication inhibitors in different concentration 
ranges. We performed replication assays to assess their inhibitory activity. The results of 
these assays were used to calculate IC50 values for replication (IC50repl), which enabled 
us to use the control compounds at equal-effect or higher concentrations than ara-A 
(Figure 13). Exponentially growing cells were sensitized very efficiently to IR by ara-A 
treatment (Figure 14 A). We compared the radiosensitizing effect of ara-A at 40 and 80 
times IC50repl to the survival of cells that had been treated with HU at 45 times IC50repl or 
aphidicolin at 220 times IC50repl (Figure 14 B). Aphidicolin did not elicit any 
radiosensitization in treated cells. HU treatment caused some radiosensitization, which 
was much weaker than that caused by ara-A.  
These experiments confirmed that radiosensitization by ara-A cannot solely be attributed 
to inhibition of replication during the treatment period. HU has been implicated as 
radiosensitizer and a number of clinical studies had been initiated in the 1960s and 70s, 
before interest declined again due to controversial results.The comparatively weak 
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sensitization that was caused by HU is likely to be related to the role of RnR in radiation 
response and possibly DNA repair (Chapman and Kinsella, 2011).  
RnR is a tetrameric complex consisting of two subunits named R1 and R2. R1 is the 
larger, regulatory subunit, which is expressed constitutively throughout the cell cycle. 
The expression of the R2 subunit is cell cycle dependent, with highest levels reached in 
the S-phase (Kuo and Kinsella, 1998). Importantly, relatively recently an alternative R2 
subunit, named p53R2, was discovered. This subunit is not cell cycle regulated, but 
becomes induced transcriptionally after exposure to IR (Tanaka, 2000). This finding 
suggests some replication independent functions of RnR in the response to IR. Ara-A is 
known to have an inhibitory effect on RnR as well (Moore and Cohen, 1967; Chang and 
Cheng, 1980). Thus, inhibition of RnR may also play a role in the radiosensitization by 
ara-A. However, the small radiosensitization elicited by HU suggests that the 
contribution of this mechanism to the overall radiosensitization by ara-A will be small.  
The highly efficient radiosensitization by ara-A demonstrated in survival assays strongly 
suggested an interference of this drug with pathways of DSB repair. We applied various 
techniques for the detection of DSB and the measurement of their repair in this study. 
Each of these methods has its individual strength and weaknesses. These will be 
discussed comparatively in the next section, before proceeding to the discussion of the 
actual results. 
 
 Methods for the measurement of DSB repair 
 PFGE 
PFGE is a physical method for the detection of DSB (Gardiner, 1991; Gurrieri, 1999). 
The amount of DSB and the kinetics of their repair are measured in the pooled total DNA 
of irradiated cell populations. For this end cells have to be exposed to high doses of IR 
and are incubated for different times afterwards. In this study 20 Gy were used as a 
standard induction dose. The clear advantage of PFGE is that it directly measures the 
actual physical presence of DSB within the genomes of cells and therefore can 
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accurately describe the kinetics with which they are rejoined. However, it cannot yield 
information about the repair pathways that conduct this repair. Switches in repair 
pathways that don´t significantly change the overall rate of repair will go unnoticed in 
PFGE experiments. Evidence from genetic studies indicates that repair as it is measured 
by PFGE in repair proficient cells mostly represents D-NHEJ, while in D-NHEJ deficient 
cells the observed DSB repair can almost entirely be attributed to B-NHEJ (Dibiase, 
2000; Perrault, 2004). HRR seems to play hardly any role in the repair that is detected 
by PFGE in D-NHEJ proficient as well as in D-NHEJ deficient cells (Wang, 2001a; 
Iliakis, 2004). This may also partly be due to a limitation of PFGE, which is the 
requirement for high doses of IR to allow sufficient resolution. Experiments with lower 
initial doses than 10 Gy become very difficult to analyze. This can be a problem, as 
radiation dose may also be a factor determining repair pathway choice (Sasaki, 2013). 
Finally, bulk analysis of cells in the standard application of this method means that 
distinct behavior of sub populations cannot be identified and distinguished. This includes 
cells from different phases of the cell cycle, which are known to show very different 
repair repertoires and potentials. However, in this study we could overcome the latter 
limitation by usage of a sophisticated combination of cell sorting and PFGE. 
 
 IRIF 
The analysis of ionizing radiation induced protein foci (IRIF) by immunofluorescence 
microscopy offers a much higher sensitivity with regard to the required dose and number 
of DSB than PFGE. Foci analysis enables the use of doses as low as 0.01 Gy for the 
production of statistically significant results (Markova, 2007). It also allows analysis on a 
single cell level, including discrimination by cell cycle phase or other criteria. However it 
is not only advantageous, as it lacks the direct physical evidence for the presence of a 
DSB. While the number of γH2AX foci for examples that is found after a given does 
correlates very well with the theoretically predicted and with other methods verified 
numbers, it has become evident that there are substantial timely differences between 
the kinetics of the disappearance of physical DSB and the generation and decay of IRIF 
(Markova, 2007; Kinner, 2008). The number of γH2AX foci for peaks about 1h after 
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irradiation in wild type cells, a time at which more than half of the DSB are already 
rejoined in repair proficient cells, as we know from physical methods like PFGE (see 
Figure 24, Figure 25 and Figure 26). Thus counting of foci may be used for the 
estimation of damage induction and residual damage, but caution must be exercised 
when drawing conclusions for the kinetics of repair, as the presence of a focus does not 
necessarily signify the presence of a physical break. Additionally it has been shown that 
phosphorylation of γH2AX does not exclusively occur only after DSB induction, but can 
be induced by other factors as well (Tu, 2013). Nonetheless, analysis of IRIF is a valid 
approach for the investigation of some aspects of DSB repair, particularly because it 
offers the opportunity to gain mechanistic insights into how breaks become repaired. 
 
 The use of I-SceI reporter assays for the assessment of DSB 
repair pathway activities 
Repair reporter constructs carrying recognition sites for rare cutting endonucleases that 
are stably integrated into the genome can be used to assay the frequency of specific 
repair events. In this type of reporter assay the expression of a site specific 
endonuclease (here I-SceI) leads to the introduction of a DSB in the reporter construct. 
The design of the construct is such, that only a special type of repair outcome, often 
specific to a single repair pathway, results in generation of a signal (Gunn and Stark, 
2012). These I-SceI reporter assays are widely used to measure the efficiency of 
different pathways of DSB repair. 
However, important differences to the repair of IR induced DSB have to be considered 
when working with these assays. These are mainly the different time frame of damage 
induction and the chemical composition of the breaks:  
At the dose rates used in this study DSB are induced by IR in a manner of seconds or 
minutes. In the case of DSB induction by I-SceI, several steps precede the cutting: After 
transfection the I-SceI gene needs to be transcribed, the mRNA translated and the 
resulting enzyme has to translocate to the nucleus and find its cutting site. Moreover, 
once expressed I-SceI remains present and active within the cell. Additionally, more I-
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SceI will continuously be expressed as long as the plasmid remains intact. Work from 
our group has shown that the levels of I-SceI protein in transfected cells remain constant 
up to 72h at least (Schipler, 2013). In the same study foci of 53BP1 were shown to be 
present for longer than 24h in repair proficient cells transfected with an I-SceI expression 
plasmid, indicating ongoing cutting of I-SceI sites (Schipler, 2013). Thus, DSB can be 
induced over a long period of time, possibly several days, in I-SceI inducible reporter 
assays. 
The chemical nature of the ends of DSB induced by either IR or I-SceI is very different. 
While IR induced DSB usually harbor chemically modified ends that prohibit ligation 
without further processing (Figure 4 B&C), DSB introduced by I-SceI can readily be 
religated due to the presence of unaltered 3´-OH and 5´-phosphate groups and 
complementary overhangs (Figure 4 A) ((Magin, 2013; Schipler and Iliakis, 2013)). 
Simple religation of an I-SceI induced DSB will result in reconstitution of the I-SceI site 
without generation of a signal. This regenerated site is again susceptible to cutting by 
the restriction enzyme, which may result in cycles of repeated cutting and religation. 
These cycles will be ended only when either a signal generating event occurs or the I-
SceI site is disrupted by another repair outcome. This can lead to under- or 
overestimation of the activity of different repair pathways and creates further uncertainty 
with regard to the time when damage induction and repair occur. 
When conditions are tested that themselves last or can be sustained for prolonged times 
(e.g. knockdown or knockout of genes or treatments with low cytotoxicity), the 
continuous damage induction in I-SceI reporter assays does not present a major 
problem. However, treatment with many drugs, including NAs, is limited by cytotoxity 
that increases with time. Furthermore, cell cycle phase specific drugs can elicit changes 
in the cell cycle distribution that could bias readings conducted at later times. Indeed we 
have found that such effects can lead to deceptive results when measurements are 
taken at 48h-72h after short term drug treatment (Figure 36 and Figure 37). Therefore, 
to avoid complications that would be associated with short term drug treatment and this 
inherent characteristic of the I-SceI system, we limited the observation time to 24h in this 
study where possible. 
Discussion 
____________________________________________________________________________________________________________________________________________ 
115 
 
Taken together, I-SceI reporter assays allow the measurement of specific repair 
outcomes indicative of DSB repair pathway activity. These results can provide valuable 
information about the effect of various treatments on these pathways. However, due to 
the different kinetics of DSB induction and the distinct chemical characteristics of the 
breaks caution has to be exercised when interpreting results and drawing direct 
comparisons to the effect of IR. 
In summary, each of the methods discussed above is able to provide a different kind of 
information about DSB repair. PFGE shows the actual presence of breaks, detection of 
IRIF by immunofluorescence sheds light on cellular responses to DSB and signaling, 
while I-SceI reporter assays provide information about how repair of some breaks has 
been completed. Each of these methods has its own limitations and peculiarities, 
knowledge about which is required for meaningful interpretation. Thus, data generated 
with each of those methods as individual piece of information has to be interpreted with 
care and under consideration of these limitations. Combination of information generated 
with multiple methods greatly strengthens the certainty with which conclusions can be 
drawn and broadens the scope of observations. Therefore we tried to address all 
question that arose in this study with a combination of methods. 
 Effects of ara-A on HRR 
 Effect of ara-A on IR induced Rad51 foci formation 
Since ara-A is an efficient inhibitor of replication we wondered if it may also effect 
mechansims of DSB repair that require substantial DNA synthesis. We used antibody 
staining and analysis by confocal microscopy to score Rad51 foci as a surrogate for 
ongoing HRR. We included cyclin B1 (CycB1) staining and labelling with EdU to enable 
the definitive discrimination of cells in G1, S and G2. 
EdU incorporation itself had no influence on Rad51 foci formation. The maximum 
number of Rad51 foci and the time when the maximal number of foci is reached for a 
given dose are dependent on the applied dose of IR. Studies in our group have shown 
that the maximum number of Rad51 foci is reached at 4 Gy and that this maximum 
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occurs at about 3h after irradiation. Thus, we chose 4 Gy as the test dose, to induce a 
maximum number of Rad51 foci.  
The results of these experiments clearly showed that the formation of Rad51 foci could 
efficiently be suppressed by ara-A treatment. Rad51 foci formation was almost fully 
abrogated at 1000 µM ara-A in S-phase cells and showed strong reduction in G2 cells 
(Figure 15 B). The requirement of higher concentrations of ara-A in G2 to reduce the 
level of Rad51 foci to similar numbers as in S-phase cells may either indicate an initial 
resistance of HRR to ara-A in the G2 phase, or could be related to higher absolute 
numbers of DSB in G2-cells that are repaired by HRR. Induction of DSB is proportional 
to DNA amount and thus is expected to be higher in G2 than in S-phase cells. In any 
case, from 100 µM onwards the curve for G2-cells followed an almost identical course 
as the curve for S-phase cells, suggesting a similar cause-effect relationship. 
These results showing suppression of IR induced Rad51 foci formation by treatment with 
ara-A, strongly indicated that successful execution of HRR was directly inhibited by this 
drug. Furthermore, the suppression of Rad51 foci formation caused by ara-A correlated 
very well with the radiosensitization elicited by ara-A in cycling A549 cells (Figure 15 C). 
Therefore we decided to test the importance of HRR inhibition in ara-A mediated 
radiosensitization in clonogenic survival assays. 
 Survival with Rad51 silenced cells 
If inhibition of HRR was a major mechanism of radiosensitization, the sensitization of 
cells already deficient for HRR should be reduced as compared to HRR proficient cells. 
Knockout of Rad51 is embryonic lethal in mice and Rad51 knockout cell lines are not 
viable. However, work by others indicated that transient silencing of Rad51 allows cells 
to remain viable (Liu, 2011; Short, 2011). Therefore we decided to induce HRR 
deficiency in A549 cells via knock down of Rad51 by RNAi. As control population we 
used cells that were transfected with a siRNA against GFP. We found that Rad51 
silenced cells retained a PE of 20% (Figure 16 B). This represented a considerable 
reduction compared to the control, but was expected and similar to reductions in PE 
after Rad51 knockdown reported by others (Liu, 2011; Short, 2011). This reduction in 
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viability is likely due to functions of Rad51 in replication (Sonoda, 1998; Daboussi, 2008; 
Petermann, 2010). 
Rad51 knockdown cells were much more radiosensitive than the controls. This as well 
was in accordance with results reported by others and confirmed that cells that retained 
viability still represented successfully transfected cells (Liu, 2011; Short, 2011). 
Importantly, treatment with ara-A did not further increase the radiosensitivity of those 
cells. Only at 5 Gy, which was the highest dose used in these experiments, some 
sensitization seemed to occur. It is important to note though, that the curve of the Rad51 
knockdown cells flattens out at this dose, displaying a resistance tail (Figure 16 C). This 
type of curvature occurs typically when radioresistant subpopulations start to dominate 
the shape of the survival curve. The higher the radiation dose, the smaller is the number 
of cells that survive. Sensitive cells become inactivated first, while more radioresistant 
cells may remain clonogenic at higher doses. A very small subpopulation of resistant 
cells will have hardly any impact on the course of the survival curve at lower doses, but 
will determine its shape almost entirely at higher doses (Iliakis and Okayasu, 1990). It is 
likely that the resistance tail of the survival curve of Rad51 knockdown cells is largely 
due to cells in which silencing was less efficient than in the bulk of the population. Those 
cells would still be at least partially proficient for HRR and thus also susceptible to 
sensitization by an HRR inhibitor. We concluded that inhibition of HRR indeed is an 
important factor in ara-A mediated radiosensitization in cycling cells. 
 Effect of ara-A on HRR of the DR-GFP reporter construct 
Initially only a CHO cell line, DRaa40, carrying a reporter for HRR (DR-GFP) was 
available to us. Development of a GFP signal in this system is indicative of successfully 
completed HRR (Figure 17 B) (Pierce, 1999). For experiments cells were transfected 
with an expression plasmid for the I-SceI endonuclease and were exposed to different 
concentrations of ara-A three hours later. After a four hour treatment the drug was 
removed. 24h after transfection the cells were collected and analyzed by flow cytometry. 
Treatment with ara-A strongly suppressed HRR in this system, showing 70% inhibition at 
a concentration of 500 µM (Figure 17 C).  
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At a later time we were able to obtain human cell lines (U2OS) carrying DR-GFP and 
other reporter constructs. Knockdown of several proteins implicated in HRR in the cell 
line harboring DR-GFP (U2OS 282C) confirmed the validity of this reporter as test 
system for HRR (Figure 19). Ara-A proved to be a very effective inhibitor of HRR of the 
DR-GFP construct in these human cells as well. The concentrations that were required 
to achieve equal suppression were higher than in DRaa40 cells (1000 µM vs. 500 µM for 
70% inhibition), which is in accordance with the higher toxicity this compound is known 
to show in rodent cells (Juranka and Chan, 1980). 
Taken together, suppression of Rad51 foci formation, lack of radiosensitization after 
knockdown of Rad51 in human A549 cells and inhibition of HRR measured by the DR-
GFP reporter in CHO and human U2OS cells confirm strong inhibition of HRR by ara-A. 
So far the exact molecular mechanisms that cause this inhibition remain unknown. The 
multistep process of HRR can be envisioned to be inhibited at several stages. This 
includes the resection of DSB ends that creates the ssDNA intermediate, formation of 
the Rad51 nucleoprotein filament, search for homology, elongation of the invading 
strand upon synapsis or resolution of recombinational structures and final ligation (Li and 
Heyer, 2008). Considering the effects of ara-A as an inhibitor of replication, inhibition of 
repair synthesis seems like an obvious mechanism for inhibition of this repair pathway. 
For ara-A inhibition of polymerase alpha/primase and polymerase beta has been 
reported (Dicioccio and Srivastava, 1977; Kuchta and Willhelm, 1991). A main 
mechanism of replication inhibition by ara-A is inhibition of RNA primer synthesis for 
lagging strand synthesis by the primase enzyme (Kuchta and Willhelm, 1991). However, 
primer synthesis is not required in HRR as the invading strand serves to prime DNA 
synthesis. Furthermore, multiple polymerases have been implicated to promote HRR, 
including the Polymerases beta, delta, eta, zeta and REV1 (Canitrot, 2004; Maloisel, 
2008; Kane, 2012; Sharma, 2012). Moreover the Polymerase delta subunit POLD3 
(POL32 in yeast) has been shown to play an important role in the BIR pathway of HRR 
(Costantino, 2014). Except for Polymerase beta for none of the other polymerases listed 
an inhibition by ara-A has been reported. Additionally, the presence of several trans-
lesion synthesis polymerases (zeta, eta and REV1) in this list suggests that HRR may 
possess the flexibility to bypass disturbances, like incorporated NAs, in template DNA. 
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Incorporation of ara-A during repair synthesis itself may hamper completion of HRR. 
However, the amount of DNA synthesis required during most HRR events is limited 
(several hundred bases) and it is unclear if incorporation of ara-A could be sufficient to 
obviate its completion, since it does not act as a chain terminator (Plunkett, 1974; Muller, 
1975; Kufe, 1983; Ohno, 1989). Therefore inhibition of DNA synthesis cannot readily be 
assumed to underlie inhibition of HRR. The strong suppression of Rad51 foci formation 
observed under ara-A treatment may indicate that suppression of HRR takes place at an 
even earlier stage, like the resection of break ends or loading of Rad51 on ssDNA. 
Further studies are required to clearly identifiy the molecular mechanisms of the 
inhibition of HRR by ara-A. However, first evidence helping to eliminate one candidate 
process came from the usage of another reporter cell line.  
 
 Effect of ara-A on SSA 
Using the SA-GFP construct integrated into U2OS 283C cells, we examined the effect of 
ara-A on the mutagenic SSA pathway. Silencing of HRR factors in the SA-GFP system 
resulted in a massive increase of SSA events. This impressively demonstrated the 
suppression of SSA that is mediated by HRR and has also been reported previously 
(Tutt, 2001; Stark, 2004; Mansour, 2008). We found that SSA could be partially inhibited 
by ara-A, but also benefited from inhibition of HRR at higher concentrations of ara-A. We 
showed that this recovery of SSA derived from an ara-A mediated release of SSA from 
the suppression exerted by HRR. This result gave further indirect evidence for inhibition 
of HRR by ara-A. It is interesting that ara-A could reduce SSA efficiency only by around 
30%. This means that the majority of SSA events is resistant to ara-A. Since all SSA 
events are dependent on extensive end-resection, this indicates that end resection is not 
inhibited by ara-A. Thus inhibition of end-resection can likely be excluded as a potential 
mechanism for the inhibition of HRR. 
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 Effects of ara-A on NHEJ 
 Effect of ara-A on distal end-joining 
Another repair reporter system, the EJ5-GFP construct integrated into U2OS 280A cells, 
allowed the analysis of the effect of ara-A on a specific subtype of NHEJ events. This 
construct does not simply measure the repair of a single I-SceI-induced DSB, but 
involves induction and misrepair of two DSB. Each of these DSB can either be repaired 
by rejoining of the proximate ends, or by rejoining of one end from the first and one from 
the second DSB (distal ends). Rejoining of distal ends results in the loss of the large 
(~1.8kb) intervening fragment, but enables expression of a GFP gene. Thus, signal 
generating events in this system have to be considered as a highly mutagenic form of 
NHEJ. Therefore, this assay should be expected not to measure the activity of the 
classical DNA-PK dependent pathway of NHEJ (D-NHEJ), but rather that of backup 
pathways of NHEJ (B-NHEJ). To confirm this interpretation we inhibited DNA-PKcs, a 
central component of D-NHEJ, with the specific inhibitor NU7441. Measurements by 
PFGE (Figure 38) or the phosphorylation of H2AX (Shaheen, 2011) show that treatment 
with this inhibitor induces a substantial defect in the repair of DSB, clearly demonstrating 
an inhibition of D-NHEJ. In U2OS cells harboring the EJ5-GFP construct on the other 
hand, treatment with NU7441 almost doubled the usage of distal ends (Figure 22 and 
Figure 39). This finding is in accordance with similar reports from others (Gunn, 2011). 
Treatment with ara-A caused distal-end joining events to increase by 30%. We 
interpreted this finding as an indication for increased activity of backup NHEJ. Taken 
together, the results obtained with this set of reporter cell lines indicated that HRR is 
inhibited by ara-A, while mutagenic pathways of homology directed (SSA) or NHEJ 
benefit from ara-A treatment.  
 Effect of ara-A on mutagenic DSB repair in the EJ-RFP system 
To further investigate whether repair by B-NHEJ is really promoted by ara-A, we 
employed another reporter cell system. The EJ-RFP system was recently developed in 
the group of Dr. Simon Powell (Bindra, 2013). In contrast to the previously used 
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reporters, in this system the expression of a signal is not based on the generation of a 
functional gene by one certain, predefined repair event. Instead, the disruption of a gene 
by any kind of mutagenic repair leads to generation of a signal. The different way of 
signal generation is mirrored in delayed appearance of the signal as compared to the I-
SceI reporter assays above. This necessitated measurement after 96h instead of 24h 
after transfection of the I-SceI plasmid. Treatment with ara-A resulted in a 2.5-fold 
increase of the DsRed signal compared to untreated controls. This showed that ara-A 
greatly promotes the mutagenic repair of DSB. In contrast to NU7441 there is no 
evidence so far for any impairment of D-NHEJ by ara-A. To address the question if ara-
A may have an inhibitory effect on D-NHEJ we examined its influence on the kinetics of 
DSB repair in D-NHEJ proficient A549 cells by PFGE. Furthermore, we were interested 
to see if the inhibition of HRR that is mediated by ara-A may be detectable in this assay. 
 PFGE of sorted G1 and G2 cells from an exponentially growing 
culture 
We used pulsed field gel electrophoresis (PFGE) to measure the repair of DSB in the 
genome of X-irradiated A549 cells. As discussed above (5.3.1) DSB repair as it can be 
observed by PFGE in repair proficient asynchronous cell populations is mainly due to 
the activity of D-NHEJ, which is generally assumed to be the dominant pathway of DSB 
repair throughout the cell cycle (Dibiase, 2000; Wang, 2001a; Iliakis, 2004; Perrault, 
2004; Mladenov and Iliakis, 2011). However, since HRR as well as B-NHEJ show strong 
cell cycle dependence in their activity, which is absent or lower in G1 and higher in G2, 
we reasoned that it might be possible to see their influence when G1 and S/G2 cells 
were analyzed separately (San Filippo, 2008; Wu, 2008a; Wu, 2008b; Heyer, 2010). 
Thus, we decided to irradiate and treat cells as exponentially growing cultures, but sort 
cells by FACS in different phases of the cell cycle for later analysis by PFGE. DNA from 
cells in the S-phase of the cell cycle has different characteristics of release migration in 
a gel, than G1 and G2 cells. This differential DNA release is related to S-phase specific 
DNA structures (Latz, 1996; Dewey, 1997). Thus, it was necessary to prepare separate 
dose response curves for each category.  
Discussion 
____________________________________________________________________________________________________________________________________________ 
122 
 
Since S-phase cells are themselves a heterogeneous population with regard to their 
progress in DNA replication and the related potential to perform HRR, we decided to 
concentrate on G1 and G2 cells. These represent two extremes of the cell cycle with G1 
cells putatively having 0% potential and G2 cells theoretically having 100% potential to 
perform HRR. Cell sorting gave us the best possible purity (Figure 24). G1 cells could be 
enriched >95% and G2>80%. It is not possible to achieve the same purity for G2 as for 
G1, because the broader distribution of the G2 peak partially overlaps with cells in late 
S-phase (and vice versa). Additionally, the smaller number of G2 cells precludes overly 
restrictive gating, due to the large cell numbers that were required for the analysis. A 
purity of >80% G2 cells however is a better enrichment than can be achieved with any 
other non-chemical method in this cell system. The cleanliness of those preparations is 
also reflected by the dose response curves of the G1 and G2 fractions (Figure 24 B). 
Both G1 and G2 cell dose responses are steeper than the curve of the asynchronous 
cells, due to the absence of S-phase cells. G1 and G2 cell dose responses are almost 
superimposable, only the G2 is minimally lower due to the slightly higher S-phase 
contamination. 
The results of this experiment clearly showed that neither in the asynchronous 
population, nor in G1 or G2 cells from the same exponentially growing culture, the 
kinetics of DSB repair were altered by ara-A in any way. This suggested that the inability 
to detect defects in HRR in asynchronous cell populations by PFGE (Wang, 2001a; 
Iliakis, 2004), which we had hoped to overcome by our sorting strategy, was not only 
due to masking effects of cells in other phases of the cell cycle. Importantly, novel, thus 
far unpuplished findings from our group demonstrate that the contribution of HRR to the 
total load of repair is diminished with increasing radiation dose. These results indicate 
that the contribution of HRR drops from as much as 70% at 0.25 Gy to about 15% at 2 
Gy. This ratio is further reduced at a slower rate at even higher doses. At the dose of 20 
Gy applied in our PFGE experiments, the fraction of DSB that remains destined for 
repair by HRR can be expected to be minuscule. Thus, the high doses required to 
achieve satisfying resolution in PFGE experiments reduce the contribution of HRR to the 
overall repair of DSB and thus render PFGE inappropriate for the investigation of the 
role of this pathway in DSB repair. 
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However, an important motivation to conduct these experiments had also been to 
observe potential signs of a shift from relatively accurate D-NHEJ to more error-prone B-
NHEJ as it had been indicated by I-SceI reporter assays. B-NHEJ as it can be observed 
in D-NHEJ deficient cells operates with slower kinetics than D-NHEJ. The repair kinetics 
in our experiments yielded no indication for a shift from a fast to a slower process. We 
concluded, that if B-NHEJ took a greater part in the repair of DSB in those cells when 
treated with ara-A, this form of B-NHEJ could not be characterized by a slower rate of 
repair. We speculated that if a fast form of B-NHEJ was enhanced by ara-A treatment, 
which was not distinguishable from D-NHEJ in A549 cells, it may be observable in D-
NHEJ deficient cells. 
 
 Ara-A enhances B-NHEJ in D-NHEJ deficient HCT116 cells 
We used a panel of human HCT116 colon carcinoma cells including two knockout 
mutants for core components of D-NHEJ. We performed experiments with exponentially 
growing and serum deprived cells. We found that for the D-NHEJ deficient HCT116 
LIG4-/- and HCT116 DNA-PKcs-/- cells DSB repair was enhanced by treatment with ara-A 
in the exponential phase of growth as well as after serum deprivation. On the other 
hand, in agreement with results previously obtained for A549 cells, the DSB repair 
kinetics of HCT116 WT cells were not altered by ara-A treatment. Previous work from 
our group has demonstrated that B-NHEJ is suppressed in the plateau phase of growth 
respectively under conditions of serum deprivation (Singh, 2011). Our results obtained 
with serum deprived D-NHEJ deficient HCT116 cells had also shown this inhibition and 
concomitantly an even greater repair enhancement after treatment with ara-A. 
 Relieve of B-NHEJ suppression in plateau phase MEF Lig4-/- cells 
by ara-A 
This indicated that ara-A treatment could not only promote B-NHEJ, but also relieve the 
suppression of DSB repair observed in the plateau phase of growth (Singh, 2012). In 
MEF Lig4-/- cells, repair is essentially absent in the plateau phase of growth (Figure 26 
B). Therefore we chose this cell system to conduct further experiments. Indeed we found 
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that DSB repair was promoted when those cells were treated with ara-A. Treatment with 
ara-A did not only restore B-NHEJ to nearly normal efficiency (25 µM-50 µM), but could 
also improve it beyond that point (125 µM- 250 µM). In fact, after 4h treatment of serum 
deprived Lig4-/- MEFs with 125 µM or 250 µM ara-A, the repair of DSBs observed was 
closer to the repair usually observed in wild type cells than to the repair in exponentially 
growing Lig4/- MEFs. 
These impressive results clearly demonstrated that backup pathways of NHEJ can be 
promoted by treatment with ara-A. This strongly suggests that ara-A treatment creates 
conditions that are generally favorable or even required for B-NHEJ, but which are 
usually prevented in G1/G0 cells. A candidate process could be 5´- 3´ resection of DSB 
ends. End resection is highly cell cycle regulated. While end resection mechanisms are 
active in the S and G2 phases of the cycle, in G1/G0 only very limited nucleolytic 
processing takes place (Jazayeri, 2006). B-NHEJ on the other hand, has been shown to 
be associated with and benefit from end-resection (Bennardo, 2008; Rass, 2009; Xie, 
2009; Bothmer, 2010; Lee-Theilen, 2011; Symington and Gautier, 2011; Grabarz, 2013). 
In accordance with this, B-NHEJ has been found to be enhanced in the G2 phase of the 
cell cycle (Wu, 2008a; Wu, 2008b), where end resection is active. Thus, end-resection 
may be enhanced under ara-A treatment, thereby facilitating repair by B-NHEJ in 
plateau phase Lig4-/- MEFs.  
 Promotion of B-NHEJ is not productive for survival 
The improved DSB repair capacity induced in plateau phase Lig4-/- MEFs by ara-A 
treatment, could have been possible to be associated with an increase of survival of 
these cells after irradiation. To verify this we performed preliminary survival experiments 
with serum deprived MEF Lig4-/- cells with or without ara-A treatment. We found no 
increase in the survival of ara-A treated cells. On the contrary we observed 
radiosensitization of treated cells, demonstrating that enhanced B-NHEJ function is not 
associated with improved chances for cell survival (Figure 40). 
Cells that show DSB repair defects are usually more radiosensitive than their repair 
proficient counter parts. However, some very radiosensitive cell lines also show only a 
mild or no DSB repair defect at all, indicating that removal of breaks as measured by 
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physical methods alone is not predictive of survival (Iliakis, 2009). It follows that not only 
the capacity for and rate of DSB repair are important for cell survival, but also the type 
and outcome of the repair. Thus over-activation of erroneous repair pathways may even 
negatively affect survival. 
B-NHEJ has been implicated in the formation of translocations and other chromosomal 
aberrations (Bunting and Nussenzweig, 2013). Formation of chromosomal aberrations is 
adverse to survival and thus increased repair by B-NHEJ may not support survival, but 
even contribute to sensitization of cells to IR.  
 
 Detection of IRIF in plateau phase MEF cells 
We sought to confirm and extend the observations we had made in the MEF Lig4-/- cells 
with a complementary method. We decided to use immunofluorescence microscopy to 
investigate formation and decay of radiation induced foci of γH2AX, 53BP1 and 
phosphorylated ATM. From this combination we hoped not only to gain information 
about the rate of DSB repair, but to gather some mechanistic information on DSB 
processing and signaling as well. 
The phosphorylation of H2AX on Serine 139 (S139), also known as γH2AX, is one of the 
first events in the response to DSB and has been frequently used as a surrogate marker 
for DSB (Rogakou, 1998; Nakamura, 2010). Formation and decay of 53BP1 foci also 
has been used to quantify induction and repair of DSB (Asaithamby and Chen, 2009). 
53BP1 is a protein that acts early in the response to DSB and forms foci that colocalize 
with γH2AX (Schultz, 2000; Polo and Jackson, 2011). Importantly, 53BP1 is not only a 
general component of the DDR, but is also known to play an important role in the 
regulation of DNA end-resection as well. It has been shown that 53BP1 and BRCA1 act 
antagonistically on end-resection and thereby influence pathway choice (Cao, 2009; 
Bouwman, 2010; Bunting, 2010; Escribano-Diaz, 2013). ATM is a central kinase in IR 
induced damage signaling. Phosphorylation of ATM at Serine 1981 (pATM) occurs in 
response to DSB and is required for its activation (Bakkenist and Kastan, 2003). pATM 
accumulates at sites of DSB where it can be detected as nuclear protein foci. 
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Phosphorylations mediated by ATM in response to DSB enable the analysis of key 
interactions during DSB repair. Thus, the presence or absence of pATM foci may 
provide important information about activation and maintenance of DDR signaling. 
Lig4-/- MEFs had developed a large number (~50/cell) of bright, distinct γH2AX foci after 
1h and untreated cells retained the same level of γH2AX foci until 24h (Figure 28). This 
finding was in full accordance with the almost complete defect in DSB repair observed 
with PFGE. In contrast, when cells were treated with 250 µM ara-A, they developed a 
pan-nuclear γH2AX staining, which intensified with time. After 8h of ara-A treatment no 
cells with scorable foci were left, but the total phosphorylation of H2AX was increased 
enormously. Pan-nuclear γH2AX staining can also be observed in cells that become 
apoptotic. However, hyperphosphorylation of γH2AX related to apoptosis has been 
reported to be preceded by a ring shaped staining of the nuclear periphery and to be 
closely correlated with apoptotic DNA fragmentation (Talasz, 2002) (Solier and 
Pommier, 2009). Furthermore, pan-nuclear γH2AX staining is ensued by the 
development of the characteristic pyknotic nuclear morphology of apoptotic cells.  
Among many thousands of cells observed we did not find any of those earlier or later 
apoptotic signs at any time point. Importantly, if the ara-A induced pan-nuclear γH2AX 
staining was due to apoptosis induced DNA fragmentation, massive DNA release into 
the gel should have been detected in PFGE experiments. Strikingly the exact opposite 
was what we had found: Reduced DNA release indicating improved repair (see above).  
In the literature a variety of reports can be found that describe pan-nuclear 
phosphorylation of H2AX, which is not related to apoptosis and can be caused by 
different stimuli or stressors. Ewald et al. found that checkpoint abrogation by a CHK1 
inhibitor in previously gemcitabine treated cells elicited pan-nuclear phosphorylation of 
H2AX, which was not related to apoptosis (Ewald, 2007). Similarly, Gagou et al. 
reported pan-nuclear staining in CHK1 depleted cells in response to prolonged treatment 
with thymidine and also excluded apoptosis as a cause (Gagou, 2010). Ewald et al., as 
well as Gagou et al., both performed their experiments in cycling cells and link the 
effects they observe to replication stress, collapsed replication forks, or the inappropriate 
firing of replication origins. Interestingly Gagou et al. report that depletion of the helicase 
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co-factor CDC45 greatly reduced pan-nuclear γH2AX staining. Pan-nuclear staining can 
also be elicited by transfection of small DNA molecules mimicking DSB, which results in 
DNA-PK hyperactivation (Quanz, 2009). Pan-nuclear H2AX phosphorylation in response 
to adeno-associated virus infection is also coordinated by DNA-PK (Schwartz, 2009). 
Furthermore, pan-nuclear γH2AX staining can be caused by UV-C radiation in G1 cells 
(Marti, 2006) or hypotonic treatment that induces chromatin changes (Baure, 2009). 
Finally, induction of pan-nuclear γH2AX has been reported to occur in cells that received 
clustered DNA damage from traversing heavy ions (Meyer, 2013).  
Taken together, our observations and the reports from others strongly suggest that pan-
nuclear H2AX phosphorylation does not have to be associated with apoptosis and that 
other factors and mechanisms are capable of inducing γH2AX in a nuclear wide manner. 
It is noteworthy, that pan-nuclear γH2AX was not only caused by the combination of 
irradiation and ara-A treatment. In unirradiated cells not treated with ara-A around 15% 
of cells exhibited pan-nuclear γH2AX staining (Figure 28 A, C&D). In irradiated cells 
without ara-A the frequency was similar. Unirradiated cells treated with ara-A for 24h 
also developed pan-nuclear γH2AX staining in 100% of the cases (Figure 28 C). 
We found high numbers of pATM foci (~60/cell), similar to the amount of γH2AX foci, in 
ara-A treated and untreated cells 1h after irradiation. Slow decay of pATM foci was 
observed in cells without ara-A treatment, but after 24h still about 50% of initial foci were 
present (~30/cell). In contrast, in cells treated with 250 µM ara-A, repair appeared to 
progress much faster and 24h after irradiation no foci were detectable. This observation 
was again in accordance with the repair defect and reactivation of B-NHEJ observed in 
PFGE experiments. However, we did also notice that the cells which lost their foci under 
ara-A treatment exhibited a diffuse, homogenous nuclear staining that appeared to be a 
little higher than background. Thus, it is possible that decline of pATM-foci number was 
not only due to completion of DSB repair, but to redistribution of pATM by the genome 
wide generation of γH2AX. It was apparent that in serum deprived Lig4-/- MEFs without 
ara-A treatment, DDR signaling remains active up to 24h and probably longer. This was 
evidenced by the persistence of bright pATM foci and was likely due to the persistence 
of DSB as also observed in PFGE. So far it is unclear if dissolution of pATM foci under 
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ara-A treatment is a consequence of ongoing DSB repair or whether loss of pATM foci is 
part of the mechanistic basis for the observed enhancement of rejoining.  
The numbers of initial 53BP1 foci we found 1h after irradiation (~12/cell) were 4-5 fold 
lower than the numbers of γH2AX or pATM foci. The initial number of foci was almost 
equal in ara-A treated and untreated cells. However, in untreated cells foci became 
brighter and appeared to increase in size over time, while in cells treated with 250 µM 
53BP1 foci formation was almost completely abolished after 4h and additional foci could 
not be detected up to 24h. This finding was again in accordance with increased repair in 
ara-A treated cells, although DSB repair-unrelated processes cannot be excluded at this 
time. 
Furthermore, the rapid disappearance of 53BP1 foci may also offer first insights for a 
mechanistic explanation as to how B-NHEJ may be reactivated in serum deprived MEF 
Lig4-/- cells. As mentioned above, 53BP1 is known to play an important role in the 
regulation of end-resection (Cao, 2009; Bouwman, 2010; Bunting, 2010; Escribano-Diaz, 
2013). 53BP1 is antagonized by BRCA1 which forms, together with its interaction 
partner CtIP, a module that promotes resection of DSB ends (Yun and Hiom, 2009). The 
balance between those two counteracting forces is shifted towards 53BP1 dependent 
end-protection in G1 and towards BRCA1-CtIP dependent promotion of end resection in 
S and G2 by cell cycle regulatory mechanisms. These shifts reflect the potential and 
requirement of a cell to perform HRR at different stages during the cell cycle. In G1/G0 a 
sister chromatid is not available and end resection is suppressed in favor of D-NHEJ 
mediated repair, while in S and G2 DNA ends become frequently resected to allow for 
repair by HRR. The fact that CtIP has also been shown to be required for the repair by 
alternative or backup pathways of NHEJ in G1 (Yun and Hiom, 2009) together with other 
reports strengthen the notion that B-NHEJ is more active in G2 than in G1 because it 
benefits from resection of DNA ends (Bennardo, 2008; Wu, 2008a; Wu, 2008b; Rass, 
2009; Xie, 2009; Yun and Hiom, 2009; Bothmer, 2010; Lee-Theilen, 2011; Symington 
and Gautier, 2011; Grabarz, 2013). 
Decay of 53BP1 foci may therefore indicate that the protection of DSB ends from 
resection typical in G1/0 cells is reverted by ara-A. B-NHEJ and possibly also SSA are 
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the only known DSB repair processes expected to benefit from resection in serum 
deprived Lig4-/- MEFs. Thus, enhancement of DNA end-resection in ara-A treated G1/G0 
cells may be an important contributor of the observed B-NHEJ reactivation. 
 Radiosensitization by other NAs 
 Clonogenic survival after exposure to IR 
The interesting results obtained for ara-A prompted us to test additional NAs and 
compare to the effects found for ara-A. First, we performed survival experiments in 
which we tested the NAs ara-C, gemcitabine and fludarabine for their radiosensitizing 
potential, and compared the results obtained to those of ara-A. Both, gemcitabine and 
fludarabine have been reported to act as radiosensitizers (Gregoire, 1994; Shewach, 
1994; Lawrence, 1996; Latz, 1998; Pauwels, 2006; Nitsche, 2008). In fact, these 
observations have lead to the initiation of a number of clinical trials to assess the 
therapeutic potential of these NAs in combination with radiation therapy (Gregoire, 2002; 
Aguilar-Ponce, 2004; Nitsche, 2012; Gurka, 2013). Ara-C on the other hand is not 
regarded as a radiosensitizer in the medical literature, but there are primary reports that 
show some inhibition of PLD repair by ara-C (Iliakis and Bryant, 1983; Nakatsugawa, 
1984; Iliakis, 1989b). 
We used a 4h post-irradiation treatment protocol like in previous survival experiments 
and concentrations that generated similar cytotoxicity as 500 µM ara-A.  
For fludarabine, we observed that treatment with 500 µM was able to generate 
significant radiosensitization in cycling A549 cells. However, the observed sensitization 
was weaker than after treatment with ara-A at the same concentration. Furthermore, we 
found that ara-C was able to sensitize A549 cells to a similar extend as fludarabine. This 
finding was not in agreement with the general tenor of the literature (D'Angio, 2005), but 
was not entirely surprising considering previous reports about inhibition of PLD repair by 
ara-C. 
We were surprised not to find any radiosensitization by gemcitabine despite the large 
amount of publications that report radiosensitization by this drug. This is most likely due 
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to the different treatment schedule we applied. The vast majority of studies reporting 
radiosensitization by gemcitabine use long pretreatments (usually 24h) at drug 
concentrations generating low cytotoxicity (Shewach, 1994; Rosier, 1999; Pauwels, 
2003). In our study, on the other hand, and as a result of its focus on the analysis of NAs 
effects on DSB repair processes, treatment was post-irradiation, relatively short (4h), 
and included only a 40 min pre-treatment allowed mainly for drug entry into cells before 
DNA damage induction. 
In a pilot study by Shewach et al. that assessed the dependence of treatment schedule 
on radiosensitization by gemcitabine, significant sensitization was only found for pre-
irradiation, but not post-irradiation incubation with gemcitabine (Shewach, 1994). The 
radiation enhancement ratios found in this study increased with the duration of pre-
treatment. It should be noted, however, that relatively low drug concentrations (10nM-
30nM) were used to produce these results, whereas in our study 100-fold higher 
concentrations were applied (1µM-10µM).  
Our results and the findings by Shewach et al. suggest that the effects of gemcitabine on 
cells when given before irradiation, seem to be indispensable for radiosensitization. 
Accumulation of cells in S-phase as well as depletion of intracellular dATP pools for 
example have been correlated with radiosensitization by gemcitabine (Shewach, 1994; 
McGinn, 1996)  
Collectively, these observations allowed us to conclude that post-irradiation treatment is 
sufficient to induce radiosensitization in the case of ara-A, fludarabine and ara-C but not 
in the case of gemcitabine. The great dependence of gemcitabine on a pre-irradiation 
treatment schedule suggests that other effects than direct inhibition of DSB repair 
pathways play the major role in radiosensitization by this NA. Therefore we did not 
include it in further test, but continued to analyze the effects of ara-C and fludarabine. 
 Effect of other NAs in reporter cell assays 
We started investigating the effects of ara-C and fludarabine on HRR, SSA and the 
joining of distal ends with U2OS reporter cell lines. For fludarabine we found inhibition of 
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HRR with efficiency similar to ara-A. Ara-C showed some, but comparatively weak 
inhibition of HRR.  
Investigation of the effects of the same NAs on SSA showed that fludarabine induced a 
biphasic response similar to that seen with ara-A. This is in accordance with the model 
discussed above, in which SSA benefits from HRR inhibition at higher drug 
concentrations. The net benefit for SSA appeared to be larger in the case of fludarabine 
than for ara-A. Ara-C showed moderate suppression of the SSA repair pathway that did 
not increase further above 5 µM. 
We also investigated effects of NAs on the joining of distal ends in U2OS cells carrying 
the EJ5-GFP construct. Fludarabine, in contrast to ara-A, showed almost no effect on 
the rejoining of distal ends. However, a very small trend for increase was observed from 
500 µM onwards. Ara-C slightly reduced distal-end joining. 
Neither nor HU showed a substantial reduction of the repair efficiency of any of the 
examined DSB repair pathways, confirming that inhibition of S-phase related DNA 
synthesis does not play a role for the effects observed with the nucleoside analogs. 
It is interesting to note that ara-A remained the only drug that caused a substantial 
increase in the rejoining of distal ends. The EJ5-GFP construct differs from all other 
reporter constructs used in this study, in that it contains two sites for the induction of a 
DSB. Only if the distal ends of these DSB interact a signal is generated. Such an event 
is highly mutagenic, as it is accompanied by a large deletion. Such sequence loss is by 
itself dangerous and highly undesirable for the cell, but may also pose larger threats to 
chromatin stability and genome integrity. Selection of distal ends over the very proximal 
ends may be the result of rare endonucleolytic cleavage of the intervening DNA segment 
and other chromatin destabilizing activities. Similar processes of misrepair are most 
likely also responsible for the generation of translocations and other chromosomal 
aberrations frequently observed in irradiated cells and implicated in cell killing and 
transformation {Nambiar, 2011 #266}{Bunting, 2013 #524}. 
By inhibiting DNA-PKcs we have shown that this reporter provides a measure for the 
activity of a form of B-NHEJ. As mentioned before, B-NHEJ has been heavily implicated 
in translocation formation. In addition, work from our Institute shows that a single DSB 
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introduced by I-SceI in a chromosome has a far lower toxicity than multiple (two or more) 
DSBs induced in close proximity (Schipler, 2013). The corresponding project was 
devised based on the assumption that increased complexity resulting from multiple 
breaks may lead to loss of whole nucleosomes or even larger chromatin units (Figure 
4 D). In conclusion: Although the repair event that is detected by the EJ5-GFP reporter 
cannot easily be assigned to a single, well defined repair pathway, it is tempting to 
speculate that it is indicative of a type of repair that can have particularly lethal 
outcomes. 
Finally, we investigated the effects of fludarabine and ara-C in EJ-DR cells. Those cells 
carried the EJ-RFP system for the measurement of the general mutagenicity of DSB 
repair. We found increased mutagenic repair when cells were treated with fludarabine. 
However, the increase was substantially smaller than in the case of ara-A. In cells 
treated with ara-C no increase in mutagenic repair could be observed. On the contrary, 
overall repair appeared to be even somewhat more accurate. 
Taken together fludarabine and ara-C exhibited a very different profile of effects on DSB 
repair pathways, when assayed with I-SceI inducible reporter systems. Fludarabine 
performed similar to ara-A with respect to the homology directed repair pathways HRR 
and SSA, but showed lower potency for increasing mutagenic repair related to NHEJ. 
Ara-C on the other hand did neither show strong inhibitory effects nor a promotional 
effect on any of the modes of repair analyzed. Nevertheless, both drugs showed similar 
radiosensitizing potential in clonogenic survival assays. In the case of ara-C this strongly 
suggests that other mechanisms than inhibition of DSB repair pathways play an 
important role for radiosensitization, as it also appears to be the case for gemcitabine, 
although ara-C was effective as a post-irradiation treatment. On the other hand, it 
appears likely that radiosensitization by fludarabine for a good part is related to its 
inhibitory effect on HRR.  
Ara-A distinguished itself from fludarabine and ara-C mostly by its superior capability to 
enhance mutagenic end-joining and was the only drug that caused a significant increase 
in the usage of distal ends. Together with the PFGE data from D-NHEJ deficient cells 
and the results of immunofluorescence detection of IRIF in plateau phase MEFs, we 
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could conclusively show that ara-A effectively promotes the activity of B-NHEJ. 
Furthermore, lack of additional radiosensitization after silencing of Rad51 and 
suppression of Rad51 foci formation by ara-A convincingly confirmed inhibition of HRR 
observed with the DR-GFP construct. We conclude that ara-A exerts its superior 
radiosensitizing effects through a shift in the balance from DSB repair that helps to 
maintain genomic stability and promotes survival, represented by HRR and D-NHEJ, to 
error-prone mechanisms that threaten genomic integrity and are adverse to survival, 
represented by B-NHEJ and SSA. 
It will be important to investigate the effects of ara-C and fludarabine with 
complementary methods as well. Future work will also focus on the This, together with 
the results obtained for distal end-joining may indicate that fludarabine has a lesser 
propensity to promote mutagenic NHEJ than ara-A. 
 
6 Summary and Conclusions 
Achieving improvements in cancer therapy is one of the major challenges of 
contemporary medicine. Combining drug treatment and radiotherapy to achieve 
synergistic killing of cancer cells is one of the most promising current approaches 
towards this goal. Aim of this thesis was to elucidate mechanisms of radiosensitization 
by nucleoside analogs (NAs), a highly promising class of chemotherapeutics, using 9-β-
D-arabinofuranosyladenosine (ara-A) as a model compound. 
Towards this goal, we investigated in detail the effect of ara-A on the repair of DSB. We 
established that ara-A inhibits homologous recombination repair (HRR) and showed that 
this inhibition plays an important role in the radiosensitization of exponentially growing 
human tumor cells. 
We also examined the effect of ara-A on pathways of non-homologous end-joining 
(NHEJ). We found an increase in the frequency of erroneous DSB repair events in two 
cellular reporter assays. However, we could not detect a decrease by ara-A in the 
overall DSB repair efficiency in repair proficient cancer cells exposed to high doses of 
IR, when tested in the G1 or G2 phase of the cell cycle by pulsed-field gel 
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electrophoresis (PFGE). This result implied a switch between DSB repair pathways, 
rather than an overall inhibition of DSB repair. 
Through examination of DSB repair by PFGE in repair deficient cells we could show for 
the first time promotion of error prone backup pathways of non-homologous end-joining 
(B-NHEJ) by a NA. Ara-A enhanced the repair of DSB by B-NHEJ in human tumor cells. 
Furthermore, ara-A treatment completely abrogated the plateau-phase-dependent 
inhibition of B-NHEJ in mouse cells, causing a dramatic restoration of DSB repair.  
Investigation of IR induced damage foci by immunofluorescence microscopy confirmed 
the above observations and implicated end-resection and deregulation of DSB signaling 
as underlying mechanisms. We conclude that in cycling cells treatment with ara-A 
causes direct inhibition of HRR resulting in radiosensitization. At the same time the 
balance of NHEJ is shifted towards the more error prone B-NHEJ. Over-activation of 
mutagenic B-NHEJ is likely to make an important contribution to radiosensitization by 
ara-A, especially in G1 and plateau phase cells, but also in G2 and S-phase cells.  
Our findings reveal a novel mechanism of radiosensitization by nucleoside analogs. That 
opens new avenues in the investigation of interactions of these drugs with IR and may 
have important implications for the clinical application of NAs as radiosensitizers. 
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8 Appendix 
 Part A: Supplementary data 
 Effect of earlier start of ara-A treatment in DRaa40 cells 
 
Figure 35 Effect of earlier start of ara-A treatment in DRaa40 cells Effect of a shift of the 4h treatment 
window to earlier times. Cells were treated with different concentrations of ara-A for 4h. Green circles and 
line represent treatment for 4h beginning immediately after transfection. Red circles and line represent 
treatment starting 1h after transfection and blue circles and line represent treatment starting 3h after 
transfection. Graph shows data from one experiment.The strong correlation between HRR 
suppression and the onset of ara-A treatment shown in Figure 18 prompted us to inquire 
whether an earlier ara-A treatment start would influence the outcome of the experiments. 
We found that treatment of cells with ara-A immediately after transfection, including a 
medium change after 4h, resulted in 70% inhibition already at 50 µM (Figure 35). This 
effect was equivalent to the maximum effect that was obtained at 500 µM when ara-A 
was given 3-7h after transfection (Figure 18 and Figure 35). Using the immediate 
treatment protocol, 88% inhibition was observed at 500 µM ara-A (Figure 35). When ara-
A treatment was initiated 1h after transfection, inhibition was also stronger than in 3-7h 
hour treatments, but allowed for a larger effect-range of approximately 53% (Figure 35). 
The results obtained with delayed treatment start as opposed to the immediate 
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treatment start, clearly indicated a strong concentration dependence of the effect, which 
we wanted to follow-up. Furthermore, results from another line of investigation showed 
that ara-A reduced the transfection efficiency when added immediately after transfection. 
Also we could not rule out direct toxicity of immediate drug treatment after 
electroporation stress. These complications and the interpretation difficulties they 
generated made us decide to use the delayed treatment schedules in further 
experiments, but initiate treatment 1.5h after transfection.  
 
 Inherent problems with the interpretation of data obtained at 
later times in I-SceI inducible reporter systems 
 
8.1.2.1 Analysis of GFP signal after 24h or 48h in U2OS 282C cells (DR-GFP) 
treated with ara-A  
As laid out in the discussion (5.3.3) it is a characteristic of I-SceI reporter assays, that 
DSB are induced over a long time span that may last several days (Schipler, 2013). With 
regard to short term drug treatment this can create complications when it is attempted to 
collect data at later times, e.g. 48h or 72h after transfection of the I-SceI plasmid. At this 
time most drugs will have been fully metabolized. Ara-A which is rapidly inactivated by 
deamination through ADA has an intracellular half-life of 1.5h-2h (Shewach and 
Plunkett, 1979; Cass, 1983), meaning that 18h after the end of treatment the cell has 
been qualitatively cleared of ara-A. Repair of DSB that are induced by cutting at this time 
will not any longer underlie any potential inhibitory or beneficial effects of the drug, which 
will likely have waned already earlier due to declining concentrations. The situation is 
further complicated by the fact that 18h after the end of ara-A treatment, a dramatic 
redistribution in the cell cycle can be observed with about 70-80% of cells accumulating 
in the S-phase (Figure 36). That means a massive concentration of cells in a phase of 
the cell cycle where HRR may occur as opposed to the normal situation in an 
exponentially growing culture, where 40% of cells or more are in the G1 phase and 
cannot perform HRR. This creates conditions in which the likelihood for HRR is 
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increased, but inhibition by the drug is no longer present. At the same time, DSB 
continue to be induced by I-SceI (Schipler, 2013). As the appearance of fluorescence 
after a signal generating event requires several hours to develop, this leads to an 
increase of the portion of GFP positive cells in ara-A treated cells that can be detected 
when cells are measured 48h or later after transfection of the I-SceI plasmid (i.e. ~42h 
after the end of ara-A treatment). This translates into an ostensible recovery of HRR 
efficiency that can be calculated at 48h. However, this increase does not represent a 
characteristic of the interaction of ara-A with HRR, but is a consequence of the 
continuous induction of DSB by I-SceI, rapid deactivation of ara-A and reassortment of 
cells in the cycle. 
 
Figure 36 Continuous damage induction and shifts in cell cycle distribution lead to deceptive 
signal generation in late measurements in I-SceI reporter assays. Upper panel: Calculated HRR 
efficiency. A pool of cells was transfected and distributed in several dishes that were treated accordingly. 
One dish from each concentration was analyzed at the indicated time point. Light red circles and solid line, 
24h after transfection. Dark red squares and dashed line, 48h after transfection. Data from one experiment 
is shown. Lower panel: PI Histograms for U2OS 282C cells 24h and 48h after transfection of the I-SceI 
plasmid. Ara-A treated cells are highly enriched in S-phase cells at 24h. At 48h Cell cycle distribution of 
treated cells is almost back to normal. 
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8.1.2.2 Development of fluorescence signals over time in EJ-DR cells (EJ-RFP & 
DR-GFP) 
The EJ-DR cell line was generated by introduction of the EJ-RFP into a U2OS cell line 
that also already harbored a DR-GFP insertion. The DsRed signal originating from the 
EJ-RFP system started to appear only 3 days after transfection and still showed strong 
increase up to 96h (Figure 37 A&B). Due to the kinetics of signal development of the EJ-
RFP system, the information provided by which was our primary interest in this series of 
experiments, measurements had to be taken 4 days after transfection. For the signal 
originating from the DR-GFP construct this meant that it was subjected to the same 
problematic described for U2OS 282C cells above (8.1.2.1). Consequently, 
measurements taken 96h after I-SceI transfection (i.e. ~90h after the end of ara-A 
treatment) showed only little effect of ara-A on the proportion of GFP positive cells in the 
EJ-DR system. To confirm that inhibition of HRR takes place in EJ-DR cells, we 
performed a time course experiment. We transfected EJ-DR cells with I-SceI and treated 
them for 4h with 1000 µM ara-A. Cells were split on 4 different dishes and analyzed at 
24h, 48h, 72h and 96h after transfection to measure the proportion of cells positive for 
GFP. We observed strong suppression in the development of a GFP signal up to 48h 
after transfection (Figure 37 C). This confirmed that ara-A had an inhibitory effect on the 
HRR mediated repair in the DR-GFP construct in the EJ-DR cells as well. As expected 
and in agreement with the findings for U2OS 282C cells, at later times GFP positive cells 
started to appear in the population, as a consequence of continuous induction of DSB by 
I-SceI and metabolic inactivation of ara-A.  
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Figure 37 Kinetics of reporter gene expression in EJ-DR cells. A) Development of the signals from the 
DR-GFP construct (GFP) and the EJ-RFP system (DsRed) over time within a population of EJ-DR cells 
transfected with I-SceI (no ara-A treatment). Significant increase of DsRed positive cells above the 
background occurs only 72h after transfection. The GFP signal begins to develop already 24h after 
transfection and has almost reached maximum after 48h already. B) Graphical depiction of the DsRed 
Data shown in (A). Measured values were corrected by the background (BG) of untransfected cells. C) 
Graphical depiction of the GFP Data shown in (A) (light green bars) together with data for the 
development of GFP expression in cells treated with 1000µM ara-A (dark green bars) collected in the 
same experiment. Measured values were corrected by the background (BG) of untransfected cells. Cells 
that were treated with 1000 µM ara-A for 4h show almost complete inhibition of HRR at 24h and 48h, but a 
robust signal starts to appear after 72h. 
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 Effects of Nu7441 on DSB repair 
8.1.3.1 Effect of Nu7441 on kinetics of DSB repair in A549 cells measured by 
PFGE 
 
Figure 38 A549 exponentially growing with or without 5 µM Nu7441.  PFGE data from an experiment 
performed with exponentially growing A549 cells irradiated with 20Gy X-rays. Incubation with 5µM of the 
DNA-PKcs inhibitor Nu7441 induces a strong DSB repair defect in D-NHEJ proficient cells. 
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8.1.3.2 Effects of different treatment durations with Nu7441 on distal end-joining 
 
Figure 39 Treatment of U2OS 280A (EJ5-GFP) with 5µM Nu7441 for different length of time. U2OS 
280A cells were transfected with an I-SceI expression plasmid and treated with 5µM Nu7441 for different 
length of time before the drug was washed away. The portion of GFP positive cells increases with time 
indicating increased usage of distal ends for re-joining. After 6h a plateau is reached. 
 
 Enhancement of B-NHEJ by ara-A does not confer 
radioresistance 
It was reasonable to assume that the improvement of DSB rejoining upon treatment with 
ara-A we observed in serum deprived Lig4-/- MEFs may allow cells to repair PLD, which 
would result in increased cell survival after irradiation. Therefore we inquired whether the 
enhancement of B-NHEJ was accompanied by an increase in radioresistance. To 
address this question we performed delayed plating survival experiments with serum 
deprived MEF Lig4-/- cells. We followed the serum deprivation protocol as described 
before. Since these cells are extremely radiosensitive, especially in G1/G0, we only 
applied up to 2 Gy in steps of 0.5 Gy. Different concentrations of ara-A or solvent were 
added 15 min before irradiation. Cells were irradiated in the plateau-phase like state and 
incubated under these conditions in the presence or absence of ara-A for 2h after 
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irradiation. After 2h, cells were collected and plated as single cell suspensions at 
appropriate dilutions. Colonies were fixed and stained after 7 days. 
We observed no improvement of survival in ara-A treated cells (Figure 40). On the 
contrary, ara-A treatment further sensitized cells. Plating efficiency values indicated that 
ara-A treatment had no strong cytotoxic effect on non-cycling MEFs. In fact we noticed, 
that the PE of cells treated with 25 µM (PE= 55%) was substantially higher than that of 
untreated cells (PE= 39%). When the ara-A concentration was further increased the PE 
declined again to 51% at 50 µM and 43% at 125 µM, which was still slightly higher than 
that for untreated cells. 
We concluded that the enhancement of B-NHEJ we had observed in serum deprived 
MEF Lig4-/- cells after treatment with ara-A had no positive effect on the repair of PLD 
and thus could not confer radioresistance. On the contrary, it appears to enhance PLD 
fixation, probably due to misrepair of DSB. 
 
 
Figure 40 Ara-A does not improve survival in serum deprived MEF Lig4-/- cells Serum deprived 
Lig4-/- cells were irradiated in the plateau phase and incubated for 2h after irradiation in the presence or 
absence of ara-A before plating. The means of double determinations from one experiment are shown. 
Black symbols and curve, no ara-A treatment (PE=0.39). Pink symbols and curve, 25µM ara-A (PE=0.55). 
Dark red symbols and curve, 50µM ara-A (PE=0.51). Light red symbols and curve, 125 µM ara-A 
(PE=0.43). 
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 53BP1 bodies in serum deprived MEF Lig4-/-  
In addition to the observations described under 4.4.6 we noticed that a large portion of 
MEF Lig4-/- cells contained one large, very bright focus of 53BP1 after 24h of serum 
deprivation in the absence of any further treatment (Figure 41). These foci always 
colocalized with γH2AX and were too big and distributed too regularly as it would be 
expected from background foci. Literature research revealed that such a phenomenon 
has already been described to arise in G0/G1 cells and has been linked to replication 
stress and common fragile sites (Harrigan, 2011). Common fragile sites are 
chromosome areas that show a higher incidence of spontaneous chromosome breakage 
than the average of genomic sequences. These 53BP1 bodies or domains were 
hypothesized to form after replication problems in these areas in the subsequent G1 
phase to protect common fragile sites against erosion. 
 
Figure 41 53BP1 bodies in serum deprived MEF Lig4-/- Depiction of 53BP1 nuclear bodies in 
unirradiated, serum deprived MEF Lig4-/- cells. Blue = DNA; red=53BP1; green=γH2AX; yellow= 
Colocalization of 53BP1 and γH2AX. 
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 Inhibition of DNA replication by ara-C and gemcitabine 
 
Figure 42 Inhibition of replication by ara-C and gemcitabine. Effects of ara-C (ara-C; violet curve) or 
gemcitabine (dFdC; green curve) treatment on DNA replication. Data points show the results of one 
experiment (Data generated by Dr. Maria Papaioannou). 
 
We performed preliminary experiments with ara-C and gemcitabine (dFdC) to evaluate 
their effectiveness as replication inhibitors. Replication was assayed by incorporation of 
tritium labeled thymidine (3H-thymidine). Inhibitors were added prior to a 20 min pulse 
treatment with 3H-thymidine. Subsequently cells were lysed and incorporation of 3H-
thymidine was measured in a liquid scintillation counter.  
Figure 42 shows the results obtained with the replication inhibitors normalized to 
controls incubated without drug. The concentration at which 50% of the maximum 
inhibition of replication was achieved (IC50repl) was determined. Gemcitabine and ara-C 
both inhibited replication very effectively with IC50repl values of 0.25 µM and 0.1 µM, 
respectively. 
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 Part B: Supplementary information on NAs 
 
In this section the intracellular metabolism and mechanisms of cytotoxicity and 
radiosensitization of some NAs that are considered to be of clinical and/or historical 
importance are described. This overview is intended as a complementary reference for 
the interested reader. 
 
 BrdU and IdU 
The first results showing radiosensitization by NAs were reported in the late 1950s, only 
a few years after it became clear that DNA is the hereditary material and its structure 
was resolved. They were obtained with the halogenated deoxythymidine analogs 5-
bromo-2´-deoxyuridine (BrdU) and 5-iodo-2´-deoxyuridine (IdU) (Djordjevic and 
Szybalski, 1960). The van-der-Waals-radius of Bromine and Iodine is comparable to the 
size of a methyl-group, thus BrdU and IdU act mainly as competitors of thymidine in the 
cell. BrdU and IdU were shown to synergistically enhance radiation induced cell killing 
when administered before irradiation and radiosensitization correlated with the degree of 
incorporation into the DNA (Dewey and Humphrey, 1965; Iliakis, 1989a; Lawrence, 
1990).  
In contrast to most NAs used in chemotherapy, these C-5 halogenated thymidine 
analogs don´t markedly interfere with replication. Many types of cells can be cultured in 
the presence of BrdU at micro molar concentrations for prolonged times without 
significant cytotoxic effects. In this way high rates of substitution for thymidine by BrdU 
can be achieved in both strands of the DNA. A specific radiochemical mechanism was 
described as an important factor for the radiosensitization elicited by these halogenated 
thymidine analogs. It has been shown that the presence of the halogenated pyrimidine 
bases in DNA during irradiation leads to the generation of uracilyl radicals by radiolysis 
that can extract hydrogen atoms from the sugar residues of nucleotides (Wang, 2006a). 
This results in the formation of strand breaks and also increases the yield of DSB per Gy 
IR (Zimbrick, 1969; Lawrence, 1995; Shewach DS, 2006).  
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Despite very promising results in vitro and some clinical phase I-II studies (Chang, 1989; 
Goffman, 1991; Levin, 1995) neither BrdU nor IdU ever achieved approval for medical 
use as radiosensitizers, because the results of phase III clinical trials did not yield 
satisfactory results (Prados, 1999). The special properties of BrdU and IdU are exploited 
in diverse labeling strategies for research purposes, e.g. for the detection of S-Phase 
cells, progression of replication forks, sister chromatid exchanges or DNA resection 
(Cavanagh, 2011). 
 
 5-FU 
In contrast, the fluorinated base analog 5-fluorouracil (5-FU) developed into a great 
clinical success. 5-FU is utilized in the treatment of breast, lung, head and neck cancers 
and has proven to be particularly effective in colorectal cancers (IMPACT, 1995). 
Several prodrugs of 5-FU exist to date (e.g. Capecitabine, Floxuridine) that have 
different pharmacokinetics but share similar or identical mechanisms of action. Upon 
entry into the cell 5-FU is converted to three major metabolites: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP) (Longley, 2003). The majority of the cytotoxic effect of 5-FU is 
usually ascribed to the inhibition of thymidilate synthase (TS) it exerts through FdUMP. 
Inhibition of TS results in depletion of dTTP pools and consequently leads to disruption 
of DNA synthesis.  
Due to the smaller van-der-Waals radius of the fluorine atom as compared to bromine or 
iodine, the nucleotides derived from 5-FU have more similarity with uridine than 
thymidine (Shewach DS, 2006). Consequently FUTP can be incorporated into RNA. This 
can lead to toxicity through disturbance on several levels, including mRNA 
polyadenylation, rRNA maturation and posttranscriptional modification of tRNAs (Carrico 
and Glazer, 1979; Kanamaru, 1986; Santi and Hardy, 1987). Another metabolite of 5-
FU, FdUTP, is also misincorporated into DNA, where it can lead to DNA strand break 
formation (Ingraham, 1986). The enzyme uracil-DNA-glycosylase excises the faulty 
base, which in the presence of high concentrations of FdUTP leads to futile cycles of 
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excision and re-incorporation (Longley, 2003). Radiosensitizing effects of 5-FU on 
transplanted tumors were recognized as early as 1958 (Heidelberger, 1958).  
Radiosensitization by 5-FU has been demonstrated in vitro for administration before and 
after irradiation (Bruso, 1990; Buchholz, 1995). For pre-incubation with 5-FU re-
distribution in the cell cycle apparently plays a significant role (Davis, 1995). An inhibition 
of DSB repair has been described as well, that may contribute to the radiosensitization 
achieved when 5-FU is administered after irradiation (Bruso, 1990). A number of clinical 
trials have shown a clear benefit in a number or tumors when radiotherapy was 
combined with 5-FU (Group, 1985; Merlano, 1996; Bartelink, 1997). Consequently 
concurrent chemoradiotherapy with 5-FU has become the standard of care for several 
solid tumor entities (Vallerga, 2004). 
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